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DNA topoisomerase I (Top1) is a highly conserved enzyme composed of four domains: a positively
charged N-terminus; a DNA binding/core domain that circumscribes duplex DNA; a non-conserved linker
domain; and a C-terminal/catalytic domain. Top1 catalyzes changes in DNA topology by transient
cleavage of a single DNA strand and the concomitant formation of a phosphotyrosyl linkage between the
enzyme and the 3’ DNA end. This covalent Top1-DNA complex is the binding site for camptothecin (CPT),
which selectively inhibits religation of the cleaved DNA strand. CPT binding stabilizes the covalent
complex, while the collision of replication forks with CPT-Top1-DNA adducts produces DNA lesions that
induce cell death. Mutation of conserved residues in close proximity to the active site tyrosine, Tyr727 in
yeast Top1 (yTop1) and Tyr 723 in human Top1 (hTop1), alters DNA cleavage-religation equilibrium,
inducing drug independent lethality. yTop1T722 A mimics the action of CPT and decreases the rate of
religation, while yTop1N726 H increases the rate of cleavage. Even though both mutants increase the
stabilization of the Top1-DNA covalent complexes, it is evident that distinct cytotoxic lesions are formed
by the different responses induced by low level expression of these self-poisoning enzymes in isogenic
yeast strains defective for the Rad9 DNA damage checkpoint, processive DNA replication, or ubiquitinmediated proteolysis. The core and C-terminal domains are connected by extended α-helices (linker
domain), which position the active site Tyr within the catalytic pocket. The physical connection of the
linker domain with the Top1 clamp as well as linker flexibility v affect enzyme sensitivity to CPT.
Crystallographic data reveal a conserved Gly residue (located at the juncture between the flexible linker
and C-terminal domains) that lies at one end of a short α-helix, which extends to the active site Tyr
covalently linked to the DNA. However, in the presence of drug, the linker is rigid and this α-helix extends
to include Gly and the preceding Leu, suggesting a dynamic interplay between active site α- helical
structure and linker flexibility. In vitro and in vivo analyses of Gly 721 mutations in yTop1 demonstrate that
charge and α-helical propensity of amino acid side chains at position 721 impact active site architecture
within the enzyme-DNA complex. In combination with the crystallographic data, these results implicate
the conserved Gly 721 as a flexible hinge within the active site of Top1 that enables linker flexibility and
the structural alterations that accompany drug binding of the covalent enzyme-DNA complex. In vitro
studies of the corresponding human mutant, hTop1G717 D, showed that this mechanism of increased
sensitivity is conserved. However, by expressing hTop1G717 D in yeast cells the increased CPT sensitivity
was not recapitulated. To determine the contribution of the divergent N-terminal and linker domains to
enzyme activity and in vivo CPT sensitivity, a series of chimeric enzymes, involving reciprocal swaps of
the yeast and human N-termini and linkers, were generated. The results demonstrate that the conserved
core and C-terminal domains dictate the intrinsic enzyme sensitivity to CPT, while it is the functional
interactions of the N-terminal and linker domains that regulate enzyme activity in vivo.
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ABSTRACT

DNA topoisomerase I (Top1) is a highly conserved enzyme composed of four
domains: a positively charged N-terminus; a DNA binding/core domain that
circumscribes duplex DNA; a non-conserved linker domain; and a C-terminal/catalytic
domain. Top1 catalyzes changes in DNA topology by transient cleavage of a single DNA
strand and the concomitant formation of a phosphotyrosyl linkage between the enzyme
and the 3’ DNA end. This covalent Top1-DNA complex is the binding site for
camptothecin (CPT), which selectively inhibits religation of the cleaved DNA strand.
CPT binding stabilizes the covalent complex, while the collision of replication forks with
CPT-Top1-DNA adducts produces DNA lesions that induce cell death. Mutation of
conserved residues in close proximity to the active site tyrosine, Tyr727 in yeast Top1
(yTop1) and Tyr723 in human Top1 (hTop1), alters DNA cleavage-religation equilibrium,
inducing drug independent lethality. yTop1T722A mimics the action of CPT and decreases
the rate of religation, while yTop1N726H increases the rate of cleavage. Even though both
mutants increase the stabilization of the Top1-DNA covalent complexes, it is evident that
distinct cytotoxic lesions are formed by the different responses induced by low level
expression of these self-poisoning enzymes in isogenic yeast strains defective for the
Rad9 DNA damage checkpoint, processive DNA replication, or ubiquitin-mediated
proteolysis. The core and C-terminal domains are connected by extended α-helices
(linker domain), which position the active site Tyr within the catalytic pocket. The
physical connection of the linker domain with the Top1 clamp as well as linker flexibility
iv

affect enzyme sensitivity to CPT. Crystallographic data reveal a conserved Gly residue
(located at the juncture between the flexible linker and C-terminal domains) that lies at
one end of a short α-helix, which extends to the active site Tyr covalently linked to the
DNA. However, in the presence of drug, the linker is rigid and this α-helix extends to
include Gly and the preceding Leu, suggesting a dynamic interplay between active site αhelical structure and linker flexibility. In vitro and in vivo analyses of Gly721 mutations in
yTop1 demonstrate that charge and α-helical propensity of amino acid side chains at
position 721 impact active site architecture within the enzyme-DNA complex. In
combination with the crystallographic data, these results implicate the conserved Gly721
as a flexible hinge within the active site of Top1 that enables linker flexibility and the
structural alterations that accompany drug binding of the covalent enzyme-DNA
complex. In vitro studies of the corresponding human mutant, hTop1G717D, showed that
this mechanism of increased sensitivity is conserved. However, by expressing
hTop1G717D in yeast cells the increased CPT sensitivity was not recapitulated. To
determine the contribution of the divergent N-terminal and linker domains to enzyme
activity and in vivo CPT sensitivity, a series of chimeric enzymes, involving reciprocal
swaps of the yeast and human N-termini and linkers, were generated. The results
demonstrate that the conserved core and C-terminal domains dictate the intrinsic enzyme
sensitivity to CPT, while it is the functional interactions of the N-terminal and linker
domains that regulate enzyme activity in vivo.
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CHAPTER 1: INTRODUCTION

1.1. DNA TOPOLOGY AND TOPOISOMERASES
“Since the two chains in our model are intertwined, it is essential for them to
untwist if they are to separate. Although it is difficult at the moment to see how these
processes occur without everything getting tangled, we do not feel that this objection
would be insuperable” (1).

In 1953 the scientific duo, Watson and Crick solved the structure of duplex DNA.
They found that DNA exists as a double helix and that the bases on each strand were
complementary to each other. This helical and complementary character of the DNA
double helix represented an elegant solution to the complicated task of housing genetic
information. It was further envisioned that to gain access to the information in this
molecule, the two strands of the double helix must separate from each other and that the
separation will have topological consequences (1). This problem leads to the fundamental
need in all cells for a class of enzymes that is able to alter DNA topology, hence DNA
topoisomerases. These enzymes are ubiquitous and found in all organisms, including
viruses, bacteria, archaebacteria and eukaryotes (2).
All DNA topoisomerases alter DNA topology through a cleavage/religation
mechanism that employs the chemistry of transesterification. Cleavage is initiated by the
nucleophilic attack of the O-4 oxygen of the active site tyrosine on a phosphorous in the
DNA backbone, resulting in a covalent phosphotyrosine linkage. Once DNA topology is
1

altered, the cleaved strand is religated through a second transesterification reaction. The
oxygen of the DNA hydroxyl group generated during the cleavage reaction now attacks
the phosphorous of the phosphotyrosine linkage, breaking the covalent bond between the
protein and the DNA and restoring the DNA backbone. These cleavage-religation cycles
create transient enzyme-linked nicks in the DNA, such that another DNA strand or
double helix can pass through (3, 4).
DNA topoisomerases are divided into two groups, type І and type II. Division of
these families was based on the number of DNA strands cleaved during each reaction
cycle and with which end of the broken strand the covalent linkage was formed in the
enzyme-DNA intermediate. Type I enzymes are ATP-independent and transiently cleave
only one strand of a DNA duplex. They are typically monomeric, with the exception of
Top1 from Leishmania donovani promastigotes. This enzyme is reconstituted by two
proteins encoded by separate genes (LdTOP1A and LdTOP1B) located on separate
chromosomes. Even though this enzyme is active as a dimer, it forms only one active site
pocket containing the catalytic Tyr required for cleaving one strand of the DNA duplex
(5). Type I enzymes are further divided into type IA and IB subfamilies. Type IA, such as
bacterial DNA topoisomerase I and III, eukaryotic DNA topoisomerase III and reverse
gyrase, are covalently attached to the 5’phosphate of the nicked strand, while type IB
enzymes attach to the 3’ phosphate of the cleaved DNA backbone (2, 6). Type IB
includes nuclear topoisomerase I found in all eukaryotic cells, vaccinia virus DNA
topoisomerase I and DNA toposiomerase V (2). In contrast to the nicking of a single
strand by the type I enzymes, both strands of the DNA duplex are transiently broken by
the type II enzymes. These enzymes, like type IA, are covalently linked to the 5’ end of
2

the cleaved DNA. Type II enzymes are also subdivided into type IIA and IIB. Type IIA
includes the eukaryotic enzymes such as mammalian topoisomerase IIα, IIβ and yeast
DNA topoisomerase II. They function as homodimers forming two catalytic pockets.
Type IIB enzymes such as archaeal DNA topoisomerase VI, have a distinct global
architecture from the type IIA enzymes in that they are active as a heterotetramer
consisting of two subunits of A and B each – A2B2 – which are encoded by two separate
genes. The amino and carboxy-terminal regions of type IIA enzymes are homologous to
the A and B subunits respectively, such that the type IIB holo-enzymes also contain only
two catalytic pockets. Despite the difference in composition of type IIB, its catalytic
mechanism is similar to type IIA enzymes (3, 4, 7, 8).
Type IA enzymes catalyze DNA strand passage by an “enzyme bridging”
mechanism, whereby the enzyme cleaves a single DNA strand and holding onto both
DNA ends at the break, bridges the opening through which an intact strand is passed. It
does not require an external energy source such as ATP, but Mg(II) is necessary for its
relaxation activity.
Type IA topoisomerases first bind to a short stretch of single stranded DNA and
therefore preferentially relaxes negatively supercoiled or underwound DNA. After
binding to the single stranded DNA, the nucleophilic O-4 oxygen of the catalytic Tyr
(Tyr 319 in E.coli Top1, indicated in pink in Fig. 1.1) attacks the scissile phosphate
forming a covalent linkage with the 5’-end of the DNA, while non-covalently holding
onto the 3’end. After cleavage, the domain covalently attached to the 5’end of the DNA
(Domain III in Fig. 1.1) moves away from the base of the enzyme. (The base is indicated
by Domain I.) This conformational change creates an opening (black arrow in Fig. 1.1)
3

FIG. 1.1. Amino terminal 67kD domain of E.coli DNA topoisomerase I. [aa 32-590,
pdb entry 1ECL (9)] The active site Tyr319 is indicated in pink.

4

through which a single DNA strand can pass. Once the non-scissile strand has moved
into the central hole of the enzyme, the clamp will close and the nicked strand is
religated. For release of the non-scissile strand, the protein opens and closes a second
time to conclude one catalytic cycle. This mechanism of relaxation elucidate the reason
type IA enzymes change the linking number, the number of times the two strands of the
duplex are wrapped around each other, in discreet steps of one (3, 7, 10).
Single molecule experiments have confirmed this model of relaxation by type IA
enzymes and further demonstrated that this enzyme is able to increase the linking number
of positively supercoiled DNA providing that there is a short stretch of unpaired DNA
(11). This demonstrates that the enzyme dictates directionality to the relaxation process.
Type IB topoisomerase is distinct from type IA in its mechanism of action as it
relaxes DNA by strand rotation. This enzyme binds to duplex DNA and can relax
positive or negative supercoils in the absence of energy cofactors or divalent cations. As
it relaxes both positive and negative supercoils, the directionality of relaxation is
determined by the torsional strain in the DNA backbone and not by the enzyme.
The protein first forms a non-covalent complex with duplex DNA by forming a
tight clamp around it (Fig. 1.2). Cleavage occurs through a transesterification reaction in
which the scissile phophodiester is attacked by the catalytic tyrosine of the enzyme,
forming a DNA- (3’-phosphotyrosyl)-enzyme intermediate and releases the 5’-OH DNA
end allowing it to rotate around a single phosphate bond in the non-scissile
strand, relieving any torsional strain. After rotation the DNA 5’-OH group acts as a
nucleophile attacking the phosphotyrosyl bond in the covalent intermediate, thereby
restoring the DNA phosphodiester backbone (4, 7). As the religation rate is much faster
5

FIG. 1.2. 70 kD C-terminal portion of human DNA topoisomerase I in non-covalent
complex with a 22 base pair DNA duplex. [aa 175-765, pdb entry 1A36 (12)] The
enzyme is shown in green and the duplex DNA in orange. The active site Tyr723 was
mutated to the Phe (indicated in pink).
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than the rate of cleavage, it ensures low steady-state levels of the covalent Top1-DNA
complexes. (3). Single molecule experiments demonstrated that the rotation of the DNA
inside the clamp is not free, but impeded by friction generated by clashes of the rotating
strand with amino-acid side chains lining the protein-DNA interface. These experiments
also demonstrated that the timing of religation depend on the proximity of 5’-OH end to
the DNA-3’-phophotyrosine adduct and therefore multiple supercoils can be removed per
cleavage-religation cycle (13). The tyrosine responsible for cleavage was mapped to the
C-terminal domain (14) and by peptide sequencing and site-directed mutagenesis found
to be located at position 727 in S. cerevisiae (15).
The type 1B enzymes are structurally and mechanistically distinct from all other
known topoisomerases, but similar to a class of enzymes called site specific/Tyrosine
recombinases. This family includes the bacteriophage HP1, λ integrases, XerC/D, Cre,
and Flp recombinases. They catalyze reciprocal DNA stand transfer reactions during the
formation and resolution of four-strand Holliday junctions (3). The Tyr recombinases are
mechanistically related to the type I topoisomerases as they also cleave a single strand of
a DNA duplex through a nucleophilic attack of the active site Tyr, yielding a covalent(3’-phosphotyrosyl)-enzyme intermediate and a free 5’-OH strand. Despite a lack of
sequence conservation, the C-terminal catalytic domain of type IB topoisomerases and
Tyrosine recombinases adopt a common fold composed of eight α-helices and a threestrand anti-parallel β-sheet with the catalytic pentad occupying similar positions in the
tertiary structures. Based on this conservation in structure and mechanism, it is proposed
that these two classes of enzyme evolved from common ancestral DNA strand
transferase. (16-19). Even though type IB enzymes can function as a strand transferase, as
7

seen from in vitro religation assays, they religate the 5’-OH end that was created during
the nucleophilic attack of the enzyme due to its proximity to the phosphotyrosyl bond.
Type II topoisomerases catalyze the ATP-dependent transport of an intact DNA
double helix through another double helix. After enzyme binding, both strands of the
DNA duplex are cleaved with a four base stagger, through coupled transesterification
reactions between a pair of tyrosyl residues, indicated in pink in Fig. 1.3, located on each
subunit of the dimer or the homologous AB complex. The tyrosine forms a
phosphotyrosyl linkage with the 5’end of the transiently broken DNA, leaving a pair of
hydroxyl groups on the 3’ recessed ends. A conformational change, driven by ATP
binding, separates the ends of the cleaved duplex creating a gate in the DNA helix such
that a second duplex can pass through the dimer interface. After passage, a second
conformational change is initiated by the hydrolysis of ATP and ATPase domain reopens.
The double strand break is resealed by a second transesterification reaction between the
3’-OH ends and the phosphotyrosyl bond to restore the continuity of the DNA. Due to
this mechanism the type II enzymes change the net linking number in steps of two (7, 8).
Six topoisomerases exist in humans, two members of each subfamily: type IA, IB
and IIA (IIB is only found in archea). Each of these enzymes has a unique function in
altering DNA topology. Top IB acts as a swivel during replication and transcription to
relieve helical tension resulting from the movement of the replication fork or
transcription machinery, while Top II specifically decatenates DNA during mitosis. There
are also overlapping functions between these enzymes as Top II is able to complement
the function of Top 1B in yeast cells devoid of Top 1B (20).

8

FIG. 1.3. The dimerization of the 43 kD N-terminal fragment of E.coli DNA Gyrase
B subunit containing an ATPase domain (aa 1-220) and the DNA capture domain (aa
221-392). [pdb entry 1EI1 (21)] The active site Tyr5 are mutated to Ser indicated in pink.
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For this study we focused on eukaryotic DNA topoisomerase I (Top1), which is a
Type IB enzyme.

1.2. EUKARYOTIC DNA TOPOISOMERASE I (Top1)
In higher eukaryotes, Top1 is an essential enzyme as it is required for viability in
mice during early embryogenesis. TOP1 knockout mice are unable to survive past the 416 cell stage suggesting that this enzyme is required early after fertilization (22). Studies
with Drosophila melanogaster showed similar results, demonstrating that Top1 is
required for embryonic cell proliferation (23). Developmental expression profiles also
suggested that Top1 is necessary during several stages of fly development, but especially
6-12 h post fertilization, when rapid DNA synthesis takes place (24). Although Top1 is
essential for multicellular organisms, yeast cells lacking Top1 are viable, but show a
slight slow growth defect and increased recombination at the tandemly repeated
ribosomal DNA (rDNA) locus (25, 26).

1.2.1. Top1 domains
Top1 is a multi domain protein that can be subdivided into four distinct regions
based on sequence conservation, sensitivity to limited proteolysis and fragment
reconstitution experiments (27, 28). The N-terminal domain is hydrophilic, unstructured
and highly protease-sensitive. This domain is not well conserved in terms of primary
sequence and size, but all nuclear Top1’s have an N-terminal domain rich in charged
residues. For example, the 24kD human Top1 N-terminal domain consists of 72%
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charged amino acids. This domain is dispensable for in vitro relaxation activity (29-31),
but is required for in vivo Top1 nuclear localization as it contains the nuclear localization
signals (NLS). The N-terminus is also important for protein-protein interactions (32-36).
An intriguing feature of this domain is that while in the human enzyme, all the nuclear
localization signals are located in the N-terminus, in yeast Top1 there is also a canonical
NLS in the linker domain. The N-terminus of human Top1 is much larger than that of
yeast Top1, while the linker domain of yeast Top1 is much larger than that of human
Top1, suggesting that there might be compensatory changes between the two domains
and that they act as a functional unit.
None of the Top1 crystal structures solved to date contains an N-terminal domain.
Therefore, the structure and also the spatial location of this domain relative to the core,
linker and C-terminus are not known. It has been suggested by experiments using the Nterminal truncated form of human Top1 that there is interaction of the N-terminus with
DNA downstream of the cleavage site (37).
The N-terminal domain is followed by the highly conserved core domain
containing all the catalytic residues; Arg488, Lys532, Arg590 and His632 (human Top1),
except for the active site tyrosine required for DNA cleavage. The catalytic tetrad located
in the core acts to position the scissile phosphate during the nucleophilic attack and
stabilizes the transition state of the reaction through interactions with the non-bridging
oxygen atom of the 3’-phosphate of the cleaved strand (38).
A protease sensitive linker connects the core to the highly conserved C-terminal
domain which contains the nucleophilic tyrosine (15). The linker domain is poorly
conserved in sequence and length, yet it is thought that the linker of all monomeric Top1
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enzymes forms a coiled-coil structure. Individually purified fragments consisting of the
core and C-terminal domain (missing the linker region) tightly associate in a 1:1 ratio to
reconstitute an active enzyme that exhibits plasmid relaxation activity and sequence
specificity similar to full length Top1 (39). This experiment shows that the linker domain
is dispensable for relaxation by the reconstituted enzyme, although its removal affects
enzyme processivity (12, 30, 39). It also demonstrates that the core and the catalytic Tyr/
C-terminal domains represent the minimal requirement for DNA relaxation in vitro.

1.2.2. Top1 structure
The first crystal structures of a C-terminal portion of human Top1 were solved
1998 by the Champoux group. Stewart et al. solved the structure of an N-terminally
truncated, catalytically inactive 70 kD form of human Top1 composed of residues Lys175
to Phe765 (Topo70) non-covalently bound to DNA (Fig. 1.4), while Redinbo et al. solved
the structure of a reconstituted enzyme consisting of the purified 58 kD core domain
(residues 175-659) and the 6.3 kD C-terminal domain (residues 713 to 765), covalently
and non-covalently bound to DNA. In all cases the protein was crystallized in the
presence of 22 basepair duplex DNA that contains the high affinity Top1 binding site
from Tetrahymena thermophilus (40). No crystals formed in the absence of this DNA.
The crystallographic results revealed a bi-lobed structure that clamps tightly
around the DNA duplex forming a central DNA-binding pore, 15-20Å in diameter. The
core and C-terminal domains associate closely with each other to completely
circumscribe duplex DNA, confirming biochemical data that demonstrated a tight 1:1
binding between the core and C-terminal domain (39).
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FIG. 1.4. Human DNA Topoisomerase I (70kD) in non-covalent complex with a 22
base pair DNA duplex. [Pdb entry 1A36 (12)] Viewed perpendicular to the pore, Core
subdomain I, II and III are shown in blue, linker in purple and COOH-terminal domain in
green (left). On the right is a view of the enzyme down the pore, rotated 90° about the
vertical axis relative to the structure on the left.
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Core subdomains I and II fold together to form the top lobe of the enzyme, also referred
to as the “cap”. The cap is structurally characterized by two long “nose cone” helices that
protrude away from the body of the enzyme. Core sub domain III and the C-terminal
domain form the bottom lobe of the enzyme and are linked to the cap by a long alpha
helix on the one side of the DNA. On the opposite side of the duplex, opposable “lip”
domains (one loop from subdomain I and two loops from subdomain III) interact through
a salt bridge to connect the cap to the bottom lobe. The majority of the interactions
between the protein and DNA involve the amino acid side chains or primary amines with
the DNA phosphates over a ten base pair stretch. The limited base specific contacts are
consistent with the lack of Top1-DNA sequence specificity. For enzyme binding and
release, the clamp is required to open and close which involves breaking the interaction
between the two lip domains and lifting the cap away from the base of the enzyme.
As there is no crystallographic data available for Top1 in the absence of DNA, it
is not known if Top1 forms a closed clamp when it is not bound to DNA and moreover,
as the DNA is packed so tightly inside the central pore of the enzyme, the crystal
structures fail to elucidate how rotation is achieved in the context of the covalent
complex. To address these questions a mutant form of human Top1 was generated that
forms reversible disulfide bonds between opposable lips such that the clamp can be
locked in a “closed” conformation. Based on structure-modeling studies mutations G365C
and S534C were introduced into full length human Top1. This mutant demonstrated that
Top1 can form a clamp in the absence of DNA and furthermore, when the clamp is
tightly locked around the DNA duplex there is no strand rotation, suggesting that protein
flexibility facilitate DNA rotation (41).
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Two extended α helices constitute the linker domain. They form an anti-parallel
coiled-coil projecting away from the globular body of the enzyme as seen in the crystal
structures of Topo70. This domain contacts the rest of the protein only between the last
helix of the core domain and the C-terminal portion of second linker helix. As there is no
crystallographic data available for the N-terminal domain, it is not known if there is any
interaction of this domain with the linker.
The linker helices are connected to each other through three interhelix salt bridges
and nine hydrophobic pair-wise interactions. The fact that there are so few contacts
between the linker and body of the protein, gives this domain a high degree of flexibility
as revealed by multiple non-isomorphous crystal structures (42), but again, as Topo70
does not contain the N-terminal domain, it is not known what effect this domain has on
linker flexibility. The region of the linker facing the DNA (proximal face) has a large net
positive charge, with only two residues – Lys650 and Arg708 – hydrogen bonding with
phosphates in the DNA backbone downstream of the cleavage site. The two interacting
residues are located in the coiled-coil structure in close proximity to the core, and are
conserved as either arginine or lysine in all type IB topoisomerases.
An anti-parallel, positively charged, coiled-coil structure, similar to the linker, is
repeated in the “nose-cone” of the cap. It also projects away for the body of the protein,
facing, but not interacting with, the DNA duplex. Due to their location and charge, it has
been postulated that the “nose cone” and the linker play a role in the rotation of the DNA
downstream from the cleavage site (12, 27). More recent data suggest that there is a
conformational change in the protein such that the clamp “breaths” during DNA rotation
and therefore the role of the “nose cone” and linker during rotation is not well understood
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(41). Also, single molecule experiments demonstrated friction between the protein and
the rotating DNA, with human Top1 rotating slower than vaccinia Top1 (13). But,
because vaccinia Top1 does not completely circumscribes duplex DNA and does not
contain a linker domain, it is not understood how much of the friction is generated by the
linker.
Cleavage occurs after the enzyme binds to duplex DNA, interacting with regions
both upstream (-7 to -1) and downstream (+6 to +11) of the cleavage site. The cleavage
site is between DNA residues -1 and +1 on the scissile strand (43, 44). The highest
concentration of protein-DNA phosphate contacts is clustered around the 5 base pairs
upstream (-5 to -1) of the cleavage site. There is only one base-specific interaction
between the enzyme and its DNA substrate, namely catalytic residue Lys532 contacting -1
thymidine (T) nucleotide through the O-2 carbonyl oxygen of the base. Mutation of T at
the -1 position has been shown to reduce the ability of the enzyme to bind to the DNA
(45). Top1 has a sequence preference for nucleotides from positions -4 to -1 as follows:
5’-(A/T)(G/C)(A/T)(T)-3’ with covalent linkage at the -1 thymine residue (46-48). Even
though Top1 is highly promiscuous with respect to sequence specificity, a strong
cleavage site for all eukaryotic Top1’s was found in the rDNA repeats of Tetrahymena
thermophilus (40). This sequence contains a T at the -1 position and formed the basis for
the 22 base pair oligo used in the crystallographic analyis (12, 27, 38, 40).
Many studies tried to map the putative binding sites for Top1 on double stranded
DNA and found that sequence specificity is not the main determinant of Top1
localization on the DNA, but that structural features such as local helical twist play a
more prominent role (49). This is underscored by the fact that the high affinity cleavage
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site for Top1 is flanked by two oligo (dA)-(dT) tracts which are associated with a stable
curvature in the DNA (50). Moreover, Top1 preferentially binds to superhelical over
relaxed DNA (51), implying that Top1 has a higher affinity for bent DNA and therefore
senses writhe rather than twist. The linking number of a DNA molecule is represented by
both twist and writhe, twist being the number of helical turns in the DNA and writhe is
the number of times the double helix crosses over itself. As writhe is independent of the
sign of supercoiling, it is consistent with the observation that Top1 binds equally well to
negative and positive supercoiled DNA (52). It was also shown by electron microscopy
that Top1 is associated with nodes where two duplexes cross each other, again suggesting
that a structural feature of curved DNA is important for Top1 binding (52-54).
Eukaryotic DNA topoisomerase I is the sole target of the anticancer drug
camptothecin (CPT) (6, 55-57). This drug has been difficult to study as it is an
uncompetitive inhibitor and only transiently binds to the protein-DNA covalent complex,
where it prevents religation (58). The crystal structure of Top1 covalently linked to DNA
in the presence or absence of topotecan, an analog of CPT, was solved by Staker et al.
using a suicide DNA substrate containing a 5’-bridging phosphorothiolate (Fig 1.5).
Top1-catalyzed cleavage of this substrate generates a 5’-sulfhydryl, instead of a 5’hydroxyl, which acts as a weaker nucleophile in the religation reaction. These structures
demonstrated that topotecan intercalates at the site of DNA cleavage, mimicking a DNA
basepair. It is stabilized by base-stacking interactions with the -1 and +1 base pairs and
one direct hydrogen bond between Top1 residue Asp533 and the 20(S) hydroxyl of the
drug. The reduction in religation is elucidated by the fact that binding/intercalation of the
drug displaces the reactive 5’ OH end of the cleaved strand 3.6Å away from the catalytic
17

FIG. 1.5. 70 kD C-terminal portion of human DNA topoisomerase I (Topo70) in
covalent complex with a 22 base pair DNA duplex (left). [Pdb entry 1K4T (59)] The
figure on the right is Topo70 in complex with the CPT derivative, Topotecan [Pdb entry
1K4S (59)].
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tyrosine, thereby impeding the religation step (59).
The most obvious difference between the crystal structures of the Top1-DNATPT ternary complex and the covalent Top1-DNA complex resides in the visibility of the
linker, as seen in Fig. 1.5. In the binary structure, the linker domain residues (Gln633 –
Gln697) are not visible in the electron density, indicating movement of this coiled-coil
structure. This is in accordance with studies by Redinbo et al., demonstrating that the
linker domain showed the greatest degree of flexibility as revealed by the nonisomorphous crystal structures (60). In contrast to the nondrug-bound protein, the crystal
structure of the ternary complex exposes the linker as an anti-parallel coiled-coil, similar
to the linker structure in the non-covalently bound Top1-DNA complex. This suggests
the posibility that binding of the drug alters enzyme conformation such that there is a
decrease in linker flexibility. However, the effect of crystal packing on linker visibility is
not known.

1.2.3. Controlled rotation mechanism
Based on structural and biochemical data, it was proposed that Top1 relaxes
supercoils by the swiveling of the scissile strand downstream of the cleavage site about a
phosphate bond. The co-crystal structures demonstrated that there is inadequate space for
the DNA to rotate unhindered around the non-scissile strand without contacting the cap
or the linker domain, and therefore a “controlled rotation’ model was suggested. This
model proposes that after cleavage, the torsional stress in the supercoiled DNA drives
rotation of DNA downstream of the cleavage site relative to the region of the duplex held
by the protein clamp and that the rotation of the DNA is controlled by steric clashes of
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the DNA within the tight Top1 clamp (12, 39). Even though the “controlled rotation”
model was supported by the crystallographic data, it failed to elucidate how rotation is
achieved in the context of the covalent complex. Single molecule experiments measuring
in real-time the velocity of DNA extension during supercoil removal demonstrated that
vaccinia Top1 has a slower DNA rotation rate compared to the unhindered rotation of a
nicking enzyme, substantiating the idea that steric clashes between the DNA and the
amino acids of the protein-DNA interface affects rotation. Moreover, mutating Tyr70 of
vaccinia Top1, such that the amino acid side chain extending into the DNA-protein
interface, is smaller, increased the rate of DNA rotation (13). Woo et al., using a mutant
Top1 protein that locks around duplex DNA, demonstrated that Top1 can still cleave
DNA in the context of the locked clamp, but that locking the clamp around the DNA
prevents DNA unwinding. Thus the protein clamp has to open for rotation to occur,
thereby reducing steric clashes (41) .
The linker appears to play a role in the relaxation process as a functional linker
prolongs the lifetime of the covalent intermediate (61). Both the N-terminus and the
linker are extremely sensitive to proteolysis, but binding of the enzyme to duplex DNA
results in proteolytic protection of only the linker, indicating that the linker is able to
interact with the DNA substrate (30). This is further substantiated by studies using
fragment complementation of the core and C-terminal domain containing no linker. The
reconstituted enzyme was comparable to wild-type in relaxation activity and sequence
specificity, but differed in its affinity for DNA as the topoisomers is more distributive in
a plasmid relaxation assay, again suggesting interactions between the linker and DNA
(39).
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The structure and function of the linker was further characterized by fragment
complementation, now using the core and a C-terminal fragment that extends to include
the linker domain. By disconnecting the linker from the core, the folding and/or
orientation of the linker was altered as assayed by gel filtration. Proteolytic studies
demonstrated that the linker is protected from proteolysis when Top1 is non-covalently or
covalently bound to DNA. Contrary to the wild type human Top1, proteolysis of the
reconstituted enzyme containing a disconnected linker showed that this domain is not
resistant to proteolysis, either when the enzyme is non-covalently or covalently linked to
duplex DNA. Moreover, the reconstituted enzymes have reduced CPT sensitivity in
cleavage assays, with no difference between the reconstituted enzyme containing a linker
or not, implying that detaching the linker from the core rendered the linker nonfunctional. These results demonstrate that a detached linker differs in
conformation/orientation and is unable to bind DNA downstream from the cleavage site
and furthermore, that a functional linker is necessary for optimal CPT sensitivity (61).
This was further underscored by a mutation in the linker domain – A653P- that is
predicted by molecular modeling to increase linker flexibility. This mutation induced
CPT resistance, again demonstrating that a functional linker is required for CPT
sensitivity (62).

1.3. TOPOISOMERASE INHIBITORS
There exists significant medical interest in topoisomerases as they constitute the
cellular targets of naturally occurring antimicrobial and anticancer drugs. Among the
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antimicrobial agents are the fluoroquinolones, such as ciprofloxacin, which target
bacterial DNA gyrase and is the most active broad spectrum spectrum oral antibiotic in
clinical use (63). Top 2 isozymes are targeted by anthracyclines (doxorubicin), Genistein,
Amsacrine (m-AMSA), Mitoxantrone and epipodophylotoxins (Etoposide) (64).
Etoposide is one of the most commonly prescribed anticancer drugs and is front line
therapy small-cell lung cancer and a variety of leukemias, lympomas, and germ-cell
malignancies (65).

1.3.1. Camptothecin (CPT)
Top1 is the sole target of the anticancer drug Camptothecin (CPT) (6, 55, 57, 66,
67). This molecule is a naturally occurring alkaloid found in the Chinese plant,
Camptotheca accuminata. It was first identified in 1960s in a screen of plant extracts for
antineoplactic drugs. Even though CPT showed promising anticancer activity, its toxicity
in phase II clinical trails precluded further use (68). There was renewed interest in CPT
when Top1 was found to be the cellular target of this compound. Biochemical studies
with mammalian Top1 and the finding that the Top1 purified from a CPT resistant human
lymphoblastic leukemia cell line was resistant to CPT, implied that Top1 is the target of
the alkaloid (67, 69-71). Moreover, studies using yeast cells (S. cerevisiae and S. pombe)
demonstrated that removing Top1 rendered the cells viable, but CPT resistant. CPT
sensitivity can be augmented by increasing the Top1 protein levels (55, 57, 66). It was
also shown that CPT specifically binds to Top1 in the presence of DNA (58) and that the
stabilization of the Top1-DNA intermediate caused single strand DNA breaks (6).
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Water-soluble derivatives of Top1 – Topotecan (TPT) and Irinotecan (CPT-11) –
have been approved for clinical use by the FDA and are among the most effective
compounds tested for treating human cancer (72). These CPT analogs are pentacyclic
structures with a lactone (closed ring) moiety in the E-ring. The lactone ring undergoes
reversible, pH–dependant hydroysis to the hydroxy acid (open ring) and although the
hydroxy acid form predominates at physiological pH, the lactone is the
pharmacologically active form (73). TPT is a 10-hydroxyl modification of CPT and is
approved for treatment of metastatic ovarian and small cell lung cancer, as well as
myeloid malignancies. CPT-11 is a prodrug, which is converted to the active compound
SN-38 by plasma and cellular carboxylesterases. It is approved for use in treatment of
metastatic colon and rectal carcinoma (74).
Camptothecin and its derivatives reversibly bind to the transient covalent Top1DNA intermediate, intercalating between the two bases of the cleaved strand and
blocking the religation step. Although they are generally referred to as Top1 inhibitors,
these compounds convert Top1 into a cellular poison by preventing religation of the
cleaved strand and thereby inhibiting the dissociation of the protein from DNA. These
Top1-DNA linked complexes are ubiquitous throughout the genome due to the enzymes’
normal activity, but because religation is faster than cleavage these cleavage complexes
are transient and difficult to detect. Therefore, by preventing religation, CPT increases
the lifetime of this covalent intermediate (57, 67, 75). Other DNA modifications such as
single nucleotide gaps, base mismatches, guanine methylation or oxidative damage also
lead to persistent Top1- DNA covalent complexes (76-78) These protein-linked DNA
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lesions themselves are insufficient for cell killing, however, in the presence of advancing
replication forks, they are converted to irreversible cytotoxic DNA lesions (2). This is in
agreement with the observation that, even though CPT can stabilize the ternary complex
in all stages of the cell cylce, its cytotoxic effect requires ongoing DNA replication (79).
Cytotoxicity is suppressed when replication is inhibited with aphidicholin in both
mammalian and yeast cells (80-82). Moreover, in vitro replication studies suggest that the
replication machinery has a key role in the conversion of the Top1-DNA lesion to
irreversible cytotoxic DNA damage (83). Analysis of the abnormal replication
intermediates in the SV40 cell-free replication system suggested that that collision
between the replication fork and the stabilized complex generates biochemically
distinguishable events. Namely, formation of a double strand break, irreversible arrest of
fork movement and formation of irreversible Top1-DNA covalent adducts. The structure
of these intermediates depends on the relative orientation of covalently–linked protein
and the advancing replication fork. For these events to occur, Top1 has to be covalently
linked to the strand that is used as the template for leading strand DNA synthesis. This
was supported by in vivo studies analyzing replication intermediates from tissue culture
cells treated with CPT (84).

1.3.2. Camptothecin resistance
Resistance to topoisomerase I inhibitors results form various mechanisms
including decrease in total cellular Top1 activity, structural mutation of Top1 and altered
cellular accumulation of the drug (73). Despite the fact that submicromolar
concentrations are necessary to destroy proliferating neoplastic cells, the clinical the
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response rate in adults is only 30%, with effects being transient and resistance occurring
frequently (85-87). More recent data from pediatric clinical trials, based on a protracted
schedule that was developed in xenografts, showed a response rate of up to 60%. As CPT
is an S-phase poison, the pediatric studies emphasized the importance of scheduling of
dosage and systemic exposure for the effectiveness of CPT and its analogs (88).
Both active and passive transport have been implicated in the intestinal uptake
and efflux of CPT (89). A human ovarian cancer cell line IGROV1 was treated with
topotecan and selected for resistance to the drug. It was found that the resistance was
caused by an increased efflux of topotecan through the overexpression of the ABC
transporter family member, ABCG2 (BCRP) (90). Moreover, mice lacking a functional
ABCG2 have an increased oral bioavailability of topotecan and also patients treated with
topotecan and GF120918, a known inhibitor of ABCG2, demonstrated an increase in
drug bioavailability from 40% to 97% (91). In yeast, the transcription factor, PDR1,
regulates the expression of various gene products including the ATP-binding cassette
transmembrane transport proteins PDR5, YOR1 and SNQ2. A dominant mutation in
PDR1 was found in a screen for mutants that resulted in CPT resistance. While the PDR1
T879M mutation seems to increase the transcription of its downstream effectors, deletion
of PDR1 or its downstream target SNQ2, increase CPT sensitivity, emphasizing the role
of the pleiotropic drug resistance network in CPT toxicity. (92).
Cellular metabolism has a significant effect on the conversion of the prodrug
Irinotecan (CPT-11) to its active form SN-38. Carboxylesterases are responsible for this
conversion and an increase in the protein levels of these enzymes correlate with increased
cellular sensitivity to CPT-11 (93).
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Top1 point mutations impacting the efficacy of CPT have been identified in both
CPT-resistant tumor cell lines and yeast cells. As of yet, there has only been one report of
a clinical sample that contained a mutation in TOP1. A patient with non-small cell lung
cancer was preoperatively treated with Irinotecan (CPT-11) and cisplatin, but did not
respond to the chemotherapy. It was found that there was a missense mutation in TOP1
that resulted in a stop codon at position 736 and in case of a read through also had a
glycine to serine substitution at position 737 (94).
Mutations in the highly conserved region preceding the active site Tyr cause CPT
resistance through different mechanisms (95). For the top vac mutant enzyme, residues
Ile725 and Asn726 in yeast Top1 were mutated to Arg and Ala, respectively, to match the
corresponding residues of the vaccinia virus Top1. Even though the specific activity was
comparable to wild-type Top1, the mutants were resistant to CPT in vivo, indicating that
resistance is caused by either a decrease in drug binding or the formation of the ternary
complex. Similar results were found by mutating the corresponding residues in human
Top1. Another resistance mechanism was uncovered with the yeast top1N726L mutant. It
resulted in a decrease in catalytic activity (95). A screen that identified intragenic
suppressors of the toxicity caused by the Top1T722A mutant, a CPT mimetic, also found
that all suppressors identified abolished catalytic activity. Biochemical analyses of some
of these mutants suggest that this was mediated by a reduction in affinity for DNA (96).
This mechanism of resistance is further supported by fact that several mammalian CPTresistant cell lines have been reported to have a reduction in Top1 catalytic activity (69,
97, 98).
Six mutations generating a CPT resistant phenotype (Phe361, Gly363, Arg364,
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Glu418, Gly503 and Asp533) have been mapped to the “lips” region of human Top1. The
lips are two loops that connect the cap with bottom lobe of the protein. Of these six
mutations, only one has a direct protein-drug interaction namely, Asp533 in human Top1
(85). The crystal structure of the Top1-DNA-TPT ternary complex does not reveal the
mechanism of resistance for the other mutations in this region, but it has been proposed
that some of these residues might assist in forming a pocket for drug binding. This
structure also shows that the Asn, adjacent to the catalytic Tyr, forms a water-mediated
hydrogen bond with the drug (85), elucidating the mechanism underlying the resistance
of the yeast top1N726S and the related human top1N722S mutant (99).
Reconstituted Top1 enzymes, either with or without the linker domain, are
resistant to CPT in plasmid relaxation assays, suggesting that a functional linker is
necessary for optimal CPT sensitivity (61). This was also demonstrated by a mutant Top1
enzyme that contained an Ala653 to Pro substitution located in the region of the linker
domain that extends away from the core (62). Molecular dynamic analysis of this mutant
protein displayed an alteration in the flexibility of this domain and in vivo studies showed
that the cells were resistant to CPT (62). Both the reconstituted enzymes and linker
domain mutant had an increased rate of religation, presumably decreasing the period for
drug binding.
Interaction of Top1 with its protein partners may also dictate cellular sensitivity to
CPT. The Top1-binding protein, nucleolin, recruits Top1 to the nucleolus (33) and
deletion of the yeast nucleolin orthologue, NSR1, is associated with relocalization of
Top1 from the nucleolus to a more diffuse nuclear distribution. These cells are also
resistant to CPT. Top1 is known to move rapidly from the nucleolus to the nucleus after
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cellular exposure to CPT. Therefore, the loss of nucleolar localization may result in a
decrease in the overall amount of Top1 associated with DNA and thus reduces the effect
of CPT (100).

1.4. REPAIR OF TOP1-MEDIATED DNA DAMAGE
The normally transient Top1 covalent complexes can be converted into
irreversible damage through various mechanisms. For example, when Top1 cleaves at or
near a variety of DNA lesions, such as uracil mismatches, nicks, gaps or base damage
caused by oxidative stress (101, 102), or the cleavage/religation equilibrium is skewed
towards cleavage, there is an increase in stabilization of covalent complexes. Alteration
in the equilibrium can be accomplished by either mutations in Top1 that increase the rate
of cleavage (Top1N726H) or decrease in the rate of religation (Top1T722A) (103) or by
blocking religation by intercalation of drugs such as CPT. These lesions are toxic to
actively replicating cells by a mechanism that involves collision of replication forks with
the covalent complexes or as more recent data suggest, the accumulation of positive
supercoils in front of the replication fork. Single molecule experiments demonstrated that
CPT preferentially prevents the unwinding of positive supercoils which leads to the
positive supercoil accumulation (104).
When the replication fork collides with the stabilized covalent complex, the
extension of the leading strand is blocked at the 5’-end of the cleaved DNA template
resulting in stalling of the replication fork and generation of single and double strand
DNA breaks. These collisions trigger S-phase-specific cell death and cell cycle arrest in
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the G2-phase (84, 105). Studies in yeast and mammalian cells have implicated various
biological pathways in the repair of these Top1-DNA lesions.
Treatment of human colon carcinoma cells (HCT116) with CPT induces
phosphorylation of H2AX (phosphorylated form is called γH2AX), an early event in the
repair cascade of DNA double strand breaks. The phosphorylation is Top1 dependent as
Top1-deleted mouse leukemia cells failed to induce γH2AX. H2AX knockout cells are
also hypersensitive to CPT indicating the phosphorylation of H2AX is important for
repair of Top1-mediated damage (106). A role for DNA double strand break repair
pathway is also supported by the observation that yeast cells deleted for proteins involved
in homologous recombination (main pathway for repair of DNA double strand breaks in
yeast), such as Rad50, Rad51, Rad52 and Sgs1 are hypersensitive to CPT (55, 66, 107109).
Little is known about the processes that regulate the cellular responses to Top1induced DNA lesions. In yeast the Mec1 and Rad53 checkpoints modulate cell sensitivity
to CPT, consistent with studies in mammalian cells demonstrating the activation of the Sphase checkpoints, ATR/CHK1, in response to CPT treatment (110-112). Checkpoint
activation prevents cells from entering mitosis with damaged DNA and provides
additional time for DNA repair. Yeast cells deleted for Rad9, a DNA damage checkpoint
protein that induces G2 arrest, also show enhanced CPT sensitivity (113).
For repair of Top1-DNA lesions, the protein must be removed, DNA breaks
repaired and the replication fork restarted. The highly conserved protein Tyrosyl DNA
phosphodiesterase (Tdp1) has been implicated in the repair of these covalent complexes
as it has the ability to hydrolyze the 3’-phosphodiester bond between the catalytic
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tyrosine of Top1 and the 3’-end of the DNA. The removal of Top1 generates a 3’phosphate that is further processed by a 3’-phosphatase (114). Yeast cells devoid of Tdp1
are not hypersensitive to CPT, but when this deletion is combined with a deletion of
RAD9 (DNA damage checkpoint protein) there is a 10-fold increase in the cytotoxicity of
CPT, indicating that Tdp1 has a role in the repair of Top1-induced damage, but also that
there are Tdp1-independent repair pathways for these lesions (114). A mutation in the
human TDP1 gene, substitution of His493 for Arg located in the catalytic pocket, results in
the hereditary neurological disease, spinocerebellar ataxia with axonal neuropathy
(SCAN1). Cells derived from SCAN1 patients have reduced Tdp1 activity and are
hypersensitive to CPT. Because hypersensitivity of these cells to CPT is not affected by
the polymerase inhibitor, aphidicholin, it is postulated that Tdp1 is involved in the repair
of Top1-induced lesions associated with transcription rather than replication (115).
Top1 can also be removed by the 3’-flap endonuclease complexes: XPF/ERCC1,
Mre11/Rad50/Nbs1 and Mus81/Eme1.Their yeast orthologs are Rad1/Rad10,
Mre11/Rad50/Xrs2 and Mus81/Mms4, respectively. Rad1/Rad10 and Tdp1 function in
redundant pathways, while Mus81/Mms4 act in parallel (116, 117). The importance of
Mus81 in repair of Top1-induced damage is highlighted by the fact that Mus81-deficient
yeast cells are dramatically more sensitive to CPT (118). This protein has been shown to
be involved in the processing of stalled and collapsed replication forks (119).
To determine events downstream of the ternary Top1-DNA-CPT complex, a
genetic screen was performed to identify essential yeast genes that normally function to
suppress cell sensitivity to CPT. As the pleiotropic drug resistance network affects yeast
cell sensitivity to CPT, a Top1 mutant (Top1T722A) was used as the DNA damaging
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agent. This mutant mimics the action of CPT by decreasing the rate of enzyme-catalyzed
religation and therefore overexpression of Top1T722A induces cell death. The screen
identified several mutants with defects in replication, amongst them Cdc45 and Dpb11.
Dpb11 suppresses mutations in Pol ε and possibly associates with the Pol ε complex.
This protein and its human homolog, TopBP, have also been shown to be components of
the S-phase checkpoint. Cdc45 acts as a processivity factor for the replication helicase, is
essential for the initiation of replication and is recruited to replication origins in an Sphase cyclin-Cdk-dependent manner (120). Both, Cdc45 and Dpb11 induce transient
accumulation of Okazaki-sized fragments and enhance sensitivity to Top1 induced DNA
damage, linking these processive DNA replication with cellular resistance (112).

1.5. TOP1 LOCALIZATION
Top1 is constitutively expressed throughout the cell cycle (121) and it is localized
to the nucleus, being enriched in the nucleolus (122). Human Top1 has five nuclear
localization signals (NLS) in its N-terminal domain, two of which seem to be mainly
responsible for localization (28, 29, 123). The N-terminal domain anchors Top1 at
distinct locations within nucleolus, concentrated in substructures identified as fibrillar
centers. These nucleolar structures contain rDNA and a cluster of proteins termed the
RNA Polymerse I holo-enzyme (124, 125). It is also the location of rDNA transcription
(126). Top1 has been shown to co-localize (127) and co-purify with RNA Polymerase I
(128) suggesting that it is part of this holo-enzyme. It was further demonstrated in S.
cerevisiae that Top1 mutants exhibit an increase in rDNA recombination supporting a
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role for Top1 in maintaining integrity of the rDNA locus (129). The Top1 N-terminus
mediates its interaction with the RNA Polymerase 1 holoenzyme at the fibrillar centers
(20), as deletion of a portion of the N-terminus leads to the distribution of Top1 in the
nucleolus in an amorphous and unstructured manner (127). Furthermore, studies from
Drosophila melanogaster demonstrated that the N-terminus of Top1 targets it to
transcriptionally active chromatin domains by interacting with transcription protein
complexes (33, 130).
Rapid and reversible relocalization of Top1 to the non-nucleolar portion of the
nucleus occurs after inhibition of RNA synthesis. This relocalization does not affect Top1
content or activity, and after the RNA synthesis inhibitor is removed, there is reversal of
Top1 relocalization. This reversal occurs even in the presence of protein synthesis
inhibitors, such as cyclohexamide (131). Top1 mobility is further revealed by FRAP
(Fluorescence Recovery After Photobleaching) kinetics of GFP-tagged Top1. Even
though the addition of a large polypeptide such as GFP can alter protein mobility, these
experiments demonstrated that Top1 is fully mobile and continuously fluxes between
nucleoli and the nucleoplasm, but with a slower mobility in the nucleoli. The catalytically
inactive mutant, Top1Y723F has the same mobility in both compartments and is therefore
evenly distributed throughout the nucleus (127).
Top1 is also lost from the fibrillar centers in response to treatment of cells with
CPT. In reponse to this drug, Top1 rapidly relocalizes from the nucleolus to the
nucleoplasm (93, 131). FRAP kinetics demonstrated that in response to CPT, the enzyme
moves more slowly in the nucleoplasm than in the nucleoli. Therefore, it accumulates in

32

the nucleoplasm and delocalizes from the nucleoli, although it is still freely exchanging
between the two compartments (132).
Even though both CPT and Actinomycin D (RNA synthesis inhibitor) cause
relocalization of Top1 away from the fibrillar centers, two separarate mechanisms appear
to be involved. The localization response of Top1 to RNA synthesis inhibitors depends
on the co-localization of the enzyme with the RNA Polymerase I complex, while the
response to CPT requires catalytic activity (122).
Another nucleolar localized protein – nucleolin – interacts directly with the Nterminus of human Top1 and has been implicated in recruitment of Top1 to the nucleolus.
Region 166-210 of human Top1 is sufficient for this binding (33). Loss of the NSR1
(nucleolin homolog in S.cerevisiae) caused a more diffused distribution of Top1
throughout the nucleus, underscoring the possible role for Nsr1 in concentrating Top1 in
the nucleolar compartment (100). Contradictory results were found with imaging live
HEK293 (human embryonic kidney) cells. Nucleolin did not co-localize with Top1 at the
subnucleolar level. Moreover, a mutant lacking most of the N-terminal domain, but
retaining the nucleolin binding site, does not show the distinct accumulation at the
fibrillar centers as that was characteristic of the native protein (127). It was further found
that the nucleolin binding region is neither sufficient nor necessary for nuclear and
nucleolar localization (133).
CPT treatment also stimulates rapid modification of Top1 with small ubiquitinlike modifiers (SUMO) in response to high concentration of CPT and this modification
correlates with nucleolar delocalization (134). In HELA cells, mutations in SUMO sites:
K103R, K117R and K153R, enhances nucleolar accumulation of Top1 and abolishes
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nucleolar clearance in response to CPT (135). Although this suggested that the transport
between nucleoli and nucleoplasm is triggered by attachment of SUMO, the results were
challenged by more recent data obtained through life cell imaging of human embryonic
kidney cells (HEK293) showing that silencing of the major SUMO sites does not affect
relocalization after CPT treatment (122). Moreover, cells treated with self-poisoning
Top1 mutant- Top1T722A demonstrated no alteration in Top1 sumoylation relative to the
wild-type enzyme (136). Due to contradictory results, it is not well understood what the
role of sumoylation in Top1 localization is.

1.6. TOP1 INTERACTORS
Human Top1 has been shown to interact with the transcription initiation and
elongation machinery, TATA Binding Protein (TBP), p53, nucleolin, SV40 large T
antigen, RING finger/RS rich protein named topors, which function as a SUMO/Ub dual
E3 ligase, and the spliceosomal protein, SF2/ASF. All of these interactions occur through
the N-terminal Top1 domain, and only the binding motifs for nucleolin and SF2/ASF
have been defined (34, 100, 127, 133, 137).
Top1 is detected along transcriptonally active genes in Drosophila (138), colocalizes with the RNA Polymerase I (RPI) holoenzyme in immunohistochemical assays
and co-purifies with RPI during biochemical purification of this enzyme (128, 139)
indicating that Top1 has a role in rDNA transcription. These studies support earlier work
in both budding and fission yeast demonstrating that rDNA transcription (highly
transcribed region of the genome) is decreased in a top1Δ strain (140).
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1.7. POST-TRANSLATIONAL MODIFICATIONS OF TOP1
Serine phosphorylation of Top1 from various organisms has been shown to
increase the relaxation activity of this protein. Novikoff hepatoma cells are rapidly
growing tumorigenic cells and Top1 isolated from these cells was phosphorylated (141).
When treating extracts of Novikoff hepatoma cells with alkaline phosphatase, Top1
relaxation activity was reduced, while phosphorylation of the dephosphorylated protein
with Type II Casein Kinase increased enzymatic activity (142, 143). Similar results were
found with purified Top1 from Xenopus laevis (144), Chinese hamster (DC3F/9-OHE)
and mouse leukemia cells (L1210) (145), where alkaline phosphatase completely
abolished activity, but activity was regained after phosphorylation with Casein kinase II.
Phosphoamino acid analysis showed that only serine residues are phosphorylated (144).
In vitro phosphorylation generated three phopho-peptides, with one of these
corresponding to the in vivo phosphorylation site found in Novikoff cells (141). In
contrast to the increase in Top1 activity caused by serine activity phosphorylation, in
vitro tyrosine phosphorylation of Top1 isolated from calf thymus decreased relaxation
activity (146), suggesting that alteration in post-translational modifications (such a
phosphorylation) is a possible mechanism for regulating Top1 activity.
Purified Top1 from calf thymus is poly (Adenosine-DiPhosphoribosylated) and
enzymatic activity is concomitantly reduced (147, 148). Moreover, in vitro poly (ADPribosylation) also decreased the relaxation activity of Top1 (149). The possible role for
this modification in repair of Top1-induced DNA damage is demonstrated by the fact that
cell lines that are deficient in poly (ADP-ribosylation) are hypersensitive to CPT. This
response is not solely for CPT induced damage, as the Top1-p53 molecular complex are
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poly (ADP-ribosylated) in response to irradiation (150), suggesting that this modification
might play a more general role in the DNA damage response.
SUMO (Small ubiquitin-related modifiers) peptides are covalently attached to
lysine residues located in a SUMO consensus sequence ψKXE, where ψ is a large
hydrophobic residue and X is any amino acid. Human Top1 has been shown to be
sumoylated in reponse to high concentrations of CPT and it was suggested that this
modification regulate Top1 localization between the nucleus and nucleolus (151).
However, more recent evidence demonstrated that sumoylation of Top1 does not affect
CPT-induced relocalization of the protein (122). Moreover, two independent yeast
genetic screens to identify conditional hypersensitive mutants identified a mutation in the
gene encoding the SUMO E2 conjugating protein, Ubc9 (136). When Pro123 was
substituted for Leu (ubc9-10), it caused a global decrease in sumoylation and enhanced
cell sensitivity to CPT at the non-permissive temperature. In contrast, when Top1 SUMO
consensus sites were altered, it did not recapitulate the sensitivity seen with the Ubc9
mutant, indicating that sumoylation of Top1 is not essential in protecting cells against
CPT (136).

1.8. STUDYING CPT SENSITIVITY IN YEAST
The remarkable conservation of basic cell cycle machinery in combination with
the multitude of genetic tools available, make the budding yeast, Saccharomyces
cerevisiae, invaluable for studies of molecular pharmacology and cancer therapeutics
(152). This unicellular organism was the first eukaryote for which the complete genome
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sequence was reported. The sequencing data revealed that the 12,068 kilobases of its
haploid genome, packaged into 16 well-characterized chromosomes, defines 5885
potential protein coding genes (152, 153).
What makes this organism such a great model organism is its tractable genetics.
Modifications such as gene disruption, gene marking, mutation or gene dosage effects, all
of which are difficult to generate in higher eukaryotes, are relatively easy to create in
yeast (152) . Therefore, with its well-defined genome and its facile genetics, budding
yeast has become the organism of choice for genomic technology. This includes genome
wide screens to elucidate cellular responses to various DNA damaging agents, such as
CPT (120, 152) and ionizing radiation (154), determining protein-protein interaction
through two-hybrid technology and high throughput screening to identify chemical
inhibitors of heterologous proteins expressed in yeast (155).
Budding yeast has been invaluable in determining the catalytic mechanism and in
vivo function of DNA topoisomerases (152). More specifically, using this system, Top1
was shown to be the sole target of the anticancer drugs camptothecin and indolocarbazole
(57, 156) and it was further utilized to reveal cellular factors that modulate cell sensitivity
to CPT and define mutations in Top1 that alters catalytic activity and confers drug
resistance (26).
There are many advantages in using this single-celled organism for the study of
DNA topoisomerase I. Unlike mammalian Top1, yeast Top1 is not essential and can be
deleted without significant consequences. Therefore, top1 alleles can be introduced and
drug sensitivity and viability assayed without the presence of the wild-type enzyme. As
homologous recombination is the major repair pathway in yeast, this characteristic can be
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utilized for the integration of DNA sequences into the genome. A single gene product can
be manipulated in the context of an isogenic cell system and construction of such
isogenic yeast strains are vital to establish the consequences of specific genetic alterations
(26, 152).
Making use of this extraordinary model organism, we identified the first single
residue in Top1 (Gly721 in yeast and Gly717 in human) that, when sunstituted for amino
acids with a higher propensity to form α-helices, increases CPT sensitivity. These
substitutions include Asp, Asn, Glu, Gln, Leu and Ala. Using biochemical assays to
uncouple the various steps in catalysis, we determined the mechanism for the increase in
CPT sensitivity. As the altered residue is in a unique position to affect flexibility of the
linker domain, and this domain of yeast and human Top1 differ in both length and amino
acid sequence, but is believed to be structurally conserved, we determined what role the
Gly to Asp substitution might have on the on the distinct linkers by generating chimeric
enzymes. The results from the chimeric proteins and also differences in CPT sensitivities
of the yeast and the human Gly mutants in vivo directed us to investigate potential
binding partners of the linker domain and differences in the binding of these proteins to
the yeast and human linker domains.
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CHAPTER 2: SUBSTITUTION OF CONSERVED RESIDUES
WITHIN THE ACTIVE SITE ALTER THE CLEAVAGE
RELIGATION EQUILIBRIUM OF DNA TOPOISOMERASE I*

2.1. INTRODUCTION
DNA topoisomerases catalyze changes in the linkage of DNA strands, playing
critical roles in DNA replication, transcription, and recombination, as well as
chromosome condensation and segregation (3, 4, 7). Alterations in DNA topology are
catalyzed in reactions characterized by the formation of a covalent enzyme-DNA
intermediate. Eukaryotic DNA topoisomerase I (Top1) is a type IB enzyme that
transiently cleaves a single strand of duplex DNA, while forming a tyrosyl linkage with
the 3’-phosphoryl end of the cleaved DNA (3, 4, 7). Rotation of the non-covalently held
DNA around the nonscissile DNA strand allows for the relaxation of positive or negative
supercoils. In a second transesterification reaction, the 5’-OH nucleophile attacks the
phosphotyrosyl linkage to religate the DNA.
In eukaryotes, the nuclear type IB enzyme, encoded by the TOP1 gene, is highly
conserved in terms of amino acid sequence and catalytic mechanism (3, 4, 7, 26, 157).
The nuclear enzyme is also the cellular target of several antitumor agents, such as
camptothecin (CPT) and indolocarbazole analogs (84, 105, 158).

*William C.Colley, Mariè van der Merwe, John R. Vance, Alex Burgin, Jr., and MaryAnn Bjornsti Journal of Biological Chemistry 279 (52): 54069-54078, 2004 (103).
Adapted by permission of publisher.
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The CPT analogs, Topotecan and SN-38 (the active metabolite of CPT-11), have
shown remarkable antitumor activity against a broad range of pediatric and adult
malignancies (73). These drugs target Top1 by reversibly stabilizing the covalent
enzyme-DNA intermediate. During S-phase of the cell cycle, the collision of advancing
replication forks with the ternary drug·Top1p·DNA complexes produces irreversible
DNA lesions that trigger S-phase checkpoint activation, cell cycle arrest, and cell death
(3, 84, 105, 152, 157). Consistent with this cytotoxic mechanism, cells treated with
aphidicolin to inhibit DNA replication are resistant to CPT (80). In the yeast
Saccharomyces cerevisiae, strains deleted for specific DNA damage and replication
checkpoint genes, such as RAD53, MEC1, TEL1, RAD9, RAD17, RAD24, and TOF1,
exhibit enhanced sensitivity to CPT and other Top1 poisons (62, 113, 154, 159-161).
Moreover, cells defective in processive DNA replication (because of alterations in Cdc45
or Dpb11) (120) or in maintaining replication fork stability (for example in cells deleted
for SGS1) (118) are also hypersensitive to Top1-induced DNA lesions.
Structural determinations of human Topo-70, a 70-kDa C-terminal fragment of
human DNA topoisomerase I, in covalent and noncovalent complexes with duplex DNA,
revealed a circumferential binding of DNA by the Top1 protein clamp (7, 12, 27). Using
molecular modeling to design a reversible disulfide bond across the opposable lip
domains that complete the clamp, we recently demonstrated that DNA rotation is
inhibited within the locked Top1·clamp·DNA complex (41). Thus, some flexibility of
Top1 domains is required for enzyme binding of DNA and the rotation of DNA strands
necessary to effect changes in DNA topology. These studies further demonstrated that
expression of the catalytically inactive Top1Y723F-clamp in yeast cells with elevated
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levels of oxidized glutathione, also sufficed to induce cell lethality independent of
covalent complex formation (41).
More subtle alterations in the DNA cleavage religation equilibrium catalyzed by
Top1 have also been shown to be cytotoxic. For example, the introduction of an abasic
site or a mismatch at the +1 position in the scissile DNA strand enhances the stabilization
of the covalent complex (162). The structural distortions induced by incorporation of
Ara-C at the +1 position of the complementary nonscissile strand also stabilize the
covalent enzyme-DNA intermediate by reducing DNA religation (163). Mutation of
conserved residues N-terminal to the active site tyrosine in the yeast and human enzymes
also induces Top1 poisoning (99, 113, 156, 164). Substitution of Ala for Thr722 in yeast
Top1 (or Thr718 in human Top1) appears to mimic the action of CPT in stabilizing the
covalent complex (113, 164). Based on the lack of detectable alterations in DNA binding
or cleavage, a reduced rate of DNA religation by Top1T722A was inferred (96), similar to
that induced by CPT (59, 75). Recent structures of the binary Topo-70·DNA and ternary
topotecan·Topo-70·DNA complexes indicate the formation of a hydrogen bond between
the hydroxyl of Thr718 and the nonbridging oxygen of the +1 phosphodiester of the DNA
(59). Thus, substitution of Ala at this position may alter the orientation of the 5'-OH
nucleophile and impede DNA religation. A distinct self-poisoning mechanism was
evidenced when Asn726 in yeast Top1 (or Asn722 in human Top1) was mutated to His. In
this case, enhanced stabilization of the covalent enzyme·DNA complex was attributed to
increased rates of DNA cleavage.
Other authors of this study demonstrated that the T722A mutation directly inhibits
Top1-catalyzed DNA religation, while Asn726 substitutions have diverse effects on
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enzyme sensitivity to CPT, Top1 binding to DNA, and enzyme-catalyzed DNA cleavage.
Mutating Asn726 to His, Tyr, or Phe indicates that a phenolic or imidazole side chain
enhanced the kinetics of DNA cleavage by Top1, whereas the CPT resistance of
Top1N726Q suggests the orientation of the amide side chain is critical for effective drug
binding. Further, the combination of the T722A and N726H mutations in a single enzyme
significantly potentiated the cytotoxic activity of the double mutant beyond that induced
by co-expression of the individual mutant enzymes. Biochemical studies indicate that the
independent alterations in DNA cleavage and religation, evident in the double mutant,
each contribute to the lethal phenotype. My contribution to this work was the genetic
studies that support the notion that the self-poisoning enzymes induce distinct cytotoxic
lesions in vivo. These findings suggest that more effective Top1 poisoning may be
achieved with a combination of therapeutics inducing distinct alterations in Top1
catalysis.

2.2. EXPERIMENTAL PROCEDURES

2.2.1. Yeast strains and plasmids
S. cerevisiae strains EKY3 (MATα, ura3-52, his3Δ200, leu2Δ1, trp1Δ63,
top1Δ::TRP1), MBY3 (EKY3, rad52Δ::HIS3), MMY3 (EKY3, rad9Δ::hisG), RRY71
(EKY3, dpb11-10), RRY72 (EKY3, cdc45-10) and RRY92 (EKY3, doa4-10) have been
described (96, 112, 113, 120, 165).
In plasmid YCpScTOP1, TOP1 is expressed from the constitutive TOP1
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promoter, (57). Plasmids YCpGAL1-top1N726H, YCpGAL1-top1N726D,
YCpSctop1T722A, YCpGAL1-eTOP1·L were described (96, 99, 113). Asn726 was
mutated to Phe (top1N726F) with a QuikChange mutagenesis kit (Stratagene, La Jolla,
CA) and oligonucleotide pairs: NFf (5'CACTGGGCACTTCCAAAATCTTTTATATAGACCCTAGAC-3') and NFr (5'GTCTAGGGTCTATATAAAAGATTTTGGAAGTGCCCAGTG-3'). Mutant top1
sequences, excised with Bsu36I and XbaI, were ligated into YCpScTOP1 and
YCpScTOP1·L vectors to yield YCpSctop1N726H, YCpSc1N726D, YCpSctop1N726F, and
a LEU2 marked YcpSctop1·L vector series.
Yeast cells were transformed by treatment with lithium acetate (166). URA3 and
LEU2 plasmid transformants were maintained on synthetic complete media lacking uracil
(SC-uracil) and leucine (SC-leucine), respectively, supplemented with 2% dextrose or 2%
galactose.
In transformation assays, isogenic yeast strains EKY3 (top1Δ), MBY3 (top1Δ,
rad52Δ) and MMY3 (top1Δ, rad9Δ), RRY71 (top1Δ, dpb11-10), RRY72 (top1Δ, cdc4510) and RRY92 (top1Δ, doa4-10) were transformed with URA3 marked vectors
(YCpScTop1, YCpSctop1N726D, YCpSctop1N726H or YCpSctop1T722A) or LEU2
marked vectors (YcpScTOP1·L, YCpSctop1N726D·L, YCpSctop1N726F·L,
YCpSctop1N726H·L, or YCpSctop1T722A·L) and plated onto SC-uracil or SC-leucine,
dextrose plates, respectively. Colony number and size were assessed after 3 days
incubation at 30 °C.
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2.2.2. Yeast cell viability
To determine the viability of top1Δ cells with the TOP1 plasmids in temperature
sensitive strains, exponential cultures of individual transformants were adjusted to an
OD595 of 0.3, serially 10-fold diluted and 5-µl aliquots were spotted onto selective plates.
Cell viability was scored following incubation at 26 and 36 °C.

2.3 RESULTS
Top1 Asn726 Mutants Induce Different Cellular Responses. The distinct
mechanisms of stabilizing Top1·DNA complexes (increased DNA cleavage (N726H),
decreased DNA religation (T722A) and defects in DNA binding (N726D)) raise the
possibility that such alterations in enzyme catalysis may induce different DNA lesions
and cellular responses. Toward this end, we determined if low constitutive expression of
the mutant enzymes was tolerated in repair-proficient, DNA damage checkpoint
competent cells. In contrast to wild-type Top1, high levels of Top1N726H, Top1N726D,
and Top1T722A expression achieved by the GAL1 promoter is sufficient to induce top1Δ
cell death in the absence of CPT (96, 99, 113). However, low constitutive levels of
Top1T722A, expressed from the yeast TOP1 promoter are tolerated in top1Δ cells, which
are otherwise wild type for DNA repair and checkpoint pathways (112, 120). On the
other hand, isogenic top1Δ strains defective in homologous recombination (because of
deletion of RAD52) or the Rad9 DNA damage checkpoint (deletion of RAD9) were
unable to tolerate low levels of DNA damage induced by this top1 mutant (112, 120)
(Fig. 2.1).
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FIG. 2.1. Distinct cellular responses to lesions induced by self-poisoning Top1
enzymes are suggested in cells deleted for the Rad9 DNA damage checkpoint.
Isogenic top1Δ strains, EKY3 (wild-type), MMY3 (rad9Δ), and MBY3 (rad52Δ), were
transformed with YcpScTOP1 vectors, where wild-type Top1 or the self-poisoning
mutants top1N726D (N726D), top1N726H (N726H), and top1T722A (T722A), were
constitutively expressed at low levels from the TOP1 promoter. Following plating on SCuracil, dextrose media, the number and size of colonies formed by the plasmid
transformed cells were determined after 3 days at 30 °C.
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In plasmid transformation assays, cells defective in homologous recombination
(rad52Δ in Fig. 2.1; or rad50Δ, data not shown) were unable to tolerate low levels of
Top1T722A, Top1N726D, or Top1N726H. However, cells deleted for the Rad9 DNA
damage checkpoint exhibited variable sensitivity to the distinct self-poisoning enzymes.
Isogenic rad9Δ cells were inviable in the presence of Top1N726H, exhibited a slow
growth phenotype in the presence of Top1T722A and were unaffected by expression of
Top1N726D. As similar levels of Top1 proteins were expressed in these isogenic top1Δ
strains, the distinct phenotypes were unlikely caused by differences in mutant enzyme
levels. Rather, these results suggest two possibilities: the formation of distinct DNA
lesions that trigger different checkpoint responses or a gradient of Top1·DNA damage in
rank order Top1N726H > Top1T722A > Top1N726D.
To further investigate potential mechanism of Top1 poisoning, an additional
substitution of Asn726 was engineered, and this mutant examined for its effect on cell
viability. Based on the co-crystal structures of human Topo-70 (59, 85), the introduction
of His at position Asn726 might enhance the formation of the phosphotyrosyl linkage by
acting as a general base to accept the proton from the attacking hydroxyl of the active site
tyrosine. Indeed, Top1N726H catalytic activity was unaltered over a wide range of pH
values (data not shown), suggesting that His at this position is not positively charged.
Asn726 was substituted with Phe (N726F) to address issue of potential for stacking
interactions, given the imidazole ring of His.
As depicted in Table 2.1, self-poisoning top1T722A, top1N726D, top1N726H, and
top1N726F mutants, constitutively expressed at low levels from the TOP1 promoter on an
ARS/CEN vector, were used in a transformation assay similar to that described in Fig. 2.1.
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TABLE 2.1. Transformation efficiency of isogenic top1 yeast strains.

TOP
top1N726D
top1N726F
top1N726H
top1T722A

Wild-type
+++
+++
+++
+++
+++

cdc45-10
+++
++
++
+++

dpb11-10
+++
+
+

doa4-10
+++
++
++
++
+++

Isogenic top1 yeast strains (wild-type or tah mutants cdc45–10, dpb11–10 or doa4–10)
were individually transformed with equal amounts of the indicated YCpScTOP1 vector
that constitutively expresses low levels of Top1, Top1N726D, Top1N726F, Top1N726H, or
Top1T722A. Following incubation at 26 °C, the number of transformed colonies was
determined. In replicate experiments, +++ indicates 200–500 large colonies, ++ indicates
100–200 small colonies, + indicates 50–100 small colonies, and (-) refers to less than 10
transformants.
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However, the vectors were transformed into isogenic top1Δ strains harboring
different temperature sensitive tah strains (cdc45-10, dpb11-10, or doa4-10). The tah
mutants were originally isolated in a yeast screen for enhanced sensitivity to the CPT
mimetic, Top1T722A, at the nonpermissive temperature of 36 °C (112, 120). In
comparison to wild-type cells, cdc45-10 and dpb11-10 strains exhibit defects in
processive DNA replication, while doa4-10 cells are defective in ubiquitin-mediated
proteolysis. As previously reported (112, 120, 13, 18), wild-type and tah mutant strains
were readily transformed with the TOP1-expressing vector and the resultant
transformants were viable at 26 and 36 °C. However, the tah mutants (cdc45-10, dpb1110, and doa4-10) were inviable at 36 °C in the presence of low levels of Top1T722A
(Table 2.2 and Refs. (112, 120)). This contrasts with the pattern of tah mutant sensitivity
to the Asn726 mutants (Tables. 2.1 and 2.2). dpb11-10 cells were unable to tolerate
Top1N726D or Top1N726F at any temperature, as no transformants were obtained (Fig.
2.2). With cdc45-10 cells, top1N726F transformants were viable at 26 °C; however,
subsequent plating at 36 °C demonstrated a conditional lethal phenotype (Fig. 2.3). Since
the cdc45-10 and dpb11-10 mutants exhibit a synthetic lethal interaction at 36 °C in the
absence of Top1 poisons (112, 120), a similar pattern of enhanced sensitivity to the selfpoisoning N726D, N726F, and N726H mutants was not surprising. However, the
temperature-sensitive lethality of doa4-10 cells expressing Top1N726D or Top1T722A
contrasts with the relative resistance to TopN726F and Top1N726H. When considered with
the transformation assay of Fig. 2.1, these data support a model of distinct DNA lesions
induced by top1N726D and topN726H mutants and further indicate that different genetic
backgrounds may be used to distinguish the cytotoxic action of distinct Top1 poisons.
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TABLE. 2.2. Growth at non-permissive temperature (36 °C).

TOP
top1N726D
top1N726F
top1N726H
top1T722A

Wild-type
+++
+++
+++
+++
+++

cdc45-10
+++
-

dpb11-10
+++
-

doa4-10
+++
++
++
-

Exponentially growing liquid cultures of individual transformants at 26 °C (Fig 2.1),
were adjusted to an OD595 of 0.3, serially 10-fold diluted and spotted onto SC-leucine
media. Following incubation of duplicate plates at 26 °C and 36 °C, cell growth was
assessed. In shaded boxes, +++ indicates equivalent growth at both temperatures, while
++ indicates 10-fold fewer colonies at 36 °C, relative to the same transformants at 26 °C.
Although viable transformants were obtained at 26 °C, the cultured cells indicated by (-)
failed to form colonies when plated at 36 °C.
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2.4 DISCUSSION
The self-poisoning activity of the Top1 mutant enzymes, Top1N726H and
Top1T722A (99, 113, 156), results from distinct alterations in enzyme-catalyzed DNA
cleavage and religation. Based on the results of suicide substrate assays, the enhanced
stabilization of Top1T722A·DNA covalent complexes could not be attributed to alterations
in DNA binding or rates of DNA cleavage (99). Rather, the data inferred a defect in DNA
religation, similar to that induced by CPT. This model was supported by crystallographic
data indicating the interaction of Thr718 (at the corresponding position in human Top1)
with the nonbridging oxygen of the +1 phosphodiester of the DNA in a covalent complex
formed by a 70-kDa C-terminal fragment of human Top1 and duplex DNA (59, 167).
Substitution of this residue with alanine might alter the optimal alignment of the 5'-OH
nucleophile in the transesterification reaction that restores the integrity of the
phosphodiester backbone.
This work demonstrates that cell sensitivity to low, constitutive levels of distinct
self-poisoning Top1 mutant enzymes varied dramatically in different genetic
backgrounds. For example, cells deleted for the Rad9 DNA damage checkpoint were
unable to tolerate low levels of Top1N726H, exhibited a slow growth phenotype in the
presence of Top1T722A and were unaffected by expression of Top1N726D (Fig. 2.1). This
contrasts with isogenic wild-type cells that easily tolerated expression of all three mutant
enzymes. Based on steady state levels of covalent Top1·DNA complexes detected in
DNA cleavage assays (99, 113), these phenotypes may reflect a gradient of increasing
DNA damage induced be these enzymes, with TopN726H being the most potent selfpoisoning enzyme. However, several lines of evidence support an alternative model,
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whereby an increase in Top1-catalyzed DNA cleavage induces DNA lesions, some of
which are intrinsically distinct from those induced by a decrease in Top1-catalyzed DNA
religation.
First, the rate of cell killing induced by Top1T722A or Top1N726H expression in
top1Δ cells was almost identical. (Data not shown) If Top1N726H were a more potent
poison than Top1T722A, the kinetics of cell death would be faster. Second, as shown in
Figs. 2.2 and 2.3, variable patterns of mutant Top1p cytotoxicity were observed in a panel
of isogenic tah mutant strains, originally isolated in a genetic screen for enhanced
sensitivity to low levels of Top1T722A at high temperature (112, 120). For example,
cdc45-10 cells, which harbor a temperature sensitive hypomorphic allele of CDC45 (18),
readily tolerate low levels of Top1T722A expression at 26 °C yet had decreased
transformation efficiency with the same vector expressing Top1N726H. cdc45-10 cells
exhibits a transient accumulation of Okazaki fragments upon shift to the nonpermissive
temperature and are defective in processive DNA replication (120). In contrast, isogenic
doa4-10 cells, which are wild-type for CDC45 but contains a nonsense mutation in DOA4
(112), are relatively resistant to Top1N726H and Top1N726F expression even at 36 °C.
Doa4 is a ubiquitin C-terminal hydrolase whose function is required to maintain free
ubiquitin pools (112). Dosage suppression studies suggest that the enhanced sensitivity of
doa4-10 cells to Top1T722A is a consequence of specific alterations in the DNA damage
checkpoint (112). Taken together, these data indicate that select genetic alterations in
otherwise isogenic genetic backgrounds profoundly alter cell sensitivity to the cytotoxic
action of different self-poisoning Top1 mutants. These findings further suggest that
distinct mechanisms of Top1 poisoning, such as the enhanced rate of DNA cleavage by
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Top1N726H or Top1N726F versus the defect in DNA religation evident with Top1T722A or
CPT induce distinct patterns of DNA lesions. In other words, how covalent complexes
form is also an important determinant of cell viability. Whether this relates to the
effective sensing and/or repair of such lesions in different genetic backgrounds has yet to
be determined.
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CHAPTER 3: SUBSTITUTIONS OF GLY721 ALTER YEAST DNA
TOPOISOMERASE I ACTIVE SITE ARCHITECTURE AND
ENZYME SENSITIVITY TO CAMPTOTHECIN

3.1 INTRODUCTION
Eukaryotic DNA topoisomerase 1 (Top1) alters DNA topology by introducing a
transient break in a single strand of the DNA duplex, thereby allowing strand rotation at
the site of DNA scission to relieve superhelical tension (3, 4, 7). The enzyme plays
critical roles in processes such as replication, transcription, recombination and
chromosomal condensation, with a reaction mechanism highly conserved from yeast to
human. The active site tyrosine (Tyr727 in yeast) acts as a nucleophile to cleave a single
DNA strand, forming a covalent phosphotyrosyl linkage between the enzyme and the 3’
end of the DNA. The free 5’ OH end of the scissile strand then rotates about the
uncleaved DNA strand in a manner dictated by torsional strain in the DNA. In a second
transesterification reaction, the nucleophillic attack by the 5’ OH resolves the covalent
Top1-DNA intermediate, and the enzyme is liberated from the religated DNA.
DNA cleavage by Top1 is, at least in part, rate limiting, thus ensuring low steady
state-levels of the covalent enzyme-DNA complex (168). However, increased
concentrations of covalent complexes, either as a consequence of drug action, Top1
mutation, or the formation of DNA adducts, converts Top1 into a cellular poison (84, 99,
101-103, 113, 152, 162, 164, 169-171). The camptothecin (CPT) class of
chemotherapeutics reversibly stabilizes the covalent intermediate by intercalating into the
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protein-linked DNA nick and displacing the 5’ OH end of the DNA to prevent religation
(84, 152, 170). Moreover, recent studies demonstrate that CPT binding preferentially
impedes Top1-catalyzed uncoiling of positively supercoiled DNA (172). Thus, during Sphase, either the ternary CPT-Top1-DNA complex itself, or the positive supercoils that
accumulate between the replication machinery and the ternary complex, present obstacles
to advancing replication forks and trigger the irreversible DNA lesions that induce cell
death. Mutation of conserved residues within the enzyme active site may also alter the
DNA cleavage/religation equilibrium catalyzed by Top1, leading to increased covalent
complex formation and cell death (99, 113, 164). For example, as with CPT treatment of
wild-type Top1, substitution of Ala for Thr722 reduces the rate of enzyme catalyzed
religation, while mutation of Asn726 to His enhances the rate of DNA cleavage (103). The
same substitutions of the corresponding residues in human Top1 also produce “selfpoisoning” enzymes with similar effects on enzyme catalysis (156, 164).
Co-crystal structures of a 70 kDa C-terminal fragment of human Top1 (Topo70)
in noncovalent or covalent complexes with DNA revealed the unusual architecture of the
monomeric enzyme (12, 27, 59). Top1 forms a protein clamp around duplex DNA, where
interaction of opposable “Lip” domains completes the circumscription of the tightly
packed DNA by the protein core. We used molecular modeling to design a reversible
disulfide bond between the lip domains, and demonstrated that locking the clamp
prevents DNA rotation within the covalent Top1-DNA complex (41). Moreover,
expression of a catalytically inactive Top1Y723F-clamp proved toxic in the absence of
DNA cleavage. The Top1 clamp consists of a conserved central core that includes all of
the active site residues necessary for enzyme catalysis, except the active site Tyr723 (12,
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27, 28). A flexible linker physically connects the protein core with the conserved Cterminal active site tyrosine domain. The linker consists of a pair of α-helices, arranged
in an anti-parallel orientation, which extends out from the Top1 clamp and positions the
C-terminal domain for enzyme catalysis. The poorly conserved N-terminal domain is
missing in the Topo70 structures. Although these sequences have been implicated in
DNA binding and in mediating protein-protein interactions, the N-terminus is dispensable
for catalytic activity (3, 31, 37, 39).
Mutation of conserved residues in catalytically active yeast and human Top1
mutants has been reported to confer resistance to CPT [reviewed in (26, 85, 170)]. The
majority of the mutated residues clusters along the Top1p-DNA interface or serve to alter
the conformation of the protein clamp. Quantitative assays of drug binding are currently
lacking; nevertheless, co-crystal structures of the CPT analog topotecan (TPT) bound to
wild-type and mutant Topo70-DNA complexes suggest mutation-induced alterations in
drug binding (59, 85).
In the covalent Topo70-DNA structures, the linker domain extends ~56Å from the
enzyme active site at an oblique angle to the DNA when TPT is bound. In the case of
yeast Top1, residues corresponding to the linker domain are predicted to form a similar
structure that would extend beyond 110Å. In the absence of drug, the structure of these
α-helices in the covalent human Topo70-DNA complex was not resolved. Although
present in Topo70, biochemical, genetic and molecular dynamic simulation data suggest
that the flexibility of the linker in the absence of TPT would preclude structural
determination (59, 61, 62, 173). Indeed, the physical connection and/or flexibility of the
linker contribute to the CPT sensitivity of Top1. For instance, when Topo70 is
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reconstituted from separate polypeptides comprising the Top1 core and the linker/Cterminal domains, the enzyme is catalytically active yet exhibits reduced sensitivity to
CPT (39). Within the N-terminal α-helix of the linker, molecular dynamic simulations
suggest mutation of Ala653 to Pro (A653P) increases the flexibility of this coiled coil
structure, to enhance the rate of DNA religation and Top1 resistance to CPT (62). More
direct evidence for physical interactions between the Top1 linker and active site come
from recent studies where the combination of the A653P mutation with the self-poisoning
T722A mutation suppressed the lethal phenotype of Top1T722A (174). Taken together,
these studies suggest alterations in the kinetics of Top1 catalyzed DNA
cleavage/religation may be induced by changes in linker flexibility or orientation.
This model raises several questions: How are alterations in the physical linkage of
the coiled coil transmitted to the active site to modulate enzyme catalyzed DNA
cleavage/religation? How does this impact CPT binding to the Top1-DNA covalent
complex? Implicit in these considerations is that a dynamic organization of the active site
is either directly or indirectly affected by the orientation or flexibility of the linker
domain. To begin to address these questions, we mutated conserved residues that bridge
the C-terminus of the linker domain and the active site tyrosine domain, and asked what
effect these substitutions had on yeast Top1 catalysis and CPT sensitivity. Our studies
suggest that Gly721 in yeast Top1 constitutes a flexible hinge between the linker domain
and a short α-helix (delineated at the C-terminus by the active site Tyr) that modulates
the geometry of the active site during enzyme catalysis, which directly impacts Top1
sensitivity to CPT.
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3.2. EXPERIMENTAL PROCEDURES

3.2.1. Chemicals, yeast strains and plasmids
Camptothecin purchased from Sigma was dissolved in DMSO and stored at -20
°C. [α- 32P] Cordycepin 5’-triphosphate was purchased from PerkinElmer Life Sciences
(Boston, MA).
Saccharomyces cerevisiae strains EKY3 (MATα, ura3-52, his3Δ200, leu2Δ1,
trp1Δ63, top1Δ::TRP1) and MMY3 (EKY3, rad9Δ::hisG) were described previously
(113, 165). In plasmid YCpGAL1-eTOP1, wild-type Top1 containing an N-terminal Flag
tag was expressed from the galactose–inducible GAL1 promoter on an ARS/CEN, URA3
vector (113). Mutants top1G721D, top1G721F or top1G721V, where residue Gly721 was
mutated to Asp, Phe or Val, respectively, and top1L720Q, where Leu720 was mutated to
Gln, were isolated from a pool of top1 mutants generated by degenerate oligonucleotidedirected mutagenesis of residues flanking the active site Tyr727, as described in (113).
Individual mutant sequences, excised in a Bsu36I-XbaI DNA fragment from YCpGAL1top1 vectors, were ligated into YCpGAL1-eTOP1 to generate YCpGAL1-etop1G721D,
YCpGAL1-etop1G721F, YCpGAL1-etop1G721V and YCpGAL1-etop1L720Q. In plasmid
pTP1-4, Gly721 was mutated to Leu, Asn, Glu, Gln or Ala (top1G721L, top1G721N,
top1G721E, top1G721Q or top1G721A respectively) or Leu720 to Glu (top1L720E) using a
Quickchange mutagenesis kit (Stratagene, La Jolla, CA) and pairs of complementary
oligonucleotides based on the following sequences: GL (5’CTCCCAGGTTTCACTGCTCACTTCCAAAATCAATT-3’); GN (5’CAGGTTTCACTGAACACTTCCAAAATC-3’); GE (5’57

CAGGTTTCACTGGAAACTTCCAAAATC-3’); GQ (5’GAAAACTCCCAGGTTTCACTGCAAACTTCCAAAATCAATTATAT-3’); GA (5’CTCCCAGGTTTCACTGGCCACTTCCAAAATCAATT-3’) and LE (5’AAACTCCCAGGTTTCAGAGGGCACTTCCAAAATC-3’). Mutant sequences were
excised with Bsu36I and Xba1 and ligated into YCpGAL1-eTOP1 to yield YCpGAL1etop1G721L, YCpGAL1-etop1G721N, YCpGAL1-etop1G721E, YCpGAL1-etop1G721Q,
YCpGAL1-etop1G721A and YCpGAL1-etop1L720E. In all cases, mutant sequences were
confirmed by DNA sequencing. For ease of presentation, the e prefix, denoting the Nterminal Flag epitope in all of the constructs used in these studies, is dropped from the
following discussions. Lithium acetate treated yeast cells were transformed with URA3marked plasmids (166) and individual transformants were maintained on synthetic
complete media lacking uracil (SC-uracil) supplemented with 2% dextrose.

3.2.2. Yeast cell sensitivity to CPT
To examine cell sensitivity to CPT, exponential cultures of top1Δ yeast cells
transformed with the indicated YCpGAL1-top1 vector, were adjusted to an A595 = 0.3,
serially 10-fold diluted and aliquots were spotted onto SC-uracil agar plates containing 25
mM HEPES (pH 7.2), 2% dextrose or galactose and the indicated concentration of CPT
in a final 0.125% DMSO. Cell viability was scored following incubation at 30 °C. In
more quantitative assays of cell viability, transformants grown in SC-uracil containing 25
mM HEPES, pH 7.2, (SC-uracil-HEPES) and dextrose, were diluted into SC-uracilHEPES supplemented with 2% raffinose. At an A595 = 0.3, galactose (2% final) was
added to induce Top1 expression, along with 50 µM CPT in a final 0.43% DMSO or
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DMSO alone. At the times indicated, aliquots were serially diluted and plated onto SCuracil, dextrose plates and the number of viable cells forming colonies was determined
following incubation at 30 °C.

3.2.3. DNA topoisomerase I expression, purification and activity assays
Extracts of galactose-induced cultures of EKY3 cells expressing plasmid encoded
wild-type or mutant Top1 proteins were prepared essentially as described (95) except the
glass beads were pre-chilled to -20 ˚C. Purified Top1 preparations were obtained by
successive ammonium sulfate fractionations followed by phosphocellulose
chromatography, as described (95). Top1 protein fractions were adjusted to a final
concentration of 30% glycerol and stored at –20 ˚C.
To assess Top1 integrity and relative concentration, crude extracts, corrected for
total protein concentration using a BioRad protein assay, or purified proteins were
resolved in 4-12% BisTris gels (Invitrogen), transferred onto activated polyvinylidene
difluoride membranes (PerkinElmer Life Sciences), immunostained with the M2-Flag
antibody (Sigma) and visualized by chemiluminescence. In the case of crude extracts,
immunostaining with tubulin antibodies served as a loading control.
DNA topoisomerase I activity was assayed in plasmid DNA relaxation reaction as
described (99, 103). Briefly, serial 10-fold dilutions of Top1 proteins, corrected for
concentration, were incubated at 30 ˚C for 30 minutes with 0.3 µg of negatively
supercoiled plasmid pHC624 DNA in 20 mM Tris (pH 7.5), 10 mM MgCl2, 0.1 mM
EDTA, 50 µg/ml gelatin and KCl concentrations ranging from 50 to 200 mM. Reactions
products were resolved in agarose gels and visualized by ethidium bromide staining.
59

3.2.4. DNA cleavage assays
Wild-type and mutant enzyme sensitivity to CPT was determined in DNA
cleavage assays as described (99, 103). A single 3’ 32P-end-labeled DNA substrate was
incubated with Top1 proteins in 50µl reaction volumes containing Cleavage buffer [20
mM Tris (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA, 50 mM KCl, and 50 µg/ml gelatin]
and the indicated concentration of CPT in a final 4% (v/v) DMSO. After 10 min at 30 °C,
reactions were terminated with 1% SDS at 75 °C, treated with proteinase K, ethanolprecipitated and resolved in 8% polyacrylamide/7 M urea gels. Cleavage products were
visualized with a PhosphorImager.

3.2.5. Suicide cleavage reactions
Oligonucleotide-based assays were used to uncouple Top1 catalyzed DNA
cleavage and religation reactions. To assess the relative rates of DNA cleavage catalyzed
by wild-type and mutant proteins, two substrates were used. First, as described in (103), a
suicide substrate containing a truncated scissile strand with a high affinity cleavage site
(5’-GATCTAAAAGACTT↓GG-3’), where ↓ indicates the phosphodiester bond cleaved
by Top1, was 5’- end-labeled with [γ-32P]ATP and T4 polynucleotide kinase. Equimolar
amounts of the labeled oligonucleotides were annealed to the non-scissile strand (5’GATCTTTTTTAAAAATTTTTCCGTCTTTTAGATC-3’) in annealing buffer [10 mM
Tris (pH 7.8), 100 mM NaCl, 1 mM EDTA] by heating to 90 °C followed by cooling to
room temperature over 3h. The DNA substrate (3 pmol/reaction) was incubated with
equal concentrations of Top1 proteins in Cleavage buffer at room temperature. At the
times indicated, 10 µl aliquots were quenched with 0.5% SDS at 75 °C to terminate the
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reaction. Following ethanol precipitation, the covalently linked protein was hydrolyzed
with trypsin in the presence of 2 M Urea and the labeled substrate and peptide-linked
oligonucleotides were resolved in 16% polyacrylamide/7M Urea gels and visualized
using a Phosphoimager. A second strategy was to monitor the liberation of a 6-mer
downstream of the Top1 cleavage site, as described by Fertala et al. (99). Here, a slightly
longer oligonucleotide containing the Top1 high affinity cleavage site (5’GATCTAAAAGACTT↓GGAAA-3’) was 3’-end-labeled with [32P]cordycepin using
terminal deoxynucleotide transferase. The labeled strand was annealed to equimolar
amounts of same complementary strand described above. The DNA substrate (20
fmoles/reaction) was incubated with equal amounts of protein in Cleavage buffer at room
temperature. At the times indicated, 10 µl aliquots were treated with 0.5% SDS at 75 °C
and the reaction products were resolved in 20% polyacrylamide/7M Urea gels and
visualized with a Phosphoimager.

3.2.6. DNA religation assays
Relative rates of Top1-catalyzed DNA religation were assessed using two
oligonucleotide-based religation assays adapted from Colley et al., (103). In the postannealed religation substrate reactions, the same 5’-end labeled DNA suicide substrate
described above, which contains the DNA scissile strand (5’GATCTAAAAGACTT↓GG-3’), was incubated with equal concentrations of Top1
proteins in Cleavage buffer at room temperature for 15 minutes to generate Top1-DNA
cleavage complexes. Religation was then initiated (time = 0) by the addition of a 10-fold
excess of the religation oligonucleotide (5’-GGAAAAATTTTTAAAAAAGATC-3’).
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Alternatively, in reactions containing the pre-annealed religation substrate, the same
DNA substrate was incubated with a 10-fold excess of the religation strand for 15 min
prior to the addition of Top1 proteins. In both assays, aliquots were processed as
described above for the 5’end labeled suicide cleavage reactions, except that when
indicated, urea was omitted from the trypsin reaction to probe for alterations in active site
architecture.

3.3 RESULTS

3.3.1. Substitution of Gly721 and Leu720 alter Top1 sensitivity to CPT
Within the active site pocket of yeast and human Top1, residues immediately Nterminal to the active site tyrosine are highly conserved (Fig. 3.1.E). Residues spanning
Thr722 to the active site Tyr727 correspond to Thr718 to Tyr723 in human Top1, which form
a short α-helical structure highlighted in yellow in the co-crystal structures of human
Topo70 covalently linked to DNA, either in the presence or absence of Topotecan (Fig.
3.1.A-D) (59, 175). Upon drug binding, however, this helical structure is extended to
include conserved residues Gly717 and Leu716 (Gly721 and Leu720 in yeast Top1). This
rather subtle transition in active site structure coincides with a more dramatic restriction
in linker domain flexibility, such that the linker is now oriented at an oblique angle to the
DNA. Additional studies suggest that linker domain flexibility as well as the physical
linkage of the linker to both the active site C-terminal domain and the protein clamp to
which the C-terminus is abutted are critical determinants of enzyme sensitivity to CPT
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FIG. 3.1. Topotecan binding to the covalent Top1-DNA complex affects enzyme
architecture and alters the geometry of the active site. Structures of the C-terminal 70
kDa of human Top1 (Topo70) covalently linked to duplex DNA in the absence (A) or
presence (C) of topotecan (TPT) [PDB files 1K4S and 1K4T (59)]. B and D, close up
views of active site of Topo70-DNA and Topo70-DNA-TPT, respectively. A ribbon
diagram of the polypeptide backbone spanning residues Thr718 to the active site Tyr723 is
colored yellow. The covalent linkage between the 3’ phosphoryl end of the DNA (green)
and Tyr723 is shown in yellow and red solid bond representation. The base pairs spanning
the Topo70-linked DNA nick are also shown and the conjugated ring structure of TPT is
in magenta. Gly717 (corresponds to Gly721 in yeast Top1p) is in orange and Leu716 in
lavender. A,B, residues spanning the N- and C-terminal ends of the linker are highlighted
in dark purple. C,D, the entire linker domain is shown in dark blue. All figures were
made with PyMol (DeLano Scientific, San Carlos CA). E, Schematic representation of
the domain structures of yeast and human Top1, with residues preceding the active site
tyrosine. Color coding of the protein clamp, linker and C-terminal domains and
conserved Leu and Gly residues correspond to that in C.
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(61, 62). Given the flexibility of Gly residues within a polypeptide chain, and the
structural transitions apparent in the co-crystal structures with drug bound, we propose
that Gly717 (Gly721 in yeast) constitutes a flexible hinge and that alterations in active site
architecture at this junction would affect the orientation and flexibility of the linker
domain. To address this hypothesis, we examined the effects of single amino acid
substitutions of yeast Gly721 and the adjacent residue Leu720. These studies were initiated
in yeast for several reasons: 1) the phenotypes of specific top1 mutants could be assessed
in the absence of wild-type Top1 (in yeast top1∆ strains) (152); 2) any confounding
effects of protein-protein interactions due to the expression of human Top1 in yeast could
be avoided and 3) mutant enzyme activity could be assayed in different genetic
backgrounds in otherwise isogenic strains.
Individual Gly721 and Leu720 substitutions were isolated from a pool of yeast Top1
active site mutants generated by degenerate oligonucleotide mutagenesis. Two
hydrophobic substituents of Gly721, (Val in G721V or Phe in G721F) led us to engineer a
Leu mutation (G721L) to expand the analysis of amino acid shape at this position. In
contrast, the isolation of a Leu720 to Gln (L720Q) mutation, prompted considerations of
charge, so an acidic residue Glu was also engineered at this position (L720E). The effect
of these single amino acid substitutions on cell sensitivity to CPT was assessed in top1∆
cells induced to express the indicated mutant allele from the GAL1 promoter on an
ARS/CEN vector. As seen in Fig 3.2.A, substituting a basic or acidic residue for Leu720
abolished the CPT sensitivity of cells expressing Top1L720Q or Top1L720E, respectively.
These proteins were expressed at slightly higher levels that wild-type Top1; nevertheless,
the specific activity of the two mutant enzymes was reduced by more than 100-fold (Fig.
64

FIG. 3.2. Mutation of Leu720 or Gly721 in yeast Top1 induces CPT resistance in vivo.
A, exponentially growing cultures of top1Δ cells, transformed with the indicated
YCpGAL1-top1constructs, were adjusted to an A595 = 0.3, serially 10-fold diluted, and
aliquots were spotted onto SC-uracil plates containing 25 mM Hepes (pH 7.2), 0.1%
DMSO and either dextrose (Dex), galactose (Gal) or galactose plus 5µg/ml CPT. The
viability of two individual transformants was assessed following incubation at 30 °C. B,
levels of galactose-induced wild-type and mutant Top1 in crude cell extracts were
determined in immunoblots with the M2-Flag antibody. Immunostaining with tubulin
antibodies served as a loading control. C, the specific activity of wild-type and mutant
Top1 enzymes was determined by incubating serial 10-fold dilutions of crude cell
extracts (corrected for protein concentration) in plasmid DNA relaxation assays as
described in Experimental Procedures. After 30 min at 30 °C, the reaction products were
resolved in a 1.2% agarose gel and visualized after ethidium bromide staining. The
relative positions of relaxed (R) and supercoiled (-) DNA topoisomers are indicated. C is
plasmid DNA control.
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3.2.B and C). These data suggest the CPT resistant phenotype of cells expressing the
L720Q or L720E mutant results from a decrease in Top1 activity, rather than specific
alterations in enzyme sensitivity to CPT. Indeed, homologous recombination defective
rad52∆, top1∆ cells expressing Top1L720E were sensitive to 10 fold higher CPT
concentrations than cells expressing wild-type Top1 (data not shown), indicating the
formation of lower levels of CPT-induced Top1L720E-DNA damage.
By contrast, substitution of hydrophobic residues for Gly721 had distinct effects on
enzyme activity and cell sensitivity to CPT. The G721L mutation has no obvious affect on
CPT-induced toxicity, while cells expressing Top1G721Vp or Top1G721Fp were CPT
resistant (Fig. 3.2.A). All three mutant enzymes were expressed at levels comparable to
wild-type Top1 (Fig. 3.2.B). The specific activity of Top1G721L was comparable to wildtype Top1, and the G721V and G721F mutants were slightly (~5-fold) less active in
plasmid DNA relaxation assays (Fig. 3.2.C). However, expression of these mutants in a
Rad9 DNA damage checkpoint defective (rad9∆) strain revealed that the G721L mutant
actually enhanced cell sensitivity to CPT, relative to cells expressing wild-type Top1 or
the G721V and G721F mutants (Fig. 3.3.A).
The side chain of Val is branched at the β carbon, while the γ carbon branch of
Leu is more distal to the polypeptide backbone. We then made additional substitutions of
Gly721, including Asp and Asn (G721D and G721N, respectively), to probe differences in
charge independent of side chain geometry, and Glu and Gln (G721E and G721Q,
respectively), wherein the acidic and basic side chains are extended by a γ-δ carbon bond.
As seen in Figs. 3.3.A and 3.4, substituting the acidic residues for Gly721 increased cell
sensitivity to CPT by more than a factor of ten. However, as with the G721L mutant, a
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FIG. 3.3. Substitution of Gly721 with residues containing γ-carbon branched side
chains enhance cell sensitivity to CPT. A, as in Fig. 3.2, exponential cultures of
isogenic top1Δ strains (wild-type for RAD9 or rad9Δ), transformed with the indicated
YCpGAL1-top1constructs, serially diluted and spotted onto SC-uracil plates containing
25 mM Hepes (pH 7.2), 0.1% DMSO, galactose and the indicated concentration of CPT.
The viability of independent transformants was assessed following incubation. B, the
specific activity of equal concentrations of purified Top1 and Gly721 mutant enzymes was
assessed in plasmid DNA relaxation assays as described in Experimental procedures and
Fig. 3.2 legend. The relative positions of relaxed (R) and supercoiled (-) DNA
topoisomers are indicated.
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FIG. 3.4. Expression of Top1G721D and Top1G721E increases the cytotoxicity of
CPT. At t=0, exponential cultures were treated with galactose, to induce expression of
plasmid-encoded Top1, Top1G721D or Top1G721E, 0.43% DMSO and, as indicated, 50
µM CPT. At the times indicated, aliquots were serially diluted and plated onto SC-uracil
media containing dextrose. The number of viable cells forming colonies was assessed
after 30 °C for 3 days and plotted relative to the number obtained at t=0. Results are an
average of three independent experiments.
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significant increase in cell sensitivity to CPT as a result of G721N or G721Q mutant
expression was only evident in checkpoint deficient strains, such as rad9∆ or rad53∆
cells (Fig. 3.3.A and data not shown).
We previously described active site mutations, such as T722A and N726H, which
enhance Top1 sensitivity to CPT in vitro (99, 113). However, these mutant enzymes
induced cell lethality in the absence of CPT and exhibited other alterations in enzyme
catalysis. In contrast, the Gly721 mutants that enhanced cell sensitivity to CPT, failed to
induce growth defects in the absence of drug. In addition, as shown for Top1G721L (Fig.
3.2.B and C), there were no detectable differences in the levels of wild-type and mutant
Top1 proteins in galactose-induced cells and the specific activities of the purified G721D,
G721E, G721N and G721Q mutant proteins were indistinguishable from that of wild-type
Top1 (Fig. 3.3.B).

3.3.2. Gly721 mutations increase Top1 sensitivity to CPT in vitro
We next asked if the increased CPT sensitivity of cells expressing the G721D,
G721E or G721N mutants was a direct effect of increased CPT-Top1-DNA covalent
complexes. First, the specific activity of these mutant enzymes exhibited the same salt
optimum as wild-type Top1; similar patterns of activity and DNA topoisomer
distributions were observed for G721D, G721E and G721N mutant enzymes (Fig. 3.5.A and
data not shown). Equal concentrations of the proteins were then incubated with a 32Psingle end-labeled DNA and increasing concentrations of CPT, to assess the intrinsic
CPT sensitivity of each mutant enzyme relative to wild-type Top1. In such DNA
cleavage assays (Fig. 3.5.B), all three mutants exhibited higher levels of drug-stabilized
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FIG. 3.5. Top1G721D, Top1G721E and Top1G721N exhibit increased levels of covalent
complexes in the presence of CPT. A, equal concentrations of Top1 and Top1G721D
were serially 10-fold diluted and incubated in a plasmid DNA relaxation assay containing
the indicated concentration of KCl. After 30 min at 30 °C, the reaction products resolved
by agarose gel electrophoresis and visualized with ethidium bromide. The relative
positions of relaxed (R) and supercoiled (-) DNA topoisomers are indicated. B, equal
concentrations of Top1 and mutant proteins were incubated with a single 3’ 32P-end
labeled DNA substrate in a DNA cleavage reaction containing the indicated amount of
CPT. After incubation for 10 min at 30 °C, covalent complexes were trapped with SDS at
75 °C and treated with proteinase K. The reaction products were resolved in 8%
polyacrylamide/7M urea gels and visualized using a PhosphoImager. C is DNA alone and
the asterisk (*) indicates a high affinity Top1p cleavage site.
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Top1-DNA covalent complexes than that observed with wild-type Top1: the acidic
substituent Glu (G721E)conferred high levels of DNA cleavage across a wide range of
CPT concentrations, while mutation to Asp (G721D) enhanced DNA cleavage to the
greatest extent at higher drug concentrations. Indeed, these findings are consistent with
the enhanced CPT sensitivity of cells expressing the G721D and G721E mutants (Figs. 3.3
and 3.4). Increased levels of covalent complexes were also evident with the G721N
mutant, but not at lower drug concentrations (as with G721E) or to the same extent as
G721D at higher concentrations. Together, these data suggest that the increased CPT
sensitivity of cells expressing these mutants can be attributed to mutation-induced
increases in drug poisoning of Top1.

3.3.3. Replacing Gly721 with acidic residues affect Top1 cleavage of DNA and
enzyme architecture in the region preceding the active site Tyr
Top1G721D and Top1G721E did not exhibit altered steady state levels of Top1DNA covalent complexes in the absence of CPT, or specific enzyme activity in plasmid
DNA relaxation assays, yet exhibited increased CPT sensitivity in vivo and in vitro (Figs.
3.4 and 3.5). We considered that changes in active site geometry induced by these
substituents might enhance CPT binding and coincide with changes in linker domain
flexibility. To address such dynamic interactions, we first used oligonucleotide-based
DNA substrates to uncouple Top1 catalyzed DNA cleavage from religation.
As depicted in Fig. 3.6.A, Top1 cleavage of a high affinity site within a suicide
DNA substrate liberates a 3’ end labeled 6-mer and traps the covalent Top1-DNA
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FIG. 3.6. Truncated suicide substrates reduce the rate of DNA cleavage by
Top1G721D. A, as diagrammed, Top1 cleavage of a suicide substrate containing a 20 mer
3’end labeled scissile strand (indicated by ↓), liberates a 32P-labeled 6 mer. In this assay,
equal concentrations of Top1 and Top1G721D were incubated the labeled 20 mer at room
temperature. At the times indicated, reaction aliquots were terminated with 0.5% SDS at
75 °C, the cleavage products were resolved in a 20% polyacrylamide/7M Urea gel and
visualized by PhosphorImaging. B, as diagrammed, Top1 cleavage (indicated by ↓) of a
suicide substrate containing a 5’-radiolabeled oligonucleotide (16 mer) liberates a GGdinucleotide and traps the covalent [γ-32P]DNA-Top1p complex (intact Top1 is indicated
by ). Trypsin digestion of the covalent complex in the presence of 2M Urea generates a
7 amino acid peptide covalently linked to a 14-mer. In this assay, equal concentrations of
Top1 and Top1G721D were incubated with the suicide substrate and at the times
indicated, reaction aliquots were terminated with 0.5% SDS at 75 °C, ethanol
precipitated, and the trypsinized products resolved in a denaturing gel and visualized by
PhosphorImaging.
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complexes (103, 156, 176). Thus, the rate of DNA cleavage by Top1 can be
approximated by the kinetics of 6-mer accumulation. With this scissile DNA strand, the
observed rates of DNA cleavage were comparable for wild-type Top1 and the G721D,
G721E and G721N mutants (Fig. 3.6.A and data not shown). When monitoring DNA
religation by Top1, a shorter scissile DNA strand is typically used (see schema in Fig.
3.7.A) (103, 156, 176). Here, the dissociation of a dinucleotide facilitates the subsequent
annealing of a complementary oligonucleotide, which provides the 5’OH necessary to
resolve the trapped covalent complex. In this assay, the suicide oligonucleotide is 5’end
labeled so both the extent of DNA cleavage and religation can be monitored. However, to
use this assay, we first needed to determine if the removal of four nucleotides 3’ to the
site of DNA scission altered the rate of enzyme catalyzed DNA cleavage. Using the
strategy depicted in Fig. 3.6.B, Top1-DNA covalent complex formation is monitored by
the accumulation of a peptide-linked 14-mer, produced by trypsin digestion of the
reaction products in the presence of urea (177). Contrary to results obtained with the
longer DNA substrate, the truncated suicide substrate revealed a decreased rate of DNA
cleavage by the G721D mutant, relative to that obtained with wild-type Top1 (Fig. 3.6.B).
These data suggest that the rate of DNA cleavage by the G721D mutant is affected by the
extent of duplex DNA structure 3’ to site of DNA cleavage.
We next considered the effects of Gly721 mutations on the rate of Top1-catalyzed
DNA religation, using the strategy depicted in Fig. 3.7.A. Following the trapping of
covalent Top1-DNA complexes with the 16-mer suicide substrate, a complementary
religation oligonucleotide is added (time = 0). At the times indicated, the reactions were
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FIG. 3.7. Distinct patterns of Top1-DNA tryptic digests obtained in religation
reactions suggest G721D-induced alterations in active site structure. A, in the postannealed religation assay, the same suicide substrate diagrammed in Fig. 4.6.B, is used to
generate covalent [γ-32P]DNA-Top1 complexes. At t=0, a 21 mer religation
oligonucleotide (complementary to the 5’end of the nonscissile strand) is added. As
shown in B and C, the resolution of the covalent Top1-DNA complex to generate a 32Plabeled 35-mer can be followed by the conversion of the tryptic 14 mer + peptide to the
35 mer. B,C, equal concentrations of Top1, Top1G721D, Top1G721E and Top1G721N were
incubated with the suicide substrate for 15 minutes at room temperature. At t=0, the 21
mer religation oligonucleotide was added. At the times indicated, reaction aliquots were
terminated with SDS at 75 °C, treated with trypsin (in the absence of urea), resolved in
16% polyacrylamide/7 M Urea gels visualized using a PhosphoImager. D, as for the
reactions shown in B, equal concentrations of Top1 and Top1G721D were incubated in the
post-annealed religation assay. However, the reaction products were digested with trypsin
in the presence of 2 M Urea prior to 16% polyacrylamide/7 M Urea gel electrophoresis.
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terminated with SDS at 75 ˚C, and the relative levels of uncleaved 16-mer, religated 35mer and covalent Top1-DNA intermediate were assessed in denaturing gels following
trypsin digestion. These reactions were initially carried out in the absence of urea,
sincetrypsin digestion of wild-type Top1 (Fig. 3.7.B) efficiently liberated a 7 amino
peptide (INY727IDPR) covalently linked to the radiolabeled 14-mer, which migrates
slower than the 16-mer suicide oligonucleotide. However, a distinct pattern of bands was
obtained in tryptic digests of covalent complexes formed by Top1G721D. As seen in Fig.
3.7.B, two additional bands are observed at 0 time, with the slower migrating band
(labeled <<) being more prominent. Following addition of the religation oligonucleotide,
the accumulation of the faster migrating band (labeled <) paralleled that of the religated
35-mer. Similar results were obtained in assays performed at 150 mM KCl (data not
shown). These extra bands do not result from illegitimate religation events. Rather, they
represent incomplete tryptic digests of the covalent Top1G721D-DNA complexes, as
trypsin digestion of these complexes in the presence of urea produced a single 7 residue
peptide linked to the radiolabeled 14-mer (Fig. 3.7.C). Moreover, digestion with
proteinase K, which cleaves at sites distinct from trypsin, failed to yield multiple bands
(data not shown). Nevertheless, if one corrects for differences in the level of covalent
complexes formed at t=0, then there was no difference in the rate of DNA religation
(accumulation of 35-mer following the addition of the religation oligonucleotide)
catalyzed by Top1 versus Top1G721D (Fig. 3.7.C).
To determine if altered tryptic digests coincided with increased enzyme sensitivity
to CPT, similar analyses of Top1G721E and Top1G721N were performed. All three
mutants produced lower levels of covalent enzyme-DNA intermediates at t=0, with no
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obvious defect in DNA religation (Fig. 3.7.B and C). However, only in the case of the
more CPT sensitive Top1G721E mutant enzyme were the longer peptide-linked
oligonucleotides obtained; these bands were not evident with the less CPT sensitive
Top1G721N (Fig. 3.7.D). Thus, substituting acidic residues for Gly721 appears to enhance
CPT poisoning of Top1 and alter the geometry of the active site in the covalent complex.
We next asked if the presence of extended duplex DNA 3’ to the site of DNA
cleavage, which affects the rate of DNA cleavage by Top1G721D (Fig. 3.6), also impacts
enzyme active site architecture and/or rates of DNA religation. To address these
questions, the religation oligonucleotide was annealed to the suicide DNA substrate prior
to the addition of Top1, as diagrammed for the “pre-annealed religation substrate in Fig.
3.8.A. Although this substrate contains a short DNA flap, the same suicide
oligonucleotide used in the “post-annealed religation substrate” (Fig. 3.7.A) was used to
restrict the overlap to 2 nucleotides. In addition to 14 mer + peptide, trypsin digestion of
the reaction products produced a longer Top1G721D-derived peptide covalently attached
to the cleaved DNA (< in Fig. 3.8.B), corresponding to the lower band obtained with the
post-annealed religation substrate in Fig. 3.7. Thus, the presence of DNA annealed to the
non-scissile strand induced distinct alterations in mutant enzyme active site architecture
when probed by trypsin digestion. Moreover, the accumulation of religated DNA
products was also diminished in Top1G721D reactions containing the pre-annealed
substrates, relative to that observed with wild-type Top1 (Fig. 3.8.B) or Top1G721D
incubated with post-annealed substrates. However, because the pre-annealed assay does
not uncouple cleavage from religation, it is difficult to determine if the presence of the
dinucleotide flap and/or duplex DNA also affects the rate of DNA cleavage.
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FIG. 3.8. Duplex DNA, 3’ to the site of DNA scission, impacts Top1G721D enzyme
architecture and the rate of enzyme-catalyzed DNA religation. A, in the pre-annealed
religation assay, the 21 mer religation oligonucleotide diagrammed in Fig.7A is annealed
prior to the addition of enzyme. DNA cleavage by Top1 liberates a GG dinucleotide to
allow formation of the 35 mer. B, equal concentration of Top1 and Top1G721D were
added to pre-annealed religation assays at t=0. At the times indicated, reaction aliquots
were quenched with SDS at 75 °C. Covalently linked Top1 proteins were hydrolyzed
with trypsin (in the absence of Urea) and the reaction products were resolved in 16%
polyacrylamide/7M Urea gels. C, tryptic digests of Top1G721D, incubated in pre-annealed
or post-annealed religation assays, were resolved by 16% polyacrylamide/7M Urea gel
electrophoresis.
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Nevertheless, the alterations in tryptic digests of the covalent enzyme-DNA intermediates
induced by the various DNA substrates coincided with increased mutant enzyme
sensitivity to CPT.
Based on these findings, we hypothesize that the increased CPT sensitivity of the
Gly721 mutant enzymes results from conformational changes within the Top1 active site
that limits linker domain flexibility and enhances CPT binding to the covalent enzyme
complex. In particular, mutation of the highly flexible Gly might extend the α-helical
structure of residues N-terminal to the active site Tyr, as seen in the structures shown in
Fig.3.1. One prediction of this model is that, independent of side chain charge, an
increased tendency for α-helical structure at position 721 would augment CPT poisoning
of Top1. Estimates of the intrinsic helix-forming tendencies of various amino acid
residues indicate that while Gly has a low propensity to form α-helices, Ala has the
highest (178). Indeed, substituting Ala for Gly721 (in Top1G721A) induced a 5-fold
increase in cell sensitivity to CPT, relative to cells expressing wild-type Top1, which was
only slightly less than the 10-fold increase induced by the G721D mutation (Fig. 3.9).

3.4 DISCUSSION
The architecture of Top1 includes a flexible linker domain, comprised of an
extended coiled coil that positions the C-terminal active site Tyr domain within the
catalytic pocket formed in concert with the central protein clamp. Biochemical, X-ray
crystallographic and molecular dynamic simulation data suggest that the integrity and
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FIG. 3.9. A propensity for a-helical structure at residue 721 enhances Top1
sensitivity to CPT. Exponential cultures of top1Δ cells, transformed with YCpGAL1TOP1, YCpGAL1-top1G721A or YCpGAL1-G721D, were serially 10-fold diluted and
spotted onto SC-uracil plates containing 25 mM Hepes (pH 7.2), 0.1% DMSO, dextrose
(Dex) or galactose (Gal), and the indicated concentrations of CPT. Cell viability assessed
following incubation at 30 °C.
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flexibility of the linker domain within the Top1 clamp are critical determinants of
enzyme sensitivity to the CPT class of chemotherapeutics (59, 61, 62, 173, 175).
Increasing the flexibility of the human Top1 linker domain, either by mutation (A653P)
(62) or by physically uncoupling the linker domain from the Top1 protein clamp (in
reconstituted Topo70 preparations) (61), reduces enzyme sensitivity to CPT. In co-crystal
structures of human Topo70 and DNA, the presence of CPT analogues appears to restrict
the movement of the linker domain thereby enabling the structural determination of this
coiled-coil. This contrasts with the mobility of the linker domain within the covalent
Topo70-DNA complex in the absence of drug. Close inspection of active site architecture
within these structures revealed an extension of a short α-helical structure, spanning
Ser719 through the active site Tyr (human Tyr723) in the absence of drug, to include
Leu716, Gly717 and Thr718 in the presence of drug (see Fig. 3.1). These data suggest a
dynamic interplay between active site α-helical structure and linker flexibility attends
drug binding to the covalent Topo70-DNA complex. Such long range molecular
interactions between the Top1 linker and active site in mediating enzyme sensitivity to
CPT are also supported by recent studies where the cytotoxicity induced by a defect in
human Top1p-catalyzed DNA religation (due to the active site mutation T722A) was
suppressed by the increased linker flexibility of the A653P mutation (174). Based on these
considerations, we hypothesized that the presence of this conserved Gly residue within
the active site of the enzyme (Gly717 in human Top1; Gly721 in yeast Top1) functions as a
flexible hinge to facilitate the alterations in active site geometry and linker domain
flexibility that impact CPT poisoning of Top1. Indeed, our analyses of Gly721 mutations
in yeast Top1, in vitro and in vivo, support this model and suggest that the charge and
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geometry of amino acid side chains at this position directly impact the helical structure of
the region preceding the active site Tyr within the covalent enzyme-DNA complex and
concommitantly the intrinsic sensitivity of Top1 to CPT.
First, our findings indicate that the introduction of a bulky aromatic residue (Phe)
or β branched aliphatic side chain (Val) decrease the specific activity and CPT sensitivity
of Top1. By contrast, the introduction of an acidic side chain, with carboxyl groups at the
β or γ carbon in G721D and G721E, respectively, dramatically enhanced Top1 sensitivity to
CPT, without any obvious alterations in specific activity in plasmid DNA relaxation
assays. In this case, side chain charge was important, as the increased CPT sensitivity of
cells expressing Top1 mutants engineered with the amide forms of these residues (G721N
and G721Q) or a γ branched aliphatic side chain (G721L) was only evident in the absence
of the DNA damage checkpoint. However, the tendency of residues at this position to
form α-helices also appears to be a critical determinant of Top1 sensitivity to CPT, as
mutating Gly721 to Ala [estimated to have the highest propensity for helix formation
(178)] also increased cell sensitivity to CPT. Together, our data support the following
rank order of mutant-induced increased in Top1p sensitivity to CPT: (G721E, G721D) >
G721A> (G721N, G721Q, G721L) > wild-type > G721V > G721F.
Second, our studies also suggest mutation-induced alterations in enzyme active
site architecture coincide with increased CPT sensitivity. The G721D, G721E mutants
exhibited the greatest CPT sensitivity in vivo and in vitro, as well as specific alterations in
tryptic digests of covalent enzyme-DNA complexes formed in DNA religation assays. A
comparison of potential trypsin cleavage sites in yeast and human Top1 with the pattern
of DNA-bound tryptic fragments obtained with yeast and human Top1 mutants (Fig. 3.7,
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3.8 and data not shown) allows for an accurate determination of the alterations in trypsin
digestion. In the residues spanning the active site tyrosine of yeast Top1,
K712EENSQYSLG721TSK724INY727IDPR, trypsin digestion of SDS-denatured wild-type
Top1-DNA covalent complexes typically yields a 7 residue peptide (INY727IDPR)
covalently attached to a 5’ end labeled 14 mer oligonucleotide via a 3’phosphotyrosyl
linkage. Mutation of Gly721 to Asp or Glu (G721D or G721E, respectively) limits trypsin
digestion at K724 to yield longer peptides linked to the DNA. One possible explanation is
that the G721D and G721E mutations alter the α-helical structure of the active site so as to
restrict trypsin digestion of the partially denatured proteins. The presence of an acidic
side chain may also preclude efficient trypsin digestion at K724. Nevertheless, the changes
in enzyme active site geometry suggested by the altered tryptic digests coincided with
increased Top1 sensitivity to CPT- alterations in trypsin digestion were only observed
with the more CPT sensitive G721D or G721E mutants and not with the less CPT sensitive
G721N mutant.
The presence of duplex DNA 3’ to the site of DNA scission also altered the rates
of Top1G721D catalyzed DNA cleavage and religation, as well as the pattern of tryptic
digests, suggesting that downstream protein-DNA contacts impact dynamic interactions
between the active site and the linker. Indeed, the linker of human Top1 is 10-fold more
resistant to limited proteolysis when the enzyme is noncovalently bound to duplex DNA,
consistent with linker-DNA contacts 3’ to the site of DNA scission (28). While mutationinduced alterations in Top1 structure await X-ray structure determination, our studies
implicate the conserved Gly721 residue as a flexible hinge within the active site of Top1
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that enable linker domain flexibility and the structural alterations that accompany drug
binding of the covalent enzyme-DNA complex.
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CHAPTER 4: DISTINCT STRUCTURAL DOMAINS REGULATE
DNA TOPOISOMERASE I ACTIVITY AND SENSITIVITY TO
CAMPTOTHECIN

4.1. INTRODUCTION
DNA topoisomerases catalyze changes in DNA topology by a concerted
mechanism of DNA strand cleavage and religation (3, 7, 179). Eukaryotic DNA
topoisomerase I (Top1) relaxes positive and negative supercoils generated during
processes such as replication, transcription, recombination and chromosome
condensation. The enzyme transiently cleaves a single strand of duplex DNA to form a
covalent DNA-(3’-phosphotyrosyl)-enzyme intermediate, which allows rotation of the
non-covalently held DNA end around the non-scissile strand to relieve torsional and/or
flexural strain in the DNA. The 5’-OH end of the cleaved DNA strand acts as a
nucleophile in a second transesterification reaction to resolve the covalent Top1-DNA
intermediate and religate the DNA phosphodiester backbone.
Top1 is the sole cellular target of the camptothecin (CPT) class of
chemotherapeutics (6, 55, 57). Several CPT analogs, including topotecan (TPT) and the
pro-drug CPT-11, have demonstrated remarkable antitumor activity against adult and
pediatric tumors, with additional analogs in clinical development (73, 170). CPTs target
the enzyme by reversibly stabilizing a covalent Top1-DNA intermediate. In co-crystal
structures of human Topo70 (a C-terminal fragment of human Top1 that lacks the Nterminus) covalently linked to DNA, intercalation of CPT (or TPT) into the protein84

linked DNA nick is stabilized by base-stacking interactions between the planar drug with
-1 (upstream) and +1 (downstream) DNA bases (59). Drug binding also induces an ~3.6Å
shift of the downstream base pairs, which displaces the reactive 5’-OH of the cleaved
strand and prevents DNA religation. Recent studies further demonstrate that drug binding
to the covalent enzyme-DNA complex preferentially slows Top1 uncoiling of positively
supercoiled DNA (180). In S-phase, the ternary CPT-Top1-DNA complex itself or the
positive supercoils that accumulate in advance of the replication machinery as a
consequence of CPT poisoning of Top1 poise an obstacle to replication fork progression
and trigger the formation of the irreversible DNA lesions that induce cell death (180,
181).
Human cells encode two closely related Top1 proteins, where distinct N-terminal
sequences direct the nuclear or mitochondrial localization of the monomeric enzyme
(182). In yeast and human cells, the nuclear Top1 is highly conserved in terms of reaction
mechanism and sensitivity to CPT (3, 152, 179). Indeed, sequence similarities, limited
proteolytic digestion, enzyme reconstitution experiments with Top1 fragments and
crystallographic data describe a unique enzyme architecture, comprising four distinct
domains (12, 15, 27, 28, 42, 59). A divergent N-terminal domain is dispensable for in
vitro activity (31), but is a determinant of intracellular localization (127) and Top1
interactions with other proteins and DNA (32, 33, 36). The conserved core domain
constitutes a clamp that circumscribes duplex DNA and contains all of the catalytic
residues except the active site Tyr, which is located in the conserved C-terminal domain.
In co-crystal structures of human Topo70 with duplex DNA, a salt bridge between
opposing protein loops completes the tight packing of the DNA within the Top1 core.
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However, some flexibility or breathing of the protein clamp is necessary for enzyme
catalysis since crosslinking of the active-site proximal loops (“Lips”), which locks the
Top1 clamp closed, inhibits DNA rotation within the covalent complex (41). Top1 also
contains a linker domain consisting of a pair of extended α-helices that connect the Cterminal domain with protein core to appropriately position the active site Tyr within the
catalytic pocket of the enzyme. The linker is dispensable for DNA relaxation activity in
vitro as an active enzyme can be reconstituted with individually purified core and Cterminal domain polypeptides (39).
The N-terminal and linker domains vary considerably in size and amino acid
sequence. Yet, despite this apparent lack of conservation, nuclear Top1 enzymes typically
contain an N-terminus rich in charged residues (3, 7). Crystallographic studies reveal the
human Top1 linker forms as an extended coiled coil with positively charged residues on
the surface facing the bound duplex DNA (27, 59). The longer linker domain of yeast
Top1 (yTop1) is also predicted to form α-helices that would extend twice the distance
from the protein clamp (110Å), with a similar distribution of positive charges. In Topo70
structures, there are few contacts between the linker and the core clamp/C-terminus of the
enzyme, giving the linker domain a high degree of flexibility (60). The unique
architectural features of nuclear Top1 enzymes – the conserved protein clamp with a
flexible linker positioning the active site tyrosine domain within the active site of the
protein core – and the paucity of structural information on the poorly conserved Nterminus, raise a number of questions concerning the effect of linker flexibility on
enzyme activity and/or CPT sensitivity and whether the N-terminus impacts these aspects
of Top1 function.
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Several lines of evidence suggest the integrity and/or flexibility of the linker
domain affects enzyme sensitivity to CPT. For instance, in X-ray structures of human
Topo70-DNA covalent complexes, the linker domain is apparent only when the drug is
bound and extends out from the active site at an oblique angle to the DNA (59). A similar
architecture is seen when Topo70 is noncovalently bound to DNA (27). However, in
covalent Topo70-DNA complexes formed in the absence of drug, these flexible coiled
coil structures were not resolved (59). When Topo70 was reconstituted from separate
polypeptides comprising the core domain and the linker/C-terminal domain, the
reconstituted enzyme was resistant to CPT (61). In this case, the absence of a physical
connection between the linker and core domains induced a shift in the cleavage-religation
equilibrium towards religation. Mutation of linker domain residue Ala653 to Pro (in
Top1A653P) induced a similar increase in DNA religation to render Top1 resistant to CPT
(62). Molecular dynamic simulations suggested these alterations in enzyme catalysis
were due to increased linker flexibility. Moreover, the ability of the A653P mutation to
suppress the lethal phenotype induced by the self-poisoning T722A mutation provides
direct evidence for the physical interaction between the Top1 linker and active site of the
enzyme (183).
To address how linker orientation impacts active site geometry to alter enzyme
catalysis, we began by mutating conserved residues in yeast Top1 (hereafter referred to as
yTop1) that lie at the junction between the linker and C-terminal domains. We previously
reported that substitution of Gly721 with residues having a higher propensity to form αhelices, such as Asp, increase yTop1 sensitivity to CPT (184). Our findings supported a
model in which this conserved Gly residue provides a flexible hinge within the active site
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to promote alterations in linker structure that accompany CPT binding of the covalent
Top1-DNA complex. Here we report that substitutions of the corresponding Gly717
residue in human Top1 (hTop1) also increased enzyme sensitivity to CPT in vitro, with
similar alterations in active site architecture. Surprisingly, however, these mutations
failed to induce CPT hypersensitivity in yeast cells. This apparent disconnect between
intrinsic enzyme sensitivity to CPT and drug-induced cytotoxicity in vivo, led us to
investigate the contributions of the divergent N-terminal and linker domains to enzyme
activity and CPT sensitivity in vivo. Using a series of chimeric Top1 enzymes, involving
reciprocal swaps of the yeast and human N-termini and linkers, we determined that
intrinsic enzyme sensitivity to CPT is dictated by the composition of the conserved core
and C-terminal domains. However, it is the functional interaction of the N-terminus and
linker domains that regulate enzyme activity in vivo. Taken together, our findings provide
important new insights into how alterations in enzyme architecture impact the catalytic
activity and drug sensitivity of Top1 in cells.

4.2 EXPERIMENTAL PROCEDURES

4.2.1. Chemicals, yeast strains and plasmids
Camptothecin was purchased from Sigma, and stock solutions of 4 mg/ml in
DMSO were stored at -20 °C. [α- 32P] Cordycepin 5’-triphosphate was obtained from
PerkinElmer Life Sciences (Boston, MA). Anti FLAG M2 affinity gel, FLAG peptide and
M2 monoclonal antibodies were purchased from Sigma-Aldrich.
88

Saccharomyces cerevisiae strains EKY3 (MATα, ura3-52, his3Δ200, leu2Δ1,
trp1Δ63, top1Δ::TRP1) and MMY3 (EKY3, rad9Δ::hisG) have been described (113). In
plasmids YCpGAL1-yTOP1 and YCpGAL1-hTOP1, wild-type yeast TOP1 and human
TOP1 cDNA were expressed from the galactose-inducible GAL1 promoter in an
ARS/CEN, URA3 vector (41, 113), while hTop1 was constitutively expressed from the S.
cerevisiae TOP1 promoter in YCpSc-hTOP1 (180). All of the constructs used in these
studies contained an N-terminal Flag epitope (DYKDDD) recognized by the M2
monoclonal antibody. The “h” and “y” designations distinguish human and yeast TOP1,
respectively. To generate the corresponding YCpSc-yTOP1 vector, yTOP1 sequences
were excised with BamHI and XbaI and ligated under the yeast TOP1 promoter in the
pRS416-based vector YCpSc•U (185). To generate htop1G717D, htop1G717Q, htop1L716E
and htop1L716Q mutants, where residue Gly717 was mutated to Asp and Gln, and Leu716 to
Glu and Gln, respectively, a SacII-ClaI hTOP1 DNA, ligated into pRS416, was
mutagenized using a Quickchange mutagenesis kit (Stratagene, La Jolla, CA) and pairs of
complementary oligonucleotides based on the following sequences: GD (5’AAACAGATTGCCCTGGACACCTCCAAACTCAAT-3’); GQ (5’AAACAGATTGCCCTGCAAACCTCCAAACTCAAT-3’); LE (5’AATAAACAGATTGCCGAGGGAACCTCCAAACTC-3’) and LQ (5’AATAAACAGATTGCCCAGGGAACCTCCAAACTC-3’). Mutant sequences were
excised with SacII and ClaI and ligated into YCpGAL1-hTOP1 to yield YCpGAL1htop1G717D, YCpGAL1-htop1G717Q, YCpGAL1-htop1L716E and YCpGAL1htop1L716Q. Yeast-human chimeras were generated using homologous recombination of
PCR-generated chimeric junctions as previously described (185) (see Table 4.1 for
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TABLE. 4.1. Composition of yeast/human Top1 chimerasa.

Chimerab
(hN)-yTop1
(hN209)-yTop1
(yN)-hTop1
(yN120)-hTop1
(hL,hC)-yTop1
(hL)-yTop1
(yL,yC)-hTop1
(yL)-hTop1

Compositionc
hTop1(1-191)yTop1(120-769)
hTop1(1-209)yTop1(138-769)
yTop1(1-119)hTop1(192-765)
yTop1(1-120)hTop1(201-765)
yTop1(1-560)hTop1(635-765)
yTop1(1-560)hTop1(635-713)yTop1(717-769)
hTop1(1-634)yTop1(561-769)
hTop1(1-634)yTop1(561-716)hTop1(713-765)

Junction sequenced
DKKVPEPDNK/EDKKAKEE
EQKWKWWEEE/NEDDTIKW
EKKKREEEEEE/KKKPKKEEEQKW
EKKKREEEEEEE/QKWKWWEEERY
VAILCNHQR/APPKTFEKSMM
QATDREENK/QVSLGTSKI
VAILCNHQR/TVTKGHAQTVEK
QLKDKEENS/QVSLGTSKI

a

Chimeric Top1 enzymes were generated by homologous recombination of PCR
products. Chimera junctions were engineered in the PCR primers. Primer sequences are
available upon request.
b

The heterologous Top1 protein domain (in parenthesis) is shaded blue for yeast residues
and pink for human residues, core and the corresponding C-terminal sequences are in
black and are designated h for human or y for yeast. N, L and C refer to N-terminal,
linker and C-terminal domains, respectively. For example, (hN)-yTop1 contains the
human N-terminus and the yeast core, linker and C-terminal domains. (yL,yC)-hTop1
contains the human N-terminus and core domains, with the yeast linker and C-terminus.
c

The numbers indicate the yeast or human amino acid residues contained in the chimeras,
with 1 refering to the first Met residue. The pink and blue shading is as described above.
The (hL,hC)-yTop1 chimera was used to generate (hL)-yTop1, while the (yL,yC)-hTop1
chimera was used to generate (yL)-hTop1.
d

Residues spanning the chimera junctions (indicated by a /) are indicated using the color
coding described above.
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primer design and junctions). To generate the Gly721 to Asp substitution in the yeast top1
chimera containing the human linker [(hL)-ytop1G721D], a pair of complementary primers
was used based on the following sequence: 5’AAACAGGTTTCACTGGACACTTCCAAAATCAAT. In all cases, mutant sequences
were confirmed by DNA sequencing. Yeast cells were transformed and maintained using
standard methods.

4.2.2. Yeast cell sensitivity to CPT
To assess cell sensitivity to CPT, exponential cultures of EKY3 (top1Δ) and
MMY3 (top1Δ, rad9Δ) yeast cells transformed with the indicated YCpGAL1-TOP1 or
YCpSc-TOP1 vector, were adjusted to an A595 = 0.3, serially 10-fold diluted and aliquots
were spotted onto SC-uracil agar plates containing 25 mM Hepes (pH 7.2), 2% dextrose
or galactose and the indicated concentration of CPT in a final 0.125% DMSO. Colony
formation was assessed following incubation at 30 °C.

4.2.3. DNA topoisomerase I expression, purification and activity assays
Wild-type, mutant and chimeric enzymes were purified from galatose-induced
cultures of top1Δ yeast cells expressing plasmid encoded Top1 proteins as described
(156, 184). Briefly, partially purified proteins were obtained by successive ammonium
sulfate fractionations followed by phosphocellulose chromatography, as described (95).
Top1 protein fractions were adjusted to a final 30% glycerol and stored at –20 °C.
Human Top1 and hTop1G717D were further purified to homogeneity by applying the
partially purified fractions to an anti flag M2 affinity gel (Sigma Chemical Co., St. Louis
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MO) and eluting the Top1 proteins with excess Flag peptide in TBS (50 mM Tris, pH
7.4, 150 mM KCl). Peptide was removed by adding the purified fractions to a
phosphocellulose column and eluting the protein in TEEG buffer (50 mM Tris, pH7.4, 1
mM EDTA, 1mM EGTA, 10% glycerol, 1 M KCl) and protease inhibitors (180). These
fractions were diluted with 50% glycerol and stored at -20 °C. Protein integrity was
assayed in immunoblots as described (103, 184).
Top1 activity was assessed in plasmid DNA relaxation reaction as described (99,
103). Briefly, serial 10-fold dilutions of purified Top1 proteins, corrected for
concentration, were incubated in 20 µl reaction volumes with 0.3 µg of negatively
supercoiled plasmid pHC624 DNA in 20 mM Tris (pH 7.5), 10 mM MgCl2, 0.1 mM
EDTA, 50 µg/ml gelatin and the indicated concentration of KCl at 30 °C for 30 minutes.
The reactions products were resolved in a 1.2% agarose gels and visualized following
staining with ethidium bromide.

4.2.4. DNA and suicide cleavage assays
Intrinsic enzyme sensitivity to CPT was assessed in DNA cleavage assays as
previously described (156). Briefly, a DNA fragment containing a high affinity Top1
cleavage site was uniquely 3’ 32P-end-labeled, incubated with equal concentrations of
Top1 proteins in cleavage buffer [20 mM Tris (pH 7.5), 10 mM MgCl2, 0.1 mM EDTA,
50 mM KCl, and 50 µg/ml gelatin] and increasing concentrations of CPT in a final 4%
(v/v) DMSO for 10 min at 30 °C. The reactions were terminated with SDS at 75 °C,
digested with proteinase K and resolved in 8% polyacrylamide/7 M urea gels. The
cleavage products were visualized using a PhosphorImager.
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Oligonucleotide-based assays were used to assess relative rates of DNA cleavage
catalyzed by wild-type and mutant proteins. As previously described, several approaches
were used (103, 184). First, substrates contained either a truncated scissile strand 5’GATCTAAAAGACTT↓GG-3’ (where ↓ denotes the Top1 cleavage site) or a longer
scissile strand containing a bridging phosphorothiolate linkage at the site of cleavage
(inducated by “s” in 5’ GATCTAAAAGACTTsGGAAAATTTTTAAAAAAGATC-3’).
The phosphorothiolates were synthesizes as described (186). These suicide
oligonucleotides were 5’- end-labeled with [γ-32P]ATP and T4 polynucleotide kinase,
while the complementary oligonucleotide 5’GATCTTTTTTAAAAATTTTTCCGTCTTTTAGATC-3’ was phosphorylated with cold
ATP. Equimolar concentrations of the oligonucleotides were annealed in 10 mM Tris (pH
7.8), 100 mM NaCl, 1 mM EDTA by heating to 90 °C followed by slow cooling to room
temperature. The suicide substrate (3 pmol/reaction) was incubated with equal
concentrations of Top1 proteins in Cleavage buffer at room temperature and, at the times
indicated, aliquots were treated with 0.5% SDS at 75 °C to terminate the reactions.
Following an ethanol precipitation, the covalently linked protein was digested with
trypsin, in the presence or absence of 2 M Urea, and the remaining substrate and peptidelinked oligonucleotides were resolved in 16% polyacrylamide/7M Urea gels and
visualized by PhosphoImage analysis. A third substrate was used to monitor the release
of a 6 mer downstream of the Top1 cleavage site (99). For these assays, a slightly longer
scissile strand 5’-GATCTAAAAGACTT↓GGAAA-3’, 3’-end-labeled with
[32P]cordycepin using terminal deoxynucleotide transferase, was annealed to equimolar
amounts of the same complementary strand as described above. Equal concentrations of
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Top1 proteins were incubated with the suicide substrate (20 fmoles/reaction) in Cleavage
buffer at room temperature. Aliquots were quenched with SDS at 75 °C at the times
indicated and the reaction products were resolved in 20% polyacrylamide/7M Urea gels
and visualized with a Phosphoimager.

4.2.5. DNA religation assays
To assess the relative rates of Top1-catalyzed DNA religation, the 5’-end labeled
DNA suicide substrate containing 5’-GATCTAAAAGACTT↓GG-3’ was used in two
oligonucleotide-based religation assays as described (184). In the post-annealed religation
assay, the suicide substrate was incubated for 15 minutes at room temperature with equal
concentrations of Top1 proteins in Cleavage buffer to generate covalent Top1-DNA
complexes. Religation was initiated at time = 0 by the addition of a 10-fold excess of a
religation oligonucleotide (5’-GGAAAAATTTTTAAAAAAGATC-3’), which is
complementary to the non-scissile strand downstream of the site of DNA scission. In the
pre-annealed religation assay, the same suicide substrate was incubated with a 10-fold
excess of religation oligonucleotide for 15 min prior to the addition of Top1 proteins. In
both assays, aliquots were taken at various times, processed as described above for the
5’end labeled suicide cleavage reactions. Where indicated, the reaction products were
hydrolyzed with trypsin in the absence of urea prior to probe for changes in enzyme
active site architecture.
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4.3. RESULTS

4.3.1. Mutation of Gly717 in human Top1 does not alter CPT-induced toxicity in
yeast cells, yet enhances enzyme sensitivity to CPT in vitro
Crystallographic and biochemical data suggest that the physical connection of the
Top1 linker to the C-terminal domain / protein clamp as well as the flexibility of the
linker domain are critical determinants of enzyme sensitivity to CPT (59, 61, 62, 184). In
the co-crystal structure of the covalent human Topo70-DNA complex, Gly717 lies at one
end of a short α-helix that extends to the active site Tyr723, which is covalently linked to
the DNA (59). In the ternary Topo70-DNA-TPT structure, this α-helix extends to include
Gly717, as well as the preceding Leu716. This seemingly subtle structural transition in
active site architecture coincides with a more dramatic restriction in linker flexibility. The
coiled coil linker, which was not resolved in the absence of drug, is now oriented at an
oblique angle to the DNA in the presence of TPT. A similar orientation of the linker is
also seen when Topo70 is noncovalently bound to DNA (Fig. 4.1) and in covalent
Topo70-DNA complexes bound with other CPT analogs (27, 85, 175).
We recently reported that mutating the corresponding yeast Gly721 residue to
amino acids with a higher propensity to form α-helices, for example Ala, Asp or Glu,
enhanced yTop1 CPT sensitivity, while the β-carbon branched Val, or the aromatic Phe
at this position induced CPT resistance (184). With the Asp and Glu substituents, CPT
hypersensitivity corresponded to detectable alterations in active site architecture, as
probed by limited tryptic digests. Based on such considerations, we hypothesized that this
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FIG. 4.1. The structure of a C-terminal 70 kD fragment of human DNA
topoisomerase I (Topo70) in a noncovalent complex with a 22 base pair DNA
duplex. A. Ribbon diagram of PDB file 1E36, viewed perpendicular to helical axis of the
DNA duplex (backbone is in orange), the core domain of Topo70 forms a protein clamp
(shades of blue). The linker domain (purple) extends from the core at an oblique angle to
the DNA and the C-terminal domain is in green. The active site Tyr is mutated to Phe
(indicated in magenta). B. The same structure rotated 90˚ around the vertical axis and
viewed down the DNA helix. Figures were made with PyMol.
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residue constitutes a flexible hinge, where changes in active site architecture at this
junction impact the orientation and flexibility of the linker domain (184). Our initial
focus on yeast Top1 avoided potential complications of heterologous human Top1
expression in yeast top1∆ strains; nevertheless, the underlying assumption was that the
high degree of sequence conservation within the enzyme active site was predictive of
structure. Yet, as all structural determinations of Top1 active site architecture are limited
to human Topo70 (27, 59, 85, 175), we asked if the same amino acid substitutions in the
human enzyme elicited similar dynamic transitions in active geometry and alterations in
CPT sensitivity.
We first engineered mutations of the conserved Leu716 in hTop1, analogous to
those known to render yTop1 resistant to CPT (184). As shown in Fig. 4.2.A, mutation of
Leu716 to Gln (in L716Q) or Glu (in L716E) induced a CPT resistant phenotype when these
mutant htop1 alleles were expressed from the galactose-inducible GAL1 promoter in
yeast top1∆ cells. Cells expressing either hTop1 mutant enzyme were resistant to 10-fold
higher CPT concentrations than cells expressing comparable levels of wild-type hTop1.
In plasmid DNA relaxation and DNA cleavage assays performed with purified proteins,
the specific activity of the L716E mutant was reduced ~10-fold relative to that of wildtype hTop1, which corresponded to a proportional decrease in enzyme sensitivity to CPT
in vitro (shown in Fig. 4.2.B and C). Similar results were obtained with the corresponding
mutation in yTop1, L720E, albeit with more severe effects on enzyme activity and CPT
sensitivity in vitro (184).This apparent conservation of hTop1 Leu716 mutant function, in
vivo and in vitro, contrasted with the phenotypic consequences of mutating the conserved
Gly717 in hTop1 to Asp (G717D) or Gln (G717Q). Expression of the corresponding yeast
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FIG. 4.2. Mutation of Gly717 to Asp (G717D) or Gln (G717Q) enhanced hTop1
sensitivity to CPT in vitro, but not in yeast. A. Exponentially growing cultures of top1Δ
cells, transformed with the indicated YCpGAL1-htop1constructs, were adjusted to an
A595 = 0.3, serially 10-fold diluted, and aliquots were spotted onto SC –uracil agar plated
supplemented with 25 mM HEPES (pH 7.2), 0.1% DMSO and either dextrose (Dex),
galactose (Gal) or galactose plus the indicated concentration of CPT. Cell viability was
assessed following incubation at 30 °C. B. Equal concentrations of purified hTop1
proteins were serially 10-fold diluted and incubated with 0.3 µg of negatively supercoiled
pHC624 DNA in a plasmid DNA relaxation assay as detailed in Materials and Methods.
The reaction products were resolved by agarose gel electrophoresis and visualized after
ethidium bromide staining. The relative positions of relaxed (R) and supercoiled (-) DNA
topoisomers are indicated. C is plasmid DNA control. C. Equal concentrations of hTop1
and mutant proteins were incubated with a single 3’32P-end labeled DNA fragment in a
DNA cleavage reaction containing a final 4% (v/v) DMSO and indicated concentration of
CPT. After a 10 min incubation at 30 °C, the covalent complexes were trapped with SDS
at 75 °C and treated with proteinase K. The reaction products were resolved in an 8%
polyacrylamide/7M urea gel and visualized using a PhosphoImager. The asterisk (*)
indicates a high affinity Top1 cleavage site.
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mutants, G721D in a top1∆ strain or G721Q in an isogenic strain deleted for the Rad9 DNA
damage checkpoint (top1∆, rad9∆), enhanced cell sensitivity to CPT by a factor of 10.
However, galactose–induced yeast top1∆ cells expressing wild-type hTop1, hTop1G717D,
or hTop1G717Q exhibited similar sensitivity to CPT, over a range of drug concentrations
(Fig. 4.2.A). Similar results were also obtained in other genetic backgrounds, such as
top1∆,rad9∆ cells (data not shown). The specific activity of the purified human G717D
and G717Q mutant enzymes was similar to that of wild-type hTop1 (Fig. 4.2.B), yet
exhibited an ~ 10-fold increase in CPT-induced covalent Top1-DNA complex formation
(Fig. 4.2.C). Surprisingly, the increased CPT sensitivity of the human G717D and G717Q
mutant enzymes evident in vitro mirrored that of the corresponding yeast mutants, yet
failed to alter yeast cellular responses to CPT. This apparent disconnect between mutant
enzyme activity in vitro and in vivo prompted us to consider whether the mechanism of
enhanced mutant enzyme sensitivity to CPT was conserved from yeast to human or if the
different phenotypes resulted from distinct functional interactions of the yeast and human
enzymes in vivo.

4.3.2. Mutation-induced changes in the DNA cleavage-religation equilibrium and
structural alteration of hTop1G717D
To assess the mechanism of enhanced CPT poisoning of human Top1G717D in
vitro, a series of oligonucleotide-based DNA substrates were used to uncouple enzyme
catalyzed DNA cleavage from DNA religation. Biochemical and structural studies
indicate that CPT reversibly stabilizes the covalent Top1-DNA intermediate by reducing
the rate of DNA religation (3, 59, 170). Indeed, recent single molecule studies suggest
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that dissociation of the drug occurs prior to the resolution of the Top1-DNA complex
(180). Thus, an increase in CPT sensitivity could result from increased covalent complex
formation, due to mutation-induced alterations in DNA cleavage or religation, or an
increase in the affinity of the drug for the mutant Top1-DNA intermediate. For example,
mutation of either the conserved Asn immediately N-terminal to the active site Tyr in
yTop1N726H or Thr722 in yTop1T722A, increased the steady state levels of the covalent
intermediates such that these “self-poisoning” enzymes were toxic to yeast and
hypersensitive to CPT in vitro (99, 103, 113). Using suicide substrates to uncouple Top1catalyzed DNA cleavage from religation, we established that yTop1N726H exhibited an
increased rate of DNA cleavage without a corresponding increase in DNA religation,
while the cytotoxicity of the T722A mutant derived from a decrease in DNA religation,
much like that induced by CPT (103). Similar alterations in enzyme catalysis were
observed with the corresponding hTop1 mutants (103). However, in the DNA cleavage
assays shown Fig. 4.2.C, there were no obvious alterations in steady state levels of G717D
or G717Q covalent complexes relative to that observed with wild-type hTop1, in the
absence of CPT.
To determine the basis for the increase in intrinsic CPT sensitivity of
hTop1G717D, we first addressed the relative rates of DNA cleavage. As diagrammed in
Fig. 4.3, two truncated oligonucleotide-based suicide substrates were used. While both
contained a Top1 high affinity cleavage site, they differed in the number of bases present
downstream from the site of scission. In our studies of yTop1G721D, the relative rates of
mutant enzyme catalyzed DNA cleavage increased with the length of the scissile DNA
strand (184). However, as shown in Fig. 4.3.A and B, the human G717D mutant enzyme
100

FIG. 4.3. hTop1G717D exhibits increased rates of DNA cleavage. A. As diagrammed,
Top1 cleavage of a 3’-labeled 20 nucleotide (20 nt) oligomer containing the high affinity
cleavage site for Top1 (indicated by ↓), liberates a 32P-labeled 6 nucleotide oligomer (6
nt). The smaller arrow indicates a second cleavage site. In this assay, equal
concentrations of hTop1 and hTop1G721D were incubated with the labeled 20 nt and, at
the times indicated, aliquots were treated with SDS at 75 °C and the cleavage products
were resolved in a 20% polyacrylamide/7M Urea gel and visualized with a
PhosphorImager. B. A 5’-radiolabeled oligonucleotide (16 nt) containing the high affinity
cleavage site (indicated by ↓) was incubated with hTop1 or hTop1G721D. A second
cleavage site is indicated by the smaller arrow. Top1-catayzed cleavage traps the covalent
[γ-32P]DNA-Top1 complex (intact Top1 is indicated by ). Trypsin digestion of the
covalent complex in the presence of 2M Urea generates a 7 amino acid peptide ()
covalently linked to a 14 nt (or 12 nt with complexes formed at the second cleavage site).
At the times indicated, reaction aliquots were terminated with SDS at 75 °C, ethanol
precipitated and trypsinized. Reaction products were resolved and visualized as above
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exhibited dramatically elevated rates of DNA cleavage independent of DNA strand
length. Enhanced DNA cleavage was assessed by the accumulation of the free 6 nt
fragment in Fig. 4.3.A and the generation of a 14 nt-peptide complex following trypsin
digestion of the reaction products in the presence of urea in Fig. 4.3.B. In both cases, the
mutant enzyme also catalyzed the cleavage of DNA at a second site, 2 nucleotides
upstream from the high affinity site (Fig. 4.3.A and B). Similar results were also obtained
using full length duplex DNA that contains a 5’ bridging phosphorothiolate at the site of
DNA scission (see Fig. 4.4). Enzyme cleavage of this suicide substrate yields a 5’ SH,
which is an inefficient in the subsequent transesterification necessary to religate the DNA
(186). In all of these assays, increased rates of DNA cleavage were observed with the
human G717D mutant, relative to wild-type hTop1 (Fig. 4.3.A, 4.3.B and Fig. 4.4).
DNA cleavage and the dissociation of Top1 from duplex DNA are rate-limiting steps in
Top1 catalysis (168). Alterations in Top1 protein binding of DNA shift the optimal salt
concentration for plasmid DNA relaxation (99). However, as the specific activity of the
G717D mutant mirrored that of wild-type hTop1 over a wide range of salt concentrations,
a defect in hTop1G717D binding of DNA is unlikely (data not shown). On the other hand,
since the rate of mutant enzyme-catalyzed DNA scission was enhanced, then a
comparable increase in DNA religation rate would be necessary to maintain similar
steady state levels of covalent Top1-DNA complexes. To address this question, enzymecatalyzed DNA religation was assessed in a post-annealed religation assay, as
diagrammed in Fig. 4.5.A. In this assay, the formation of covalent enzyme-DNA
complexes (using the suicide substrate in Fig. 4.3.B) is followed by the addition of a
complementary religation oligonucleotide, such that Top1-catalyzed DNA religation can
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FIG. 4.4. Substitution of Gly717 with Asp increases the rate of Top1-catalyzed DNA
cleavage. A. Schematic representation of a DNA cleavage assay using a 5' end labeled
suicide substrate (35 nt) that contains a 5’ bridging phosphorothioate (designated s) at the
high affinity Top1 cleavage site (indicated by ↓). The 5'-SH generated by Top1 cleavage
at this site prevents DNA religation, such that the accumulation of covalent Top1-DNA
complexes approximates the rate of DNA scission. B. Equal concentrations of hTop1 or
hTop1G717D were incubated with 5' end labeled suicide substrate diagrammed in A. At
the times indicated aliquots were treated with SDS at 75 °C, ethanol precipitated and
digested with trypsin in the absence or presence of urea. Cleavage products were resolved
in a 16% polyacrylamide/7M urea gels and visualized with a PhospoImager. The relative
mobility of the starting substrate (35 nt), the cleaved DNA strand linked to a 7 amino acid
peptide following trypsin digestion (14 nt-peptide) and a longer peptide linked to the 14
nt (<<) resulting from of a partial tryptic digest.
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FIG. 4.5. Tryptic digests of hTop1G717D-DNA complexes during DNA religation
suggest mutant-induced alterations in active site structure. A. In a post-annealed
religation assay, the same suicide substrate diagrammed in Fig. 4.2.B was used to
generate covalent [γ-32P]DNA-Top1 complexes. At 0 time, a 21 nt oligonucleotide
(complementary to the 5’end of the nonscissile strand) is added to initiate religation. As
shown in B and C, the resolution of covalent hTop1-DNA complexes to generate a 32Plabeled 35 nt product can be followed by the conversion of the tryptic 14 nt-peptide to a
35 nt. B. Equal concentrations of purified hTop1 and hTop1G717D were incubated with
the suicide substrate for 15 minutes at room temperature. The 21 nt was added at t=0 and
reaction aliquots were terminated at the indicated times with SDS at 75 °C, treated with
trypsin, resolved in 16% polyacrylamide/7 M Urea gels and visualized using a
PhosphoImager. In partial tryptic digests (indicated by < and <<), increased peptide
length retards band migration. C. The same reactions as in B, except trypsin digests were
performed in presence of 2 M Urea.

104

be assessed by the accumulation of a radiolabelled 35 nt product. In this assay, 40% less
G717D mutant protein was used such that the amount of covalent complex formed at t=0
was more comparable to reactions containing wild-type Top1. Aliquots, taken at the
indicated time points were treated with trypsin in the presence of 2 M urea (Fig. 4.5.B).
In comparison with hTop1, the increased levels of covalent hTop1 G717D-DNA
complexes evident at t=0, coincided with elevated levels of religated product (Fig. 4.5.B).
Thus, consistent with steady state DNA cleavage assays, the G717D mutant failed to
increase covalent enzyme-DNA intermediate stability. In the absence of CPT, elevated
rates of DNA religation attended the increased rates of DNA cleavage. However, when
the reaction products were subjected to trypsin digestion in the absence of urea (Fig.
4.5.C), additional bands of intermediate size were obtained with hTop1G717D (arrow
heads in Fig. 4.5.C). These bands were completely resolved as 14 nt-peptides in urea
denatured tryptic digests (as in Fig. 4.5.B), and corresponded to 14 nt oligos covalently
linked to peptides longer than 7 amino acid residues. These data suggest that the presence
of Asp at position 717 alters the local architecture of the active site to limit trypsin
digestion in the absence of urea. Indeed, similar results were obtained with the
corresponding yeast Top1G717D mutant enzyme, and in both cases, corresponded to the
increased intrinsic CPT sensitivity of the mutant enzyme.
We next asked what effect duplex DNA downstream of the cleavage site, would
have on active site structure. In the pre-annealed DNA religation assay (diagrammed in
Fig. 4.6.A), the presence of the religation oligo prior to DNA cleavage by the G717D
mutant altered the pattern of tryptic-DNA fragments obtained, such that the faster
migrating band accumulated (Fig. 4.6.B). Moreover, these changes coincided with a
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FIG. 4.6. The presence of duplex DNA downstream from the site of DNA scission
reduces the rate of hTop1G717D-catalyzed DNA religation. A. In a pre-annealed
religation assay, the 21 nt religation oligonucleotide is annealed prior to the addition of
enzyme. DNA cleavage by hTop1 liberates a GG dinucleotide, which allows religation to
generate a 35 nt product. B. At t=0, equal concentrations of hTop1 and hTop1G717D were
added to pre-annealed religation assays and reaction aliquots were quenched with SDS at
75 °C at the times indicated. Covalent DNA-Top1 complexes were hydrolyzed with
trypsin and the reaction products resolved in 16% polyacrylamide/7M Urea gels and
visualized with a PhosphorImager. Partial tryptic digests corresponding to those obtained
in the post-annealed religation assay (Fig. 4.3.B) are indicated by <<.
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decreased rate of DNA religation (reduced amounts of the 35 nt product over time,
relative to that observed with wild-type hTop1). Thus, as with the yeast mutant enzyme
(184), the presence of the religation substrate within the active site of hTop1G717D, but
not wild-type hTop1, altered the rate of DNA religation and the architecture of the active
site as probed by limited trypsin digests. A similar alteration in G717D enzyme active site
architecture was revealed in tryptic digests of covalent complexes formed with the
suicide substrate containing the 5’ bridging phosphorothiolate (see Fig. 4.4). Thus, the
structural changes revealed by the accumulation of the longer 14 nt-peptide in Fig. 4.6.B
was also observed with a substrate comprising two intact DNA strands prior to DNA
cleavage.
The relative migration of such peptide linked-DNA oligonucleotides in denaturing
gels is proportional to the length of the peptide bound (184, 187). Based on comparisons
of peptide-linked oligos obtained with yTop1G721D and the relative positions of potential
trypsin cleavage sites in close proximity to the active site Tyr residue, the identity of the
peptide-linked oligos was readily determined. As shown in Fig. 4.7.B and C, when TPT
is bound within the covalent Topo70-DNA complex, an α-helix extends from the active
site Tyr723 (magenta) to include Gly717 (yellow) and a rigid linker extends from the Top1
core at an oblique angle to the DNA. The Lys720 residue cleaved by trypsin to generate
the canonical 14 nt + 7 residue peptide is now positioned immediately adjacent to Gly717
on the same face of the α-helix. In the absence of drug, Gly717 is found in a loop and the
flexibility of the linker domain precludes structural determination. As Asp is predicted to
have a higher propensity to form an α-helical structure than Gly (178), we reasoned that
the extension of this α-helix in the absence of drug might preclude efficient trypsin
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FIG. 4.7. Co-crystal structure of TPT bound to the covalent Topo70-DNA complex.
A. Potential trypsin cleavage sites around the active site Tyr723 (Y) are marked with green
dots. Trypsin cleavage after Arg (R marked with black arrow) and Lys720 (K marked with
red arrow, 3 residues N-terminal to the active site Tyr) will generate a 14 nt DNA linked
to a 7 residue peptide via a phosphotyrosyl linkage (14 nt-peptide). Cleavage sites
predicted to yield the < and << DNA-peptide products observed in Fig. 4.3.B and 4.4.B
are also indicated (Lys712 - K red arrow for <; Arg708 – R green dot for <<). The Gly717
residue mutated to Asp in hTop1G717D is in large bold font. B and C. Full view and close
up ribbon diagrams of the co-crystal structure of Topo70 (light blue) covalently linked to
DNA in the presence of TPT (pink), (PDB file 1K4T (59)). Orange traces the DNA
phosphodiester backbone with green-blue sticks for bases. The active site Tyr is in
magenta, Gly717 is in yellow, while Lys720 and Lys712 are in red. The figure was made
with PyMol (DeLano Scientific, San Carlos CA).
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digestion at residue Lys720, thereby generating the longer 15 amino acid peptide bound to
the 14 nt DNA (<< in Figs. 4.5.C and 4.6.B). The presence of the religation oligo prior to
DNA cleavage, also precluded efficient trypsin digestion of hTop1G717D-DNA
complexes at the more N-terminal Lys712. As this residue lies at the C-terminal end of the
linker domain, these data suggest that the alterations in DNA structure within the G717D
mutant active site also impact protein structure. Together with the results obtained with
yTop1, these data suggest conserved aspects of active site architecture impact the
intrinsic CPT sensitivity of Top1.

4.3.3. N-terminal and linker human/yeast Top1 chimeras
Expression of hTopG717D failed to enhance CPT-induced toxicity in yeast, despite
an apparent increase in mutant enzyme sensitivity to CPT in vitro. This surprising result
prompted us to ask if the different phenotypes induced by conserved Gly to Asp
mutations in yeast and human Top1 were due to the distinct structural features of these
enzymes. For instance, while the N-termini of human and yeast Top1 are rich in acidic
and basic residues, the N-terminal domain of yTop1 is ~ 2/3 the size of the corresponding
domain of hTop1 (diagrammed in Fig. 4.8.A). This contrasts with the inverse relationship
in linker length between the human and yeast enzymes (184). In fragment
complementation experiments, polypeptides comprising the conserved core and Cterminal domains can reconstitute an active enzyme in vitro (39). However, the Nterminal domain has been shown to mediate Top1 interaction with other proteins, such
TATA Binding Protein (TBP), nucleolin, SV40 large T antigen (32, 33, 36), while linker
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FIG. 4.8. Reciprocal swaps of the N-terminal domains of yeast and human Top1 do
not alter enzyme activity or yeast cell sensitivity to CPT. A. Scheme of N-terminal
residues exchanged between yeast and human Top1 via homologous recombination. The
chimeric N-terminal junctions were engineered at human residue 215 (for hN) and yeast
residue 143 (for yN) to ensure that the conserved clamp domains were intact. (hN)yTOP1 encodes the yeast enzyme with a human N-terminal domain; (yN)-hTOP1
encodes human Top1 with the yeast N-terminus. B. Exponential cultures of top1Δ cells,
transformed with the indicated YCpGAL1-TOP1 constructs, were adjusted to an A595 =
0.3, serially 10-fold diluted, and aliquots were spotted onto SC –uracil agar containing 25
mM HEPES (pH 7.2), 0.1% DMSO and either dextrose (Dex), galactose (Gal) or
galactose plus the indicated concentration of CPT. The viability of two independent
transformants was assessed following incubation at 30 °C. C. Equal concentrations of
purified Top1 proteins were serially 10-fold diluted and incubated in a plasmid DNA
relaxation assay. After 30 min at 30 °C, the reaction products were resolved by agarose
gel electrophoresis and visualized with ethidium bromide. The relative positions of
relaxed (R) and supercoiled (-) DNA topoisomers are indicated. C indicates DNA alone.
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flexibility appears to dictate enzyme sensitivity to CPT (59, 61, 62, 184). To address the
function of these Top1 domains in regulating enzyme activity in vivo, homologous
recombination [as previously described (185)] was used to generate reciprocal swaps of
the N-terminal and linker domains of yTop1 and hTop1.
As diagrammed in Fig. 4.8.A and described in Table 4.1, a series of N-terminal
domain chimeras were engineered, including reciprocal swaps where (hN)-yTop1
contains human residues 1-191 fused to yeast residues 120-769 and (yN)-yTop1 contains
yeast residues 1-119 fused to human residues 192-765. However, exchanging these
domains had no effect on the pattern of in vivo CPT sensitivity in yeast. Cells expressing
(hN)-yTop1 were sensitive to the same concentrations of CPT as cells expressing wildtype yTop1, while cells expressing either wild-type hTop1 or (yN)-hTop1 were sensitive
to 10-fold lower concentrations of drug (Fig. 4.8.B). The levels of chimeric proteins
expressed and the specific activity of the purified proteins also mirrored that of the
corresponding wild-type enzyme (Fig. 4.8.C and data not shown). Similar results were
also obtained with N-terminal chimeras containing different junctions upstream of the
core domain (see Table 4.1 and data not shown). These findings eliminate the simple
explanation that differences in yeast protein interactions with the N-terminal domains of
yeast or human Top1 alone could account for the differences in hTop1G717D CPT
sensitivity in vitro and in yeast cells.
We next engineered reciprocal exchanges of the linker domains. To accomplish
this, the linker and C-terminus of each enzyme was replaced with the corresponding
residues of the other. These chimeras were then used in reciprocal swaps to reintroduce
the corresponding C-terminal domains, such that the (yL)-hTop1 chimera consisted of the
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human N-terminal, core and C-terminal domains, yet contained the yeast linker. The
precise chimera junctions correspond to the conserved residues found at the N- and Cterminal ends of the coiled coils of the linker, evident in the co-crystal structure of the
drug bound covalent Topo70-DNA complex (59), i.e, hTop1 residues 635 and 712 and
yTop1 residues 561 and 716 (for details see Table 4.1).
Replacing the shorter hTop1 linker with the longer yeast linker, in (yL)-hTop1,
induced a surprising phenotype in yeast cells expressing this chimera, with no apparent
alteration in enzyme activity in vitro. As shown in Fig. 4.9.B, galactose-induced
expression of (yL)-hTop1 suppressed yeast cell growth, even in the absence of CPT.
However, when the corresponding human N-terminal domain was introduced into this
chimera [to generate (yN,yL)-hTop1], such that the conserved core and C-terminal
domains were hTop1, while the divergent N-terminal and linker domains were of yeast
Top1 origin, this toxic phenotype was suppressed. Moreover, the cells expressing this
(yN,yL)-hTop1 chimera were just as sensitive to CPT as cells expressing the wild-type
human Top1. This was true whether the chimeras contained the yN or yN120 N-terminal
fusion (Table 4.1, data not shown). In all cases, comparable levels of Top1 protein were
expressed in these cells (data not shown). Also, as both N- terminal domains contain
nuclear localization signals (127), it is unlikely that the observed phenotypic differences
were due to changes in nuclear import. The specific enzyme activities of the purified
chimeras were indistinguishable from that of wild-type hTop1 over a range of salt
concentrations (Fig. 4.9.C). As shown in Fig. 4.10, at least 100-fold higher concentrations
of CPT were required to induce similar levels of covalent yTop1- DNA intermediates as
that observed for wild-type hTop1. These results are further consistent with the
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FIG. 4.9. The introduction of the yeast N-terminal domain suppresses the lethal
phenotype of a human Top1-yeast linker domain chimera. A. As in Fig. 6A, a scheme
of the N-terminal and linker domains used to generate the indicated chimeras. Residues
corresponding to the chimera junctions are as numbered. (hN-yL)-hTOP1 encode human
Top1 with a yeast linker domain; (yN-yL)-hTOP1 encodes human Top1 with a yeast Nterminal and yeast linker domain. B. As in Fig. 4.6.B, serial dilutions of exponential
cultures of top1Δ cells, transformed with the indicated YCpGAL1-htop1constructs, were
spotted onto SC –uracil agar containing 25 mM HEPES (pH 7.2), 0.1% DMSO and either
dextrose (Dex), galactose (Gal) or galactose plus the indicated concentration of CPT and
cell viability was assessed following incubation at 30 °C. C. Equal concentrations of
purified hTop1 and chimeric proteins were serially 10-fold diluted and incubated in a
plasmid DNA relaxation assay containing the indicated concentration of KCl. After 30
min at 30 °C, the reaction products were resolved by agarose gel electrophoresis and
visualized with ethidium bromide. The relative positions of relaxed (R) and supercoiled
(-) DNA topoisomers are indicated.
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FIG. 4.10. CPT sensitivity and sequence specificity are dictated by the core and Cterminal domains of Top1. Equal concentrations of the purified Top1 proteins
(described in Fig. 4.7.A) were incubated with a single 3’ 32P-end labeled DNA substrate
in a DNA cleavage reaction containing 0, 0.5, 2, 10 or 50 µM CPT. After incubation for
10 min at 30 °C, the covalent Top1-DNA complexes were trapped with SDS at 75 °C and
treated with proteinase K. The reaction products were resolved in 8% polyacrylamide/7M
urea gels and visualized using a PhosphoImager. C is DNA alone and the asterisk (*)
indicates a high affinity Top1 cleavage site.
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differences in in vivo CPT sensitivity seen in Fig. 4.8.B. Yet, independent of linker and/or
N-terminal domain composition, the intrinsic CPT sensitivity of these hTop1 chimeras in
vitro mirrored that of wild-type hTop1, not yTop1. Moreover, the subtle differences in
sequence specificity between the yeast and human enzymes, as indicated by the arrow
heads in Fig. 4.10, was also retained by the hTop1 chimeras.
Thus, the toxic phenotype of (yL)-hTop1 expressing cells was not due to any
obvious alterations in enzyme binding to DNA, sequence specificity or shift in cleavagereligation in the absence of CPT. Indeed, as shown in Fig. 4.11, the growth defect
induced by (yL)-hTop1 was independent of DNA cleavage, as galactose-induced
expression of a catalytically inactive (yL)-hTop1Y723F mutant induced the same
phenotype. Taken together, these findings support a model whereby the intrinsic CPT
sensitivity of Top1 is dictated by the composition of the core and C-terminus, while the
functional interaction of hTop1 with other proteins/ protein complexes in yeast is affected
by linker composition. In the context of hTop1, the ability of the yeast N-terminal domain
to suppress the growth defect induced by the yeast linker, further implies the coordinated
function of these poorly conserved in regulating hTop1 interactions with other, as yet
unidentified, proteins or protein complexes.
As the human linker is half the size of that of yeast Top1, with a proportionally
larger N-terminal domain, we next assessed the consequence of mis-pairing the shorter
human linker with the yeast enzyme (see Table 4.1). GAL1-promoted expression of this
(hL)-yTop1 chimera induced a CPT resistant phenotype (Fig. 4.12.A), which
corresponded to a > 10-fold reduction in enzyme activity in a plasmid DNA relaxation
assay in comparison with wild-type yTop1 (Fig. 4.12.B). Moreover, the optimal KCl
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FIG. 4.11. Catalytically inactive hTop1 containing a yeast linker is toxic to yeast
cells. Exponentially growing cultures of top1Δ cells, transformed with the indicated
YCpGAL1-top1constructs, were adjusted to an A595 = 0.3, serially 10-fold diluted, and
aliquots were spotted onto SC-uracil plates containing 25 mM Hepes (pH 7.2), 0.1%
DMSO and either dextrose (Dex), galactose (Gal) or galactose plus 0.05 µg/ml CPT.
Viability was assessed following incubation at 30 °C.
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FIG. 4.12. Yeast Top1G721D containing the human linker domain exhibits increased
CPT sensitivity. A. Exponentially growing cultures of top1Δ cells, transformed with the
indicated YCpGAL1-TOP1constructs, were adjusted to an A595 = 0.3, serially 10-fold
diluted, and aliquots were spotted onto SC-uracil plates containing 25 mM Hepes (pH
7.2), 0.1% DMSO and either dextrose (Dex), galactose (Gal) or galactose plus 0.05 µg/ml
CPT. Viability was assessed following incubation at 30 °C.
B. Extracts of galactose induced top1Δ cells, expressing wild-type yTop1 or (yN-hL)
yTop1 from a YCpGAL-TOP vector, were corrected for protein concentration, serially
10-fold diluted and incubated in a plasmid DNA relaxation assay containing the indicated
concentration of KCl. After 30 min at 30 °C, the reaction products were resolved by
agarose gel electrophoresis and visualized with ethidium bromide. The relative positions
of relaxed and supercoiled DNA topoisomers are as in Fig. 4.9.C.
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concentration for plasmid DNA relaxation was lower for (hL)-yTop1, suggesting a
reduction in DNA binding. When the yeast Gly721 residue (corresponds to human Gly717)
was mutated to Asp in this chimeric enzyme [(hL)-yTop1G721D], cell sensitivity to CPT
sensitivity was enhanced, albeit not to the same level as with cells expressing the fully
yTop1G721D (Fig. 4.12.A, data not shown). These data demonstrate that mutation of the
conserved Gly to Asp increases Top1 sensitivity to CPT, independent of the linker
composition of the enzyme.

4.4. DISCUSSION
In eukaryotes, the unusual structural organization of the nuclear Top1 enzyme
comprises a protein clamp, formed by a highly conserved core domain, that completely
circumscribes duplex DNA (12, 27, 59). The extended coiled-coil of the linker domain
connects the core with another conserved C-terminal domain, which contains the active
site tyrosine and is positioned against the clamp to complete the catalytic pocket of the
enzyme. These nuclear enzymes also contain a highly charged N-terminal domain, for
which little structural information is available, but has been implicated in regulating the
intracellular localization of Top1, Top1-protein interactions and the catalytic activity of
Top1 in DNA relaxation assays (34, 37, 127).
Questions concerning the relative movement of Top1 protein domains during enzyme
catalysis and how these movements impact Top1 sensitivity to drugs that target this
enzyme, such as CPT, have been of considerable interest. For instance, in co-crystal
structures of human Topo70 with DNA, the tight packing of the DNA duplex within the
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pore of the protein clamp indicated considerable flexibility was necessary for Top1 to
bind DNA (12, 27, 59). Using molecular modeling, we designed a reversible disulfide
bond that locked the Top1 clamp around duplex DNA, which prevented DNA strand
rotation within the covalent enzyme-DNA intermediate (41). Thus, some breathing of the
protein clamp is necessary for Top1 binding of DNA and for DNA strand rotation. The
flexibility of the linker domain has also been implicated as a critical determinant of
enzyme sensitivity to the CPT class of chemotherapeutics. The movement of this coiledcoil in covalent Topo70-DNA complexes precludes structural determination, while drug
binding apparently restricts the orientation of the linker to an angle oblique to the DNA
(59). Increasing the movement of this domain, either by physically uncoupling the Top1
linker and core domains in reconstitution experiments (61), or by mutation of Ala653 to
Pro in hTop1 (62), decreases enzyme sensitivity to CPT. The concept of long range
molecular interactions between the linker and the active site of the enzyme are further
supported by two recent studies. First, the lethal phenotype induced by the human
Top1T722A mutant, which is defective in enzyme-catalyzed DNA religation, was
suppressed by the increased linker flexibility of the A653P mutation (183). Second, we
showed that substitution of Gly721 within the active site of yeast Top1 with residues
estimated to have a higher propensity for α helix formation, induced alterations in
enzyme active site architecture and increased yTop1 sensitivity to CPT (184). On the
basis of structural considerations, where the extension of a short a helix within the active
site of Topo70 to include the corresponding Gly717 residue of human Top1 was
coincident with drug binding and a restriction of linker orientation (59), we posited that
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this conserved Gly provided a flexible hinge to facilitate the alterations in linker
flexibility induced by CPT.
Here we show that mutation of Gly717 in hTop1G717D also enhances enzyme
sensitivity to CPT, which further supports a model whereby the flexible hinge provided
by Gly allows for alterations in active site geometry and linker flexibility that attend CPT
poisoning of hTop1. However, the inability of the hTop1G717D to alter yeast cell
sensitivity to CPT led us to consider the relative contribution of individual protein
domains to Top1 sensitivity to CPT and enzyme function in vivo.
First, our studies demonstrate that, in the context of full length human Top1, the
G717D mutation increased intrinsic enzyme sensitivity to CPT by selectively enhancing
the rate of DNA cleavage. This effect on enzyme catalysis was only evident in assays
using a variety of suicide substrates to uncouple Top1-catalyzed DNA cleavage from
religation. Under steady state conditions with duplex DNA, an increase in covalent
Top1G717D-DNA complexes was only evident in the presence of CPT. As DNA cleavage
is, in part, the rate limiting step in enzyme catalysis (168), there was no apparent defect in
the rate at which these covalent complexes were resolved. However, in the presence of
CPT, the bound drug increases the stability of the covalent complex by reducing the rate
of DNA religation (59, 180). Taken together, these data suggest the increased rate of
DNA cleavage induced by the G717D mutant coupled with the decreased rate of DNA
religation induced by drug binding, enhance CPT poisoning of hTop1G717D, relative to
that observed with wild-type hTop1.
This increase in CPT sensitivity also coincided with G717D mutant induced
alterations in active site architecture as probed by trypsin digests of the covalent hTop1
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G717D-DNA intermediates. These results contrasted with assays of wild-type hTop1,
which yield the canonical 14 nt- 7 residue peptide diagrammed in Fig. 4.7.A. In this
context, it is worth noting that when hTop1G717D cleavage of DNA occurred in the
absence of duplex DNA 3’ to the site of scission (the post- annealed religation assay of
Fig. 4.5), partial tryptic digests were obtained at two Lys residues that flank the G717D
mutation, i.e., Lys712 and Lys720. This stretch of amino acids constitutes the physical
connection between the α helix that contains Tyr723 covalently attached to DNA and the
C-terminal end of the coiled-coil of the linker domain at Lys712 (59). In the absence of
CPT, the α helix does not extend to include Gly717. However, when a CPT analog is
bound in the Topo70-DNA complex, this α helical structure is no extended to include
Gly717 and Leu716 (59). Since Asp is predicted to have a higher propensity to form an α
helix than Gly (178), the extension of this α helical structure in the G717D mutant, in the
absence of CPT, would position Asp three residues N-terminal to Lys720 and on the same
face of the α helix. Such a structural transition might preclude efficient trypsin digestion
in the absence of urea denaturation and possibly enhance CPT poisoning of Top1 by
stabilizing an active site geometry that facilitates drug binding. In the presence of a 2 nt
flap and downstream duplex DNA prior to mutant G717D cleavage of the suicide DNA
oligo (in the pre-annealed religation assay of Fig. 4.6), only trypsin digestion of Lys720
was affected by urea denaturation; no defect in proteolytic cleavage of the C-terminal end
of the linker (Lys712) was detected. These data suggest that in the presence of duplex
DNA 3’ to the site of scission, the structure of the C-terminal end of the G717D mutant
linker is distinct from that observed in the absence of DNA. Arguably, the presence of the
2 nt flap in these assays may constitute a typical DNA substrate for hTop1. However, as
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similar results were obtained with the covalent hTop1G717D-DNA complexes formed
with the duplex suicide substrate containing a 5’ bridging phosphorothiolate at the site of
scission (Fig. 4.4), the alterations in G717D mutant active site architecture revealed by
trypsin digestion were not an artifact of flap-induced distortions in the DNA. Rather they
reveal distinct differences in the catalytic pocket of covalent hTop1-DNA complexes
induced by the G717D mutation.
Second, our analyses of yeast /human Top1 chimera activity in vitro and in yeast
indicate that in the context of full length enzymes, comprising an N-terminal, core, linker
and C-terminal domain, the intrinsic CPT sensitivity is dictated by the composition of the
core and C-terminus. Independent of the origin of the N-terminal and/or linker domains
(yeast or human), enzymes consisting of the human core and C-terminal domains
exhibited comparable specific activity in plasmid relaxation assays and CPT sensitivity in
DNA cleavage assays. However, distinct patterns of enzyme activity were evident in
top1∆ yeast cells expressing these various chimeras from GAL1-promoted constructs.
Reciprocal swaps of the highly charged yeast and human N-termini (at a juncture
corresponding to human residue 192 or yeast residue 120), did not impact cell viability or
the relative levels of cell sensitivity to CPT. Thus, any Top1-protein interactions
mediated solely by these domains do not affect the extent of CPT-induced toxicity in
these cells. Human Top1 residues 201-206 have also been implicated as playing a critical
role in enzyme catalysis (37). However, fusing human Top1 residues 1-191 or 1-209 with
the corresponding C-terminal residues of yTop1 failed to alter the CPT sensitivity of cells
expressing these chimeras, relative to cells expressing wild-type hTop1 (Fig. 4.8 and data
not shown). These data suggest that the critical function of these human residues
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(KWKWWEEE) in enzyme catalysis is retained in the corresponding residues of yeast
Top1 (EYKWWEKE).
In contrast, the introduction of the longer yeast linker domain in hTop1
profoundly altered enzyme function in vivo. Indeed, the toxicity induced by
overexpression of (yL)-hTop1 chimeras, containing the yeast linker, was independent of
DNA cleavage. Yet in vitro, the CPT sensitivity and specific activity of the (yL)-hTop1
chimera was similar to that of hTop1. These findings suggest that the presence of the
yeast linker may promote protein-protein interactions that alter the association of hTop1
with other cellular complexes in yeast, which adversely impact cell growth. The context
of these associations and whether such complexes are DNA bound have yet to be
addressed. However, the ability of the complementary yeast N-terminal domain to
suppress the toxicity induced by the presence of the yeast linker in hTop1 suggests a
negative role for the N-terminus in suppressing these interactions. Moreover, these data
support a functional interaction between these two domains. Whether this is due to the
direct physical association of these domains or indirect interactions mediated by DNA
/other proteins has yet to be determined. In this context, it is noteworthy that the Nterminal domain, which has defied structural determination is absent from the human
Top1 enzyme that is targeted to the mitochondria (182). Thus, the function of the Nterminal domain appears to be restricted to nuclear-Top1 interactions.

123

CHAPTER 5: IDENTIFICATION OF PROTEINS INTERACTING
WITH TOP1 LINKER AND C-TERMINAL DOMAIN

5.1 INTRODUCTION
Eukaryotic DNA Topoisomerase I (Top1) is a highly conserved enzyme that plays
a role in the alteration of DNA topology during processes such as replication,
transcription, recombination and chromosomal condensation. This enzyme consists of
four domains: 1) an N-terminal domain that is not required for in vitro activity, but has
been shown to interact with other proteins; 2) a core domain that forms a clamp
circumscribing duplex DNA and contains all the catalytic residues except the catalytic
Tyr (Tyr723 in human Top1); 3) a linker that forms a coiled coil extending away from the
body of the enzyme, and 4) a C-terminal domain that is connected to the core through the
linker and contains the catalytic Tyr responsible for cleavage (3, 4, 39).
Even though this enzyme is highly conserved from budding yeast to humans,
there are regions that deviate both in size and amino acid sequence. The core and Cterminal domains are the most conserved regions of Top1. An active enzyme can be
reconstituted by combining individually expressed core and C-terminal domain
polypeptides, indicating that these two domains are the minimal requirement for Top1
relaxation activity (39).
The N-terminus and linker domains are the most divergent regions of the enzyme.
The yeast Top1 N-terminus is much smaller than that of human Top1, although both
contain a high percentage of charged residues. Unfortunately no crystallographic data are
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available to establish the position of the N-terminus relative to the rest of the protein (12).
In contrast to the N-terminus, the human linker is much smaller than that of yeast Top1.
Crystallographic data of the 70 kD C-terminal region of human Top1 and molecular
modeling of the yeast Top1 linker indicate that this domain is structurally conserved,
forming an extended coiled coil ( ∼56Å for human Top1; ∼110Å for yeast Top1). There
are few contacts between the linker and the body of the enzyme giving this domain a high
degree of flexibility (12, 59). No protein binding sites have been mapped to the linker
domain.
Top1 does interact with various proteins and protein complexes, including the
transcription initiation and elongation machinery, TATA Binding Protein (TBP), p53,
nucleolin, SV40 large T antigen, a RING finger/RS rich protein named topors, which
functions as a SUMO/Ub dual E3 ligase, and the spliceosomal protein, SF2/ASF (34,
100, 127, 133, 137). Top1 has also been functionally linked to (138), or co-localized and
co-purified with RNA polymerase I (128, 139). All of the above mentioned interactions
occur through the N-terminal Top1 domain and the binding motifs within Top1 have
been defined for nucleolin and SF2/ASF (34, 100, 127, 133, 137).
Our studies of chimeric proteins, in which human Top1 was engineered with a
yeast linker, showed that this protein is toxic to yeast cells when overexpressed from a
GAL1 promoter (See chapter 4). No differences in specific enzyme activity were detected
between wild-type human Top1 and this chimera. Moreover, in DNA cleavage assays,
where the steady state levels of covalent Top1-DNA intermediates were assessed in the
presence of the Top1 poison CPT, no alteration in the CPT sensitivity or sequence
specificity of the stabilized covalent complexes formed were detected. The surprising
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finding was that when the human Top1 N-terminus of this chimera was replaced with the
yeast N-terminus, this protein was no longer toxic when expressed from the GAL1
promoter and the cells were sensitive to same level of CPT as cells expressing wild type
human Top1, indicating a functional interaction between the N-terminus and the linker
domain. This idea is supported by the experiments of Lisby et al. (37), which suggest that
the N-terminus interacts with DNA downstream of the cleavage site, the same segment of
DNA that the linker has been shown to interact with in the crystallographic data of
Topo70 non-covalently linked to a 22 basepair DNA duplex (12). More surprising was
the fact that when an inactive chimeric protein of human Top1 containing the yeast linker
((yL)-hTop1) was overexpressed in yeast cells, it was still toxic, demonstrating that the
toxicity is not due to the catalytic activity of the enzyme, but rather a loss or gain of
function dictated by the linker domain.
To test this hypothesis, a two-hybrid screen was performed to identify specific
proteins interacting with the linker domain, and then determining whether any differences
exist in the binding of these proteins to the yeast and human linker. An additional reason
for investigating potential binding partners of the linker, was the fact that while both the
hTop1G717D and the corresponding yeast mutant, yTop1G721D were hypersensitive to the
anticancer drug CPT in vitro, only the yeast mutant enzyme enhanced yeast cell
sensitivity to CPT (See chapter 3 and 4). These data suggest distinct functional
interactions of yeast and human Top1 with protein complexes in yeast cells. In chapter 4,
we demonstrated that exchanging only the N-terminal domain of yeast and human Top1
did not alter cell sensitivity to CPT, suggesting that it is either the linker or the
combination of the linker and N-terminus that dictate these functional interactions.
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5.2 EXPERIMENTAL PROCEDURES

5.2.1. Chemicals, yeast strains and plasmids
S. cerevisiae strain L40 (MATa, his3Δ200trp1-901 leu2-3112 ade2
LYS2::4lexAop-HIS3 URA3::(lexAop-lacZ) GAL4), the Hybrid hunter kit, ZeocinTm and
AntiLex A antibody were purchased from Invitrogen. Plasmid pACT and Escherichia
coli (E.coli) strain BNN132 containing the cre gene (188) were bought from ATCC. 3Aminotriazol was purchased from Sigma and X-gal from Promega.

5.2.2. Construction of bait
Bait proteins were constitutively expressed from the ADH promoter on a 2µ
Zeocin+plasmid, (pHybLex/Zeo) and contained the LexA carboxy-terminal
oligomerization region that contributes to operator occupancy by LexA derivatives (189).
Two yeast bait constructs were generated by PCR amplification of yeast TOP1 DNA
sequences encoding the linker and C-terminal domains (Link/C). The following forward
primers were used to amplify yTop1Link/C-1and yTop1Link/C-2: primer (yTop1Link/C-1) 5’ATCCGGAATTCACTGTCACGAAGGGGCATGCAC and primer (yTop1Link/C-2) 5’ATCCGGAATTCAAAGGATCTGTCGCAGAGAA. The same reverse primer was used
for both amplifications: primer 5’- GATCGAGCTCTTAAAACCTCCAATTTTCATC.
The forward primers contained an EcoRI and the reverse primer a SacI cleavage site
(underlined) near the 5’-ends to allow subcloning into pHybLex/Zeo.
To generate the human Top1 bait corresponding to yTop1Link/C-1, human TOP1
sequences encoding the linker and C-terminus (hTop1Link/C) were PCR amplified using
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primers containing either a Sac1 or Kpn1 site near the 5’-ends for subcloning into
pHybLex/Zeo: Forward primer 5’- TGAGAGCTCGCACCACCAAAAACTTTTGAG
and reverse primer 5’- TACGGTACCCTAAAACTCATAGTCTTCATCAG. The
amplified DNAs were cleaved and ligated into pHybLex/Zeo to generate pHybLx/ZeoyTop1Link/C-1, pHybLex/Zeo-yTop1Link/C-2 and pHybLex/Zeo-hTop1Link/C. All constructs
were confirmed by DNA sequencing and protein expression and integrity in yeast cells
assessed by immunoblotting. Briefly, whole cell extracts were prepared by breaking
open yeast cells using cracking buffer ( 8M Urea, 5% SDS, 40 mM Tris-HCl (pH 6.8),
0.1 mM EDTA 1% β-mercaptoethanol, 0.4% mg/ml bromophenol blue) and cold glass
beads. Cell/glass bead suspension was incubated at 70 °C for 10 minutes and then
vortexed for 1 minute. 30 µl of the whole cell extract was used for immunoblotting.
Proteins were resolved in a 4-12% BisTris gel (Invitrogen), transferred onto activated
polyvinylidene difluoride membrane (PerkinElmer Life Sciences), immunostained with
the anti-LexA antibody (Invitrogen) and visualized by chemiluminescence.

5.2.3. Automatic subcloning of plasmid library
The λ-ACT library was converted into a plasmid library by Cre-LoxP
recombination. λ-ACT, a Saccharomyces cerevisiae cDNA library in phage λ, was
purchased from ATCC. The cDNAs were made using standard methods outlined by
Durfee et al. 1993 and ligated into the Xho1 site on the λ-ACT arms (190). The cDNA
insert and surrounding sequences are flanked by two LoxP sites. The conversion of λACT into plasmid (pACT) was accomplished by incubating 109 phage with a 1 ml
overnight culture of BNN132 cells in 10 mM MgCl2 for 30 min at 30 °C without shaking.
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E.coli strain BNN132 has been engineered to constitutively express the Cre recombinase
such that site-specific recombination by Cre at the LoxP sites would generate pACT
plasmid harboring random yeast cDNAs that is N-terminally HA-tagged and located
downstream of the sequence encoding the GAL4 activation domain (188). Two milliliters
of LB was added and cells were incubated with shaking for 1h at 30 °C. Cells were then
plated on ten 150 mm LB-plates with 50 µg/ml ampicillin and incubated at 37 °C
overnight. Apr cells were scraped from these plates, added to 3 liters of terrific broth
with ampicillin and grown overnight. Plasmids were isolated used a Quigen maxiprep kit.

5.2.4. Screening for yeast Top1Link/C-1 interactors
Library screening was performed according to the Invitrogen Hybrid hunter
protocol. Briefly, the bait strain, L40-yTop1Link/C-1 was generated by transforming strain
L40 with pHybLex/Zeo-yTop1Link/C-1, which contains the Zeocin resistance gene, by
treatment with lithium acetate and heat shock in presence of DMSO. Transformants were
selected and maintained on yeast extract-peptone-dextrose medium containing 0.1%
adenine (YPAD) and 300 µg/ml Zeocin.
For the two-hybrid screen, 5x108 L40-yTopLink/C-1 cells were transformed with 500
µg library plasmid DNA in a 1L volume using lithium acetate, and heat shock (42 °C) in
the presence of DMSO. The cells were the incubated in YPAD at 30 °C for 1h with
constant shaking, pelleted and resuspended in YC-LU Z300 (synthetic medium lacking
leucine and uracil and supplemented with 300 µg/ml Zeocin) and incubated, with
shaking, at 30 °C for 16h.
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To confirm that sufficient numbers of transformants were screened, 1x10-5 and
1x10-6 dilutions, of the transformed cells, were plated on YC-LU Z300 to gauge
transformation efficiency. To screen for interactions that restore histidine prototrophy,
5µl, 10µl, 25µl and 50µl of cells from the culture were plated on YC-LHUK Z300 (YC
Z300 lacking leucine, histidine, uracil and lysine). All plates were incubated at 30 °C for
3-5 days.
A secondary screen was performed on the His+ colonies to assess expression of
the reporter gene, lacZ, using a X-gal filter assay as described in the Hybrid hunter
protocol. Nitrocellulose filters sized to fit a 100 mm plate were laid on top of the His+
colonies grown, removed and frozen in liquid nitrogen. After the filter was thawed at
room temperature, it was incubated with 1.5 ml Z-buffer (60 mM Na2HPO4, 40 mM
NaH2PO4, 10 mM KCl, 1 mM MgSO4, pH 7.0) and 30 µl of 50 mg/ml X-gal in a Petri
dish, covered with foil and incubated at 30 °C for 30 minutes. As expression of the lacZ
gene product, β-galactosidase, is driven by binding of the LexA DNA binding domain
(DBD) and recruitment of the Gal4 Activation domain (AD), a positive interaction is
evident by the expression of β-galactosidase, which metabolizes X-gal to an insoluble
blue product (5,5’-dibromo-4,4’-dichloro-indigo).

5.2.5. Isolation of plasmid from yeast cells
To identify yeast gene products which induces histidine prototrophy and βgalactosidase expression, plasmids were isolated from His+, blue colonies amplified in
E.coli and the cDNA insert were sequenced. Briefly, a 5 ml culture of each colony was
grown overnight to an OD600 of 1. The cells were pelleted and resuspended in 500 µl 1 of
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M sorbitol/20 mM EDTA. 30 µl 20T zymolase (5 mg/ml in 1 M sorbitol) was added and
suspension was incubated at 37 °C for 30 minutes. Cells were again pelleted, the plasmid
DNA was extracted using using a Qiagen miniprep kit, transformed into E.coli and
isolated from ampicillin-resistant transformants.
The cDNA inserts were sequenced using the following sequencing primer: 5’
GCTTACCCATAACGATGTTCCA. The DNA sequences obtained were then used to
query the Saccharomyces Genome Database (http://www.yeastgenome.org/) to establish
the identity of individual cDNAs.

5.2.6. Confirmation of interaction, elimination of false positives and testing
interaction with human Top1 linker and C-terminal domain
To test for false positives and determine if the interactors found interacting with
yTop1Link/C-1 also interact with hTop1Link/C, L40 cells were transformed with
pHybLex/Zeo-yTop1Link/C-1, pHybLex/Zeo-hTop1Link/C or pHybLex/Zeo. Each strain was
co-transfomed with a library plasmid isolated from the screen and plated on YC-LU
Z300. After 3 days of incubation at 30 °C, 5 colonies from each plate were diluted in TE,
adjusted to OD600 = 0.3 and streaked onto YC-LU Z300, YC-LUHK Z300 and YCLUHK Z300 with 3 mM 3-Aminotriazole (3-AT) plates. 3-AT is a competitive inhibitor
of imidazole-glycerolphosphate dehydratase, the product of the HIS3 gene. The addition
of 3-AT allows discrimination between weak and strong interactors, as 3-AT will inhibit
low levels of dehydratase which will result in no growth on histidine-deficient medium.
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5.2.7. Detection of physical interaction between yTop1Link/C-1 and proteins identified
in two-hybrid screen using immunoprecipitations
L40 cells were co-transformed with pHybLex/Zeo-yTop1Link/C-1 and a library
plasmid isolated from the two-hybrid screen. These cells were grown in YC-LU Z300
media until they reached an OD600 = 1, washed in cold dH2O and resuspended in TG
buffer (50 mM Tris-HCl, 150 mM NaCl, pH 7.5, 1% Triton X-100 and 10% glycerol), 2
ml/g of wet cells. For 5 ml of TG buffer also add 50 µl Phosphatase inhibitor cocktail I
(Sigma), 50 µl Phosphatase inhibitor cocktail II (Sigma) and one protease inhibitor
cocktail tablet (Complete Mini, Roche). Cells were frozen at -80 °C overnight,
transferred to eppindorf tubes containing cold glass beads and vortexed 10 times, one
minute each and incubating the tubes on ice between each minute. Cell suspension was
centrifuged at 4°C for 20 minutes and supernatant transferred to new tubes. Protein
concentration was determined using a Biorad protein assay. 500 µl cell extract containing
equal protein concentration was added to 20 µl protein A/G PLUS agarose beads (Santa
Cruz Biotechnology) and rocked for 1h. Suspension was centrifuged and supernatant
transferred to new tubes. 0.4 mg/ml anti-LexA antibody and 30 µl protein A/G PLUS
agarose beads were added to the supernatant and rocked overnight at 4 °C. Sample was
centrifuged and supernatant removed. The beads were washed 5 times with TG buffer
containing phosphatase inhibitors, protease inhibitor and 0.05% sodium dodecyl sulphate
(SDS). Beads were resuspended in 50 µl SDS sample buffer (60 mM Tris-HCl (pH 6.8),
1.7% SDS, 5% glycerol, 0.1 M dithiothreitol, 0.002 % Bromophenol blue), boiled for 5
minutes and centrifuged. Proteins in the supernatant were resolved in 4-12% BisTris gels
(Invitrogen), transferred onto activated polyvinylidene difluoride membranes
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(PerkinElmer Life Sciences), immunostained with the anti-HA anitibody (Roche) and
visualized by chemiluminescence.

5.3 RESULTS
The two-hybrid system exploits the fact that transcription factors consist of two
domains, a DNA binding domain (DBD) and an activation domain (AD), and both need
to be present at the promoter region for transcriptional activation. For this screen two
hybrid proteins were constructed. The first is a Lex DBD/Bait fusion and the second a
Gal4 AD/Prey fusion. These two proteins are encoded by separate plasmids and both
proteins are constitutively expressed from the ADH promoter (Fig. 5.1).
To perform the screen, both plasmids are transformed into a yeast strain that
contains two reporter genes, lacZ and an auxotrophic marker, HIS3. The regulatory
region for both reporter genes contain the LexA DNA binding sites that acts as upstream
activating sequences (UAS) in yeast. If the bait protein interacts with the prey, the
activation domain will be recruited to the DNA binding domain to reconstitute a
functional transcription factor, resulting in the expression of the reporter genes (Fig. 5.2).
The goal of this experiment was to determine what proteins, if any, specifically
interact with the linker and C-terminal domain of yeast Top1 (yTop1Link/C) and if any of
these interactions were altered in the context of the human Top1Link/C. Therefore, we first
used the yeast Top1 linker and C-terminal domains to avoid heterologous protein
expression in yeast cells (Fig. 5.3). Previous reports that an active enzyme can be
reconstituted by fragment complementation of the human Top1 core (expressed in SF9
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FIG. 5.1. Plasmids used for the construction of the bait and the prey. A. yTop1Link/C-1
and yTop1Link/C-2 were amplified and ligated into the EcoRI and SacI sites of
pHybLex/Zeo, while hTop1Link/C was ligated into the SacI and KpnI sites. B. S.cerevisiae
cDNAs were ligated into the XhoI site located in the pACT sequences embedded in λ
DNA flanked by LoxP sites. Site specific recombination by the Cre recombinase
generates a library of pACT plasmids that contain random yeast cDNA inserts, Nterminally HA tagged and located downstream of the Gal4 activation domain (AD). ∼ 1/3
are expected to be in frame with the Gal4 AD and therefore encode a chimeric prey.
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FIG. 5.2. Schematic representation of the two-hybrid system. A and B. The LexA
DBD/Bait or the Gal4 AD/Prey fusion proteins alone are unable to activate transcription.
C. Interaction of the Bait and Prey will recruit the Gal4 AD to the LexA DBD and
together they will form a functional unit that is able to activate transcription.
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FIG. 5.3. Polypeptides used as bait. A. Structure of the C-terminal 70 kDa human Top1
(Topo70) covalently linked to duplex DNA in the presence of topotecan (TPT) [PDB file
1K4T (59)]. TPT is indicated in red and the active site Tyr723 is in yellow. The region in
magenta corresponds to the residues used by Stewart et al. (39) to reconstitute an active
enzyme when combined with the hTop1 core. The black arrow indicates the Thr561which
is the beginning of the bait that was used in the screen. B. Schematic representation of
the domain organization of yeast and human Top1. The magenta bar at the top
corresponds to the region (shown in magenta in A) that was used for reconstitution
experiments and the gray bars represent the regions of human and yeast Top1 that was
used to generate the bait constructs. yTop1Link/C-1 was used for the two-hybrid screen. C
and D. Levels of the fusion proteins in crude cells extracts were determined in
immunoblots with the LexA antibody. Expression of the LexA DBD by itself was used as
a positive control. LexA DBD is 26 kD, yTop1Link/C-1 is 49 kD, yTop1Link/C-2 is 52 kD and
hTop1Link/C is 40 kD.
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insect cells) with the linker/C-terminal domain (expressed in E.coli and represented in
magenta Fig. 5.3.A and B), suggest proper folding of both polypeptides. Based on these
results and the sequence alignment of yeast and human Top1, two bait constructs were
generated. yTop1Link/C-1 (Thr561-Phe769) includes the complete linker plus C-terminal
domain, while yTop1Link/C-2 (Lys535-Phe769) starts within the C-terminal portion of the
core, corresponding to exon 17/18 junction of hTop1, and includes the linker and Cterminal domains ( polypeptides are indicated in gray in Fig. 5.3.B). Both constructs were
examined for stable protein expression in immunoblots of yeast cell extracts (Fig. 5.3.C).
As yTop1Link/C-1 fusion protein levels were consistently higher than that obtained with the
yTop1Link/C-2 bait, and this construct was restricted to only the linker and C-terminal
domains, yTop1Link/C-1 was used as bait in the screen (Fig 5.3.C). As the C-terminal
domain is largely buried within the co-crystal structures of Topo70 and DNA, we further
reasoned that any artifactual protein binding to C-terminal residues would be eliminated
in subsequent studies with full length Top1 proteins. A construct containing the
hTop1Link/C, which corresponds to the yTop1Link/C-1, was also generated and tested for
stable expression of the LexA DBD-hTop1Link/C fusion protein (Fig. 5.3.D).
To confirm that the LexA DBD-yTop1Link/C-1 fusion protein did not activate
transcription of the reporter genes, pHybLex/Zeo-yTop1Link/C-1 was co-transformed with
the pACT (vector backbone of the cDNA library), which encode only the Gal4 AD
polypeptide, into L40 yeast cells. The transforments were assayed for histidine
prototrophy and β-galactosidase activity, the yTop1Link/C-1 fusion protein failed to induce
HIS3 or lacZ gene transcription (Data not shown).
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For an unbiased screen of protein interactions with the linker and C-terminal
domains of yeast Top1, the prey used comprised of a yeast cDNA library. It was cotransformed with pHybLex/Zeo-yTop1Link/C-1 and transformants selected on histidinedeficient plates. Positive interactions would allow growth on His- plates. His+ colonies
were a rare event relative to the number of primary transformants (plating 100µl of a
1x10-6 dilution of the primary transformants on His+ plates gave a lawn of cells, while 5
µl of the transformation reaction plated on His- plates generated about 8
His+colonies/plate) and only 50%-60% of the His+ colonies expressed active βgalactosidase. Plasmids were isolated from 70 His+, β-galactosidase+ colonies and 16
potential interactors identified (listed in Table 5.1).
Many of the cDNAs retrieved from the screen were not full length. For example,
all of the POL30 (PCNA) clones sequenced are missing the N-terminal 172 bases.
Complete coding regions were identified for UBC9, NSE5 and MRM1.
Ubc9, Nis1 and Pol30, but not Mrm1 interact with both yeast and human linker
and C-terminal domain. Based on the number of clones identified for each cDNA and
interactions with Top1 reported in the literature, the following potential interactors were
chosen for the subsequent experiments; Ubc9, Nis1, Pol30, Mrm1 and Nse5 (all fused to
the Gal4 AD). We first confirmed the interaction between these proteins and yTop1Link/C-1
and then assessed potential interactions with hTop1Link/C (Table 5.2). Each fusion protein
was coexpressed with yTop1Link/C-1, hTop1Link/C (both fused to a LexA DBD) or a
polypeptide corresponding to the LexA DNA binding domain. The proteins were
expressed in the L40 yeast strain that contains the HIS3 reporter gene and the subsequent
transformants were grown on His- plates in the presence or absence of 3 mM 3138

TABLE 5.1. Proteins identified in the two-hybrid screen.

Name

#

Function (Saccharomyces genome database)

a

Tif4631

1

Translation initiation factor eIF4G, subunit of the mRNA cap-binding
protein complex (eIF4F) that also contains eIF4E (Cdc33p); associates
with the poly(A)-binding protein Pab1p, also interacts with eIF4A
(Tif1); homologous to Tif4632

a

Rsc9

1

Component of the RSC chromatin remodeling complex; DNA-binding
protein involved in the synthesis of rRNA and in transcriptional
repression and activation of genes regulated by the Target of
Rapamycin (TOR) pathway

a

Asc1

3

WD repeat protein (G-beta like protein) involved in translation
regulation; required for repression of Gcn4 activity in the absence of
amino-acid starvation; core component of the ribosome; ortholog of
mammalian RACK1

b

Ubc9

2

SUMO-conjugating enzyme involved in the Smt3 conjugation
pathway; nuclear protein required for S- and M-phase cyclin
degradation and mitotic control; involved in proteolysis mediated by
the anaphase-promoting complex cyclosome

b

Siz2

1

SUMO ligase, catalyzes the covalent attachment of SUMO (Smt3) to
proteins; involved in maintenance of proper telomere length

b

Nse5

4

Essential subunit of the Mms21-Smc5-Smc6 complex; required for cell
viability and DNA repair

c

His7

1

Imidazole glycerol phosphate synthase (glutamine
amidotransferase:cyclase), catalyzes the fifth and sixth steps of
histidine biosynthesis and also produces 5-aminoimidazole-4carboxamide ribotide (AICAR), a purine precursor

c

Pdc1

1

Major of three pyruvate decarboxylase isozymes, key enzyme in
alcoholic fermentation, involved in amino acid catabolism

c

Prs2

1

5-phospho-ribosyl-1(alpha)-pyrophosphate synthetase, involved in
nucleotide, histidine, and tryptophan biosynthesis; one of a five related
enzymes, which are active as heteromultimeric complexes

8

Protein component of the small (40S) ribosomal subunit, required for
assembly and maturation of pre-40 S particles

d

Rps19A
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TABLE 5.1. (continued)

Name

#

Function (Saccharomyces genome database)

d

Rpl3

1

Protein component of the large (60S) ribosomal subunit

e

Nis1

17

Protein localized in the bud neck at G2/M phase; physically interacts
with septins; possibly involved in a mitotic signaling

e

Mrm1

7

Ribose methyltransferase that modifies a functionally critical,
conserved nucleotide in mitochondrial 21S rRNA

e

Clf1

1

Essential splicesome assembly factor; contains multiple
tetratricopeptide repeat (TPR) protein-binding, may serve as a scaffold
during splicesome assembly

e

Swd3

1

Essential subunit of the COMPASS (Set1C) complex, which
methylates histone H3 on lysine 4 and is required in transcriptional
silencing near telomeres

Pol30
(PCNA)

4

Proliferating cell nuclear antigen (PCNA), functions as the sliding
clamp/processivity factor for DNA polymerase delta; may function as a
docking site for other proteins required for mitotic and meiotic
chromosomal DNA replication and for DNA repair

e

a

Proteins involved in TOR (Target of Rapamycin) signaling. Tif4631 has been shown to
physically interact with Top1p through affinitycapture-ms (191).
b

Proteins involved in sumoylation. Ubc9 genetically interacts with Top1 (136).

c

Proteins involved in amino acid metabolism, more specifically histidine biosynthes. As
these proteins are involved in histidine metabolism, they might restore histidine
prototrophy and potentially be false positives.
d

Proteins that form components of the ribosome. Rps19A is a ribosomal protein that is
highly expressed and therefore might lead to non-functional interactions.
e

Miscellaneous proteins. Nis1 is located in the bud neck during G2/M phase, while Top1
is a nuclear protein and therefore this might not be a functional interaction. Clf1, which is
involved in spliceosome assembly, is an interesting find as the Top1 N-terminal domain
is known to bind to other spliceosomal proteins SF2/ASF (137). Mammalian PCNA has
been shown to interact with human Top1 by affinity chromatography (192).
# refer to the number of clones identified in screen.
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Aminotriazol (3-AT). A positive interaction is indicated by growth on plates lacking
histidine. Strong and weak interactions can be discriminated based on growth on plates
containing 3-Aminotriazole. Fig. 5.4. shows an example of the above mentioned
experiment using Ubc9, while Table 5.2. provides a summary of results for all the
interactors tested (Ubc9, Pol30, Mrm1, Nis1and Nse5).
Expression of the Nse5 fusion protein with the LexA DBD by itself cause growth
on His- plates, indicating that this interaction is not dependent on Top1 and is therefore
scored as a false positive. Ubc9, Pol30 and Nis1 interact with both the yTop1Link/C-1 and
hTop1Link/C, albeit to a lesser extend with the human protein. Mrm1 interacts strongly
with the yTop1Link/C-1, but no interaction was detected with hTop1Link/C.
Next, immunoprecipitations were performed to confirm the physical interactions
defined with the two-hybrid screen. As the cDNAs were ligated into the λ vector that
contains sequence encoding a HA-tag N-terminal to the inserted cDNA, the Gal4 ADfusion protein can be detected in immunoblots using the HA-antibody. Fusion proteins of
the predicted size were detected for Nis1, Nse5, Pol30 (PCNA), Mrm1 and Rps19A (Data
not shown). Cells expressing these fusion proteins also contain a protein product that is
12 kD smaller than the fusion protein and corresponds to the protein without the Gal4
AD. Even though a correct size band was detected for the Ubc9 fusion protein (29kD), a
second band (∼ 43kD) was also observed. It had been reported that Ubc9 are able to form
dimers through a thioester bond (193), but as the protein was resolved in the presence of
the reducing agent, 0.1 M dithiothreitol (dtt), it is unlikely that the extra band is a dimer.
Ubc9 has also been shown to be sumoylated on Lys153, which is a non-consensus SUMO-
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FIG. 5.4. Ubc9 interacts with yTop1Link/C-1 and hTop1Link/C equally well. Gal4 ADUbc9 fusion protein coexpressed with LexA DBD-hTop1Link/C fusion protein, LexA
DBD-yTop1Link/C-1 fusion protein or the LexA DBD by itself, were assayed for growth on
plates deficient for histidine in the presence or absence of 3-AT.
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TABLE 5.2. Distinct interactions with yTop1Link/C-1 and hTop1Link/C.

Ubc9

Pol30

Mrm1

Nis1

Nse5

Yeast Bait

+

++

++

++

+

Human Bait

+

+

-

+

+

LexA DBD

-

-

-

-

+

(-) indicates no growth on a His- plate, (+) indicates growth on a His- plate and (++)
indicates growth on His- plates containing 3 mM 3-AT.
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site (194). The size of the higher molecular band corresponds to a polypeptide that is
potentially a sumoylated Ubc9-fusion protein.
For immunoprecipitations, Ubc9, Mrm1, Pol30, Nse5, Nis1 or Rps19A
fusionproteins were coexpressed with yTop1Link/C-1-LexA fusion protein (Fig.5.5).
Immunoprecipitation was performed using the LexA antibody, followed by
immunoblotting with HA-antibody. A physical interaction with the yeast linker and Cterminal domain could only be detected for Mrm1 and Pol30 (PCNA).

5.4 DISCUSSION
Top1 interacts with various protein partners such as TATA binding protein and
nucleolin (34, 100). All of these interactions are dictated by the N-terminal domain of
Top1. From studies using a chimeric Top1 protein, where the human Top1 linker domain
has been replaced by the much larger yeast linker, it was found that this protein was toxic
to yeast cells when overexpressed from GAL1 promoter. In vitro experiments, using
purified protein showed no difference between hTop1 and this chimeric protein in
specific activity or covalent complex formation in the presence and absence of CPT.
Moreover, there was also no difference in the optimum salt concentration for specific
acitivity between these two proteins, indicating that it is not a binding defect that is
inducing the toxicity. Further experiments showed that the catalytically inactive chimeric
protein is also toxic, suggesting that the toxicity is not due to the catalytic activity
(Chapter 4). This led us to hypothesize that the linker domain might be involved in
protein-protein interactions that differ between the yeast and human Top1 proteins.
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FIG 5.5. Mrm1 and Pol30 physically interact with yTop1Link/C-1. YTop1Link/C-1 fused to
the LexA DBD was coexpressed with Gal4 fused HA-tagged Ubc9, Rps19A, Mrm1,
Pol30, Nse5 and Nis1. Immunoprecipitation was performed using the LexA antibody and
immunoblotting with an HA antibody.
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Using a two-hybrid system where the bait was the yeast Top1 linker and Cterminal domain (yTop1Link/C-1), we screened a S.cerevisiae cDNA library for proteins
that interact with this region of Top1. From the screen we identified 16 proteins that
allowed for growth on selective media and also activated transcription of the reporter
gene, lacZ. Of the 16 proteins, three are involved in amino acid metabolism, Prs2, His7
and Pdc1 are potentially false positive.
Nis1, Mrm1, Pol30 and Ubc9 fusion proteins were confirmed as true interactors
with yTopLink/C-1 domain and tested for interaction with human Top1 linker and Cterminal domain. Pol30 and Nis1 interact with both the human and yeast linker and Cterminal domain, with a slight decrease in binding to the human protein. A physical
interaction between yTop1Link/C-1 and Pol30 was further confirmed by
immunoprecipitaion. An interaction between full length yTop1 and Pol30 was further
demonstrated by a postdoctoral fellow in the lab, Clifford Toleman, also using
immunoprecipitations. As a Top1 interactor, Pol30 (PCNA) is of specific interest as it
acts as a sliding clamp moving along with the replication fork and functions as a scaffold
with which various replication proteins interact (195). During replication Top1 acts as a
swivel to relieve torsional strain created by the movement of the replication fork. It is
therefore plausible that crosstalk exists between Top1 and Pol30. The function of this
interaction can be to either recruit Top1 to DNA regions that is under increased torsional
strain (due to ongoing replication) or a mechanism for Top1 to sense the approaching
replication fork.
Ubc9 interacts with the yeast and human protein equally well. Even though the
interaction with yTop1Link/C-1 with Ubc9 could not be confirmed with the
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immunoprecipitation, it is still an intriguing result. Ubc9 is the second enzyme (E2) in the
sumoylation cascade and can either by itself or with the help of an E3 ligase transfer
SUMO (Smt3 in yeast) to a Lysine on the target protein. The regions of both yTop1Link/C-1
and hTop1pLink/C used in the bait constructs contained consensus SUMO-sites, one in
yTop1pLink/C-1 (Lys600) and two in hTop1Link/C (Lys654, Lys669), and it is therefore possible
that Ubc9 is binding to these regions. There had been conflicting reports in the literature
about the role of sumoylation of Top1. It was initially shown that sumoylation of hTop1
in response to high concentration of the anticancer drug, camptothcin (CPT), resulted in
relocalization of the enzyme from the nucleus to the nucleolus (134). However, more
recent data using life cell imaging concluded that this modification did not affect CPTinduced nucleolar transport (122). Moreover, mutations of the sumoylation sites on Top1
had no effect on CPT sensitivity, indicating the sumoylation of Top1 does not affect CPT
sensitivity directly (136). In the immunoblot results of Ubc9, there were two protein
populations, a band corresponding to the Gal4-Ubc9 fusion protein and then a second
band that is potentially a sumoylated Ubc9 fusion protein. Ubc9 has been shown to be
sumoylated on Lys153, which is a non-consensus SUMO-site (194). This leads to the
possibility that Top1 only interacts with either sumoylated or unsumoylated Ubc9. This
issue can be resolved by mutating Lys153 on Ubc9 and testing if the interaction between
Ubc9p and yTop1Link/C-1 still exists.
Another protein identified in this screen that is involved in the sumoylation
pathway is Siz2. This protein is a SUMO E3 ligase that increases the efficiency of SUMO
conjugation. It functions by binding to Ubc9, and accelerate the rate of SUMO
modification in a substrate specific fashion. It can therefore be imagined that the
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recruitment of Siz2 is not directly through the interaction with yTop1Link/C-1, but rather
indirectly through the binding of Ubc9. As Ubc9 is an essential protein and the binding
region for E3’s overlap with the binding region of E1’s, mutating Ubc9 to loose the
interaction with Siz2 will be problematic. A more feasible approach would be to generate
recombinant proteins and determine interaction using electromobility shift assays. Using
this technique, it can be established if Siz2 binds to Ubc9p or yTop1Link/C-1 individually,
or if it requires both proteins for binding.
From the proteins that had been tested for differential binding between the
yTop1Link/C-1 and hTop1Link/C, Mrm1 was the only protein that interacted strongly with the
yeast bait and not at all with the human bait. It also physically interacted with
yTop1Link/C-1 in immunoprecipitations. Mrm1 is a ribose methyltransferase that is
essential for the formation functional mitochondrial ribosomes. No connections have
been made between this protein and any Top1 function.
This study was the first step in identifying proteins that interact with the Top1
linker domain. We found various binding partners that had already been shown to have
physical or genetic interaction with Top1, such as Pol30 (PCNA) and Ubc9. The next
challenge would be to determine what the biological meaning of these interactions are in
the context of regulating Top1 function and Top1 targeted drug sensitivity.
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CHAPTER 6: DISCUSSION

DNA topoisomerase IB (Top1) is a highly conserved enzyme found in all phyla of
the evolutionary tree and is capable of relaxing both positive and negative supercoils in
the absense of an energy donating cofactor (4, 7). Top1 became medically important with
the discovery that it is the sole target of the anti-tumor drug camptothecin, CPT, a
cytotoxic plant alkaloid (6, 57, 67). CPT and its derivatives act by intercalating between
the ends of the cleaved strand, interacting with both the DNA and the enzyme, preventing
the religation step of the catalytic cycle and extending the lifetime of the covalently
linked Top1-DNA intermediate (59, 196). This mechanism of action is unique as it not
the inhibition of catalytic activity that is toxic to the cell, but the replication machinery
moving along the DNA and encountering the covalently linked intermediate that results
in irreversible lesions which leads to cell death (181). Dogma has held that it is the actual
collision between the replication machinery and drug stabilized enzyme that creates the
cytotoxic lesions. However, more recent in vitro and in vivo data demonstrate that in the
presence of CPT there is a decrease in the relaxation of positive supercoils, suggesting
that in the context of an advancing replication fork it might be the accumulation of
positive supercoils between the covalent Top1 lesion and the advancing replication fork,
rather that the actual collision, that is inducing the DNA lesions (104). Because of this
mechanism of cytotoxicity, understanding the downstream pathways that are affected by
the formation of this DNA lesion, is of critical importance.
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6.1. MUTATIONS IN THE ACTIVE SITE REGION OF TOP1 INDUCE
DISTINCT SELF POISONING ACTIVITIES
yTop1N726H has an increased rate of cleavage, while yTop1T722A has a decrease
in the rate of religation, mimicking the action of CPT (103). Even though the result of
both mutants is an increase in covalent complex formation, yeast cell sensitivity to
constitutively low level expression of these mutants in different genetic backgrounds
varied dramatically. A model whereby these mutants do not induce different levels of
DNA damage, but actually create distinct lesions is supported by the variable patterns of
cytotoxicity observed when these mutants were expressed in a panel of isogenic tah
mutant strains. The tah strains were originally isolated in a genetic screen for enhanced
sensitivity to low levels of yTop1T722A at a non-perminssive temperature of 36 °C (120).
As shown in chapter 2, the cdc45-10 strain can tolerate low levels of yTop1T722A at 26
°C (permissive temperature), but had decreased transformation efficiency with the same
vector expressing yTop1N726H. These cells contain a temperature sensitive hypomorphic
allele of CDC45 and are defective in processive DNA replication at the non-permissive
temperature. A second strain, defective in processive DNA replication at the nonpermissive temperature, dpb11-10, could not tolerate the yTop1N726H at any temperature.
This result indicates that Cdc45 and Dpb11 are involved in either the sensing or repair of
the damage induced by these specific mutants. In contrast, doa4-10 cells, which contains
a nonsense mutation in DOA4, are resistant to expression of yTop1N726H and
yTop1N726F at the non-permissive temperature. Doa4 is an ubiquitin C-terminal
hydrolase, which functions to maintain free ubiquitin pools. The generation such variable
phenotypes in the different genetic backgrounds indicate that the mechanism of lesion
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formation affects the cells’ response to the lesions induced. It can be imagined that in the
intracellular multi-protein environment, different protein complexes will sense and repair
distinct lesions and that understanding these downstream sensing and repair pathways
will be important in the development of therapeutics targeting Top1.
With the knowledge that distinct Top1-induced lesions exist, it will be of great
interest to perform additional genetic screens to define distinct and common downstream
pathways that regulate cellular responses to DNA lesions induced by Top1N726H and
Top1T722A. As a conditional yTop1T722A sensitive screen has already been performed, a
second screen using yTop1N726H can be done to compare conditional mutant proteins
between these two screens. Another great resource for the yeast research community is
the existence of yeast gene deletion libraries, which contains a collection of strains where
all the non-essential genes are deleted. With the development of robotic platforms, the
use of this deletion set is now feasible and one should be able to use this technology to
define genes that suppress cell sensitivity to, for example, the yTop1N726H mutant.

6.2. THE GLY RESIDUE LOCATED IN THE TRANSITION REGION
BETWEEN THE LINKER AND THE ACTIVE SITE TYR ACTS AS A HINGE
TO ALTER ACTIVE SITE GEOMETRY AND LINKER FLEXIBILITY AND
THEREBY INFLUENCE CPT SENSITIVITY
Crystallographic data revealed Top1 as a protein clamp that wraps around duplex
DNA, with the linker domain forming a coiled coil structure extending away from the
body of the enzyme (12, 59). The linker also positions the C-terminal active site domain
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within the catalytic pocket formed by the core. Several lines of evidence suggest that the
linker domain is a critical determinant of CPT sensitivity. For instance, altering the
flexibility of this domain either by physically disconnecting the linker from the core (as
in the reconstituted Topo70 preparations) or through a mutation (A653P) in the linker
domain of hTop1, CPT sensitivity was decreased (61, 62). Crystallographic data of the
covalent Topo70-DNA complex demonstrated that in the presence of the CPT analog,
topotecan, there is a decrease in linker domain flexibility enabling the structural
determination of the coiled coil. This structure is not visible in the binary Top1-DNA
covalent complex, indicating increased linker domain movement (59). A closer
assessment of the region of the enzyme that connects the coiled coil to the active site Tyr
domain revealed a subtle change in structure. A α-helix extending from the active site
Tyr towards the core is extended in the presence of the drug to include the conserved
residues Leu716 and Gly717 (Leu720, Gly721 in yeast Top1). These data suggest the
existence of a dynamic relationship between intercalation of the drug, alterations in active
site α-helical structure and the flexibility of the linker domain. Such long range
molecular interactions between the linker and active site in mediating enzyme sensitivity
to CPT are further supported by recent studies in which the cytotoxicity induced by a
defect in human Top1-catalyzed DNA religation (due to the active site mutation T722A)
was suppressed by the increased linker flexibility of the A653P mutation (197).
Based on these considerations, we hypothesized that the Gly located in the
transition region between the linker and the active site Tyr acts as a flexible hinge to alter
active site geometry and linker flexibility and thereby influence CPT sensitivy. In vitro
and in vivo analyses of Gly721 mutations in yeast Top1p suggest that the charge and α152

helical propensity of amino acid side chains at position 721 directly impact active site
architecture within the covalent enzyme-DNA complex and the intrinsic sensitivity of
Top1 to CPT.
Our mutational analyses of substitutions at position 721 demonstrate that the
introduction of a bulky aromatic residue (Phe) or β branched aliphatic side chain (Val)
decreases the specific activity and concomitantly the CPT sensitivity of Top1. In contrast,
the introduction of an acidic side chain, with carboxyl groups at the β or γ carbon in
G721D and G721E, respectively, dramatically enhanced Top1p sensitivity to CPT, without
any obvious alterations in specific enzyme activity in plasmid DNA relaxation assays or
increase in covalent complex formation in steady state DNA cleavage assays. The
negative charge of Asp and Glu appears to enhance drug sensitivity as the increased CPT
sensitivity of cells expressing Top1 mutants engineered with the amide forms of these
residues (G721N and G721Q) and the γ branched aliphatic side chain (G721L) was only
evident in the absence of the DNA damage checkpoint. In addition to charge, a second
determinant of CPT sensitivity appears to be the tendency of residues at this position to
form α-helices, as mutating Gly721 to Ala [estimated to have the highest propensity for
helix formation(178)] also increased cell sensitivity to CPT. These data indicate the
following rank order of mutant-induced increased in Top1p sensitivity to CPT: (G721E,
G721D) > G721A> (G721N, G721Q, G721L) > wild-type > G721V > G721F.
Our studies using purified protein and suicide substrates demonstrate that an
increase in CPT sensitivity coincided with mutation induced alterations in enzyme active
site structure. The G721D, G721E mutants exhibited the greatest CPT sensitivity in vivo
and in vitro, as well as specific alterations in tryptic digests of covalent enzyme-DNA
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complexes formed in DNA religation assays. Comparing the pattern of DNA-bound
fragments obtained with the yeast and human Top1 mutants and correlating them with the
potential trypsin cleavage sites in yeast and human Top1 amino acid sequence allowed us
to determine the alterations in tryptic cleavage sites. In the residues spanning the active
site tyrosine of yeast Top1p, K712EENSQYSLG721TSK724INY727IDPR, trypsin digestion
of SDS-denatured wild-type Top1p-DNA covalent complexes results in a 7 residue
peptide (INY727IDPR) covalently attached to a 5’ end labeled 14 mer oligonucleotide via
a 3’phosphotyrosyl linkage. Mutation of Gly721 to Asp or Glu (G721D or G721E,
respectively) decrease efficiency of trypsin digestion at K724 to yield longer peptides
linked to the DNA. These longer peptides were not present when the protein was
denatured with urea, indicating that the restricted tryptic digests are due to structural
alterations in the mutant protein. One possibility is that the structure is altered such that
trypsin cannot gain access to K724 and digestion is therefore restricted at this site. A
second possibility is that the negative charge of D721 or E721 is precluding digestion.
Position 721 is 3 amino acids away from the trypsin cleavage site at K724, therefore a
structural alteration would still be required to position the negative charge in close
enough proximity to K724 to impact trypsin digestion. As there are 3.6 amino acids per αhelical turn, amino acids 3 or 4 residues apart are spatially quite close to each other. Our
results therefore suggest that in the absence of CPT the mutant proteins have an extended
α-helical structure between Lys724 and position 721, such that D721 or E721 are now in
close proximity to K724. This proposed structural change would mimic what is seen in the
co-crystal structure of the covalent Top1-DNA complex in the presence of topotecan,
raising the possibility that these substitutions induce a structural change to create a pocket
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that facilitate CPT binding. To determine if it is the negative charge of D721or E721 that
precludes trypsin digestion at K724, trypsin digests of the CPT hypersensitivity G721A
mutant could be assessed and should reveal if it is charge by itself or the structural
alteration that it leading to the diminished digestion at K724.
Using suicide substrates to uncouple cleavage from religation, we further
demonstrated that the presence of duplex DNA 3’ to the site of DNA cleavage site also
altered the rates of Top1G721D catalyzed DNA cleavage, religation, and the pattern of
tryptic digests. This suggests that downstream protein-DNA contacts impact dynamic
interactions between the active site Tyr/C-terminal domain and the linker. The human
Top1 linker has been shown to be 10-fold more resistant to limited proteolysis when the
enzyme is noncovalently bound to duplex DNA, consistent with linker-DNA contacts 3’
to the site of DNA scission (28). An interesting observation from these experiments is
that only when duplex DNA is present downstream of the cleavage site do we see the
decrease in the rate of religation. As this assay is performed with an oligonucleotide that
creates a flap at the site of cleavage, this extra dinucleotide might alter the active site
pocket of yTo1pG721D, leading to a decrease in the rate of religation. This result is
specific for the G721D mutant, but as there is no increase in the covalent complex
formation in the absence of CPT in the steady state cleavage assays, this result might be
an artifact of this assay or may reflect the distortion in the DNA structure induced by
CPT binding.
The differences seen in tryptic digests in the presence and absence of downstream
DNA, implies that there is an alteration in structure that allows cleavage at previously
limited sites. This indicates that the presence or absence of duplex DNA downstream of
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the cleavage site, which would be the DNA interacting with the linker, affects the
architecture of the active site/C-terminal domain. Even though the X-ray structure of the
mutation-induced alterations in Top1p is not currently available, these studies suggest
that the conserved Gly721 residue acts as a flexible hinge within the active site of Top1
that enable linker domain flexibility and the structural alterations that accompany drug
binding of the covalent enzyme-DNA complex.
As the Gly residue is conserved in human Top1 (Gly717 in hTop1), our next step
was to determine if this residue has the same characteristics as in yTop1. When Gly717 in
hTop1 was mutated to the negatively charged Asp there was no increase in CPT
sensitivity when this mutant was expressed in yeast cells. This contrasts with the CPT
hypersensitivity of yeast cells expressing yTop1G721D. However, important to note is that
expressing wild-type hTop1 in yeast cells increases cell sensitivity to CPT one hundred
fold compared to cells expressing yTop1. We considered that an upper threshold of CPTinduced DNA damage may have already been attained by CPT treatment of hTop1expressing yeast cells such that expression of hTop1G717D had no effect. However,
purified hTop1G717D recapitulated the increase in enzyme sensitivity to CPT and also the
alteration in tryptic digests seen with the yeast mutant enzyme, suggesting that mutation
of this conserved residue induces a similar mechanism of increased CPT sensitivity in
both yeast and human Top1, namely an structural alteration that drives CPT binding.
Using aforementioned suicide substrates, we observed that hTop1G717D exhibited
a dramatic increase in the rate of cleavage, regardless of the length of the DNA 3’ to the
site of scission. This mutant is distinct from the self-poisoning mutant yTop1N726H,
which also displays an increased rate of DNA cleavage, in that hTop1G717D did not
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produce elevated levels of covalent complex formation in the absence of CPT and in vivo
toxicity in the absence of the drug. In cleavage reactions with the suicide substrates,
increased cleavage at a second site was also observed, while in the steady state DNA
cleavage assays no alteration in sequence specificity was detected. Based on these results,
it might be that the increase in DNA cleavage is specific for the suicide substrates. As
CPT does increase stabililization of the covalent, a second possibility might be that the
increase rate of DNA cleavage by G717D coupled with the decreased rate of DNA
religation induced by CPT binding enhance CPT poisining of hTop1G717D.

6.3. THE DISTINCT LINKER DOMAINS PLAY A ROLE IN REGULATING CPT
SENSITIVITY AND ENZYME CATALYSIS IN VIVO
The differences between yeast and human Top1 Gly mutants in enhancing cell
sensitivity to CPT and the altered DNA cleavage rates of hTop1G717D prompted us to
probe the role of the distinct linker domains in regulating CPT sensitivity and enzyme
catalysis in vivo. This was accomplished by generating chimeric proteins where the
various domains were exchanged using homologous recombination in yeast. The core and
C-terminal domains of Top1 are the most conserved regions of the enzyme, while the Nterminus and the linker are the most divergent in both amino acid sequence and size.
Human Top1 has an N-terminus consisting of approximately 200 amino acids, while the
smaller linker domain comprises only 45 amino acids. In yeast Top1, the relative length
of the shorter N-terminal domain is only 140 amino acids long, while the yeast linker is
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twice the lenght of the human linker domain. However, overall the combined sizes of the
N-terminal and linker domains are conserved.
Most of the protein-protein interactions involving Top1 have been mapped to the
N-terminal domain. For our experiments we first wanted to investigate what role these
protein interactions might play in regulating cell sensitivity to CPT and therefore
exchanged the N-termini between the two enzymes. No difference in CPT was observed
when these N-terminal chimeric enzymes were expressed in yeast cells, refuting the
simple notion that protein-protein interactions dictated by the N-terminus impacts CPT
sensitivity.
Next, we exchanged the linker domains between the human and yeast Top1
proteins. The chimeric yeast enzyme, which contained the much smaller human linker,
exhibited decreased specific enzyme activity and a concomitant decrease in CPT
sensitivity in yeast cells. Interestingly, the chimeric human enzyme containing the much
larger yeast linker was cytotoxic in the absence of any drug. No alteration in specific
activity, DNA affinity or covalent complex formation in the presence of absence to CPT
could be detected in vitro, indicating that the toxicity might not be due to alterations in
enzyme catalysis. To determine if toxicity was independent of Top1 catalyzed DNA
cleavage, the active site Tyr was substituted with Phe, rendering the enzyme inactive.
This catalytically inactive chimera was still toxic when overexpressed in yeast cells,
indicating that cytotoxicity was not a consequence of covalent Top1-DNA adduct
formation. These results lead us to posit that the lethal phenotype of cells expressing this
inactive (hN, yL)-hTop1Y723F mutant protein resulted from alterations in protein
interactions directed by the linker domain.
158

Indeed, the expression of hTop1G717D did not increase cell sensitivity to CPT,
while expression of the corresponding yeast mutant (yTop1G721D) did. Yet, both mutant
proteins demonstrated increased CPT sensitivity in steady state DNA cleavage assays.
Taken together, these findings suggest that differences in the protein interactions between
the yeast and human enzymes in yeast may be directed by the linker domain.
As the N-terminus is not present in any of the Top1 crystal structures solved to
date, the position of this domain relative to the rest of the protein in unknown. However
there has been suggestion that this domain interacts with the DNA downstream of the
cleavage site (37). This region of the DNA has also been shown to interact with the linker
domain (12). To determine if the N-terminus has any affect on the cytotoxicity induced
by the lethal chimera, the human N-terminus was replaced with that of the yeast Nterminus to yield a protein that contained the human core and C-terminus and the yeast
linker and N-terminus. Surprisingly, cells expressing this “double” chimera were viable
and sensitive to the same level of CPT as cells expressing wild-type hTop1. Moreover,
the in vitro CPT sensitivity and sequence specificity of the (yN,yL)-hTop1 chimeric
protein was comparable to that exhibited by wild-type hTop1, demonstrating that the
CPT sensitivity of hTop1 is dictated by the core and C-terminal domains. The
combination of the linker and the N-terminal domain, on the other hand, appear to
regulate the in vivo activity of the enzyme, possibly in directing the formation of protein
complexes that do nor occur are inappropriately regulated in the absence of the correct Nterminus/Linker combination.
To determine what role the linker might play in the increased sensitivity of the
Gly mutant, the residue was mutated to Asp in the yeast Top1 chimera containing the
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human linker ((yN,hL)-yTop1). In comparison with wild-type yTop1, expression of (yN,
hL)-yTop1 rendered cells resistant to CPT. However, mutating the Gly residue to Asp in
(yN, hL)-yTop1pG721D restored CPT sensitivity albeit not to the level of yTop1G721Dp.
These experiments demonstrate that the G721D mutation increases CPT sensitivity
independent of which linker domain is present, human or yeast. The human linker in the
context of the yeast Top1 clamp did decrease the specific activity of the chimeric
enzyme, although it does not appear to be due to a DNA binding defect, as the salt
optimum for specific activity was not altered as compared to wild-type yTop1. As the
linker domain places the active site Tyr/C-terminal domain in the correct position within
the catalytic pocket, the shorter human linker might not position the yeast active Tyr/Cterminal domain in its optimal location for catalytic activity. The decrease in enzyme
activity does not appear to be due to protein misfolding as it is stably expressed. One way
to address the question would be to use suicide substrates to determine if this chimeric
protein exhibits a defect in DNA cleavage and therefore a decrease in specific activity.
As the Gly to Asp substitution increases Top1 sensitivity to CPT independent linker
composition, the question then becomes if a linker domain is necessary at all to cause this
increase. To answer this question, a linkerless yTop1 protein can be generated and then
used to substitute the Gly with Asp. If this mutant enzyme still exhibits increased CPT
sensitivity then the structural change induced by the mutation increases the binding of
CPT, while alterations in linker flexibility may play an indirect role in mediating
interactions between the drug stabilized Top1-DNA intermediates and other protein
complexes.
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To further test the hypothesis that there are differences in protein interactions
dictated by the linker domain, we performed a two-hybrid screen to identify linker
domain binding partners. The hTop1 linker and C-terminal domain fragment has
previously been shown to fold correctly such that an active enzyme could be
reconstituted with a separate polypeptide encoding the hTop1 core domain (39). For this
screen, the corresponding yeast linker and C-terminal domain was used to avoid
heterologous protein interactions. Using this polypeptide as bait, we identified 16
proteins that induced the expression of reporter genes. Three of these proteins have been
previously shown to either physically or genetically interact with Top1 giving validity to
the results. The three previously identified were Ubc9, Pol30 (PCNA) and Tif4631 (136,
191, 192), although no biological function have been demonstrated for these interactions.
At this time, four of these proteins have been tested and confirmed as true
interactors. Pol30 (PCNA), Nis1 and Ubc9 have been shown to interact with both the
yeast and human Top1 linker domains, while Mrm1 only interacts with yTop1 linker.
Mrm1 is a ribose methyltransferase and is essential for the formation of functional
mitochondrial ribosomes. Mrm1 is located in the mitochondria, while Top1 is a nuclear
protein. Although possibility therefore exist that this is not a true interaction due to their
separate location, it is of interest to note that a human mitochondrial Top1 encoded by a
different gene than its nuclear counterpart exist. This enzyme also contains a linker, but
lacks the N-terminal domain. A longstanding question had been whether a Type 1B
enzyme is required for mitochondrial DNA replication and transcription in yeast. This
result might help elucidate this problem.
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Nis1 is located in the bud neck at the G2/M phase of the cell cycle, but has also
been found in the nucleus. It is believed to be involved in mitotic sigaling, but not much
more is know about this protein. As Top1 is known to play a role in maintaining
chromosome condensation, this interaction might be of significance during mitosis.
The interaction of yTopl linker and C-terminal fragment with Pol30 (PCNA) is an
intriguing result as this protein functions at multiple levels in directing DNA metabolic
pathways. It has been shown to promote localization of replication factors with a
consensus PCNA-binding domain, although the Top1 fragment used for this study did not
contain this binding motif. When bound to DNA, Pol30 organizes various proteins
involved in DNA replication and repair. It forms a homotrimer that clamps around duplex
DNA and slides spontaneously along the bases. This sliding clamp moves along with the
replication fork and functions as a scaffold for the recruitment of various proteins such as
Polε and Polδ, both involved in processive DNA replication (198). Many of the protein
interactions with Pol30 are directed by post translation modification of this sliding clamp.
For example sumoylated PCNA has been shown to recruit Srs1 and thereby prevent
recombination during S-phase (199). Human Top1 has already been shown to bind to
PCNA by affinity chromatography (192), but the binding site has not been mapped to a
specific region or domain of Top1. As the C-terminal domain of Top1 is buried within
the active site pocket created by the core, it is therefore very likely that Pol30 interacts
with the linker region that extends away from the body of the enzyme. To map the exact
Pol30 binding site on Top1, smaller fragments of Top1 can be tested for interaction.
Top1 acts as a swivel to relieve torsional strain in the DNA created by the movement of
the replication fork and it is possible that Pol30 will recruit Top1 to regions of high
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torsional strain. A second possible role for this interaction might be that the linker acts as
a sensor for approaching replication forks to trigger the dissociation of Top1 from the
DNA, thereby preventing DNA damage caused by the collision of the replication
machinery and Top1 covalently bound to the DNA. The linker acting as a sensor might
also function in sensing the increase in torsional strain caused by the oncoming
replication forks which might increase catalytic activity or dissociation of the enzyme
from the DNA. As Pol30 (PCNA) undergoes extensive post-translational modification to
regulate replication and repair, it will be of interest to determine if Top1 binding is driven
by a specific modification of Pol30.
The region of Top1 (both yeast and human) that was used as bait, namely the
linker and C-terminal domain contains consensus SUMO sites (one in the yeast and two
in the human fragment) and it is therefore not surprising to find that the second enzyme,
Ubc9, in the sumoylation cascade can interact with this region of Top1. This also raises
the question of whether sumoylation of the linker affects the binding with the other
proteins, for example the interaction with Pol30. Ubc9 can by itself or with the help of an
E3 ligase transfer SUMO (Smt3 in yeast) to Lys residues of target proteins, in this case
Top1. Top1 has been shown to be sumoylated and initially the modification was believed
to affect CPT sensitivity. Jacquiau et al. (136) however, showed that mutating the SUMO
sites on Top1 did not affect CPT sensitivity. Interestingly, Siz2, an E3 ligase in the
sumoylation cascade was also identified in this screen. The Top1-Siz2 interaction might
be directed by Ubc9, such that Siz2 interacts with Ubc9 and not directly with Top1.
Another interesting finding was that there seemed to be two Ubc9 populations in the cells
expressing the Ubc9 fusion protein. The molecular weight of the smaller polupation
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corresponded to the Gal4 activation domain (AD)-Ubc9 fusion protein, while the other
may be sumoylated Gal4 AD-Ubc9. Ubc9 is known to be sumoylated on Lys153 (194),
thus it is possible that Top1 only interacts with sumoylated Ubc9. As all of these
interactions were identified using fusion proteins, they will have to be confirmed by using
full length wild-type Top1 (human and yeast) and Ubc9. To determine if the second Ubc9
population is truly sumoylated Ubc9, a mutant Ubc9, where Lys153 is mutated to an Ala
or Arg, can be generated and tested to see if this population is still present. This mutant
can also be used to determine if the interaction between Top1 and Ubc9 requires a
sumoylated Ubc9. To determine if Top1 linker sumoylation is required for its interaction
with other protein, the linker SUMO site can be mutated and this mutant tested for
interactions with its binding partners.
Even though the results of the two-hybrid screen were not conclusive, the results
are intriguing and it suggests specific paths that will be explored to expand our
understanding of Top1 interactions and what role they mighty play in the function and
regulation of this enzyme. It will be of great interest to know if the Top1 interaction with
Pol30 in dependant/independent on the presence of DNA, if the two protein colocalize
and if this colocalization changes during the cell cycle or with the treatment of CPT.
Using ChIP-Chip analysis we might be able determine if the if the colocalization is a
genome wide phenomena which might help us understand if the interaction is part of a
repair pathway or if Top1 is simply recruited as a component of the replication machinery
to replication despots.
In conclusion, the work presented here revealed that a single mutation in Top1
can increase the intrinsic CPT sensitivity of the enzyme. The mechanistic basis of this
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increased sensitivity appears to be a structural alteration of the active site Tyr/ C-terminal
domain that enhances CPT binding to the covalent Top1-DNA intermediate. This result is
of importance in this era of rational drug design to generate new compounds that might
mimic/induce this structural change, thereby increasing the efficiency of CPT.
We further demonstrate that not only the N-terminus, but also the linker domain
function as a docking site for interacting proteins, such as Pol30 (PCNA) and Ubc9, and
knowledge of the biological function of these interactions will lead to a better
understanding of the regulation of Top1 function and also pathways affecting the lesions
induced by Top1 targeting drugs.
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